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Abstract 
This thesis aimed to evaluate the feasibility and utility of a sickle cell disease registry for 
clinical patient management and research. Five hospitals out of nine in the North West 
London health region participated in the registry, with 78 percent coverage of the sickle 
cell disease population. There was 80% case ascertainment in participating hospitals.  
 
Aggregated anonymised demographic and diagnostic data was collected for all 
haemoglobinopathy patients. This provided the core dataset for quantifying prevalence of 
sickle cell and thalassaemia and mapping local hospital workloads and service 
requirements. Thirteen percent of HbSS adult patients were taking hydroxycarbamide. 
 
The cohort of patients treated with hydroxycarbamide was evaluated. Sixty two of the 80 
patients started on treatment were included. Follow-up was censored after 9 years, totalling 
249 person-years of data with a median follow-up of three years (IQR, 1-6). Results 
showed that haematological benefits were maintained in the long-term with treatment, but 
evidence of long-term clinical effectiveness was less strong. This appeared to be due to the 
patterns of clinical management in everyday practice. Patients tend to be treated with 
modest doses of hydroxycarbamide due to intolerance or inability to attain or maintain 
maximum tolerated dose. For example maximum tolerated dose was the aim of treatment 
for 91% of patients but it was achieved for 65% of participants. Non- compliance with 
treatment and monitoring schedule was the main reason for non- attainment. 
 
Results suggest that it is sensible to strive for maximum tolerated dose to ensure therapy 
remains effective, but with more realistic expectations of the dose patients can attain and 
maintain. Doses in adult patients average 20mg/kg/day and 25mg/kg/day in children. Adult 
patients may be able to achieve a higher dose, if there was more stringent monitoring and 
improved management of non-compliance. 
 
The North West London HU Sub-Registry proved useful for measuring long-term 
effectiveness and tolerability of hydroxycarbamide. Routinely collected data was utilized 
for both clinical management and research purposes. The novelty lay in examination of the 
nuances of routine clinical practice. An electronic patient record was developed as a 
clinical management tool. It is the first study reporting long-term outcomes for UK sickle 
cell disease patients on hydroxycarbamide.  
 
Findings should help clinicians devise effective treatment protocols and strategies for 
managing patients commenced on this therapy. Interventions need to be targeted at 
increasing utilisation, patient adherence and persistence with treatment. The electronic 
patient record could be used to maximise treatment benefit and improve adherence. More 
effective involvement of the multidisciplinary team and primary care colleagues in patient 
education and management should improve usage. Patients and carers need up to date and 
easy to assimilate information to make informed decisions about treatment options.  
 
Maintaining a SCD registry is challenging. Models which operate as clinical information 
systems provide an incentive for participation. These enable active involvement of local 
care providers in registry management and the ability to keep and utilize their own data. 
Clinicians require accurate and current data for patient management and to enable them to 
benchmark their local outcomes against national outcomes and care standards. 
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Definitions of Key Terms 
Disease register 
A disease register is defined as a file of data concerning all cases of a particular disease in 
a defined population. Cases are regularly followed up and information on remissions, 
exacerbation, prevalence and survival can be obtained (Goldberg et al, 1980; Donaldson, 
1992). The register is the actual document and the registry is the system of ongoing 
registration (Weddell, 1973) therefore it is possible for a registry to support several 
registers (Thompson, 1989). 
 
Health technology 
A health technology includes all methods used by health professionals to promote health, 
prevent and treat disease and to improve rehabilitation and long-term care (Dept of Health, 
1992 cited in Raftery et al, 2005)). This definition includes different levels of interventions 
from organisational structures to individual components of healthcare including drugs 
(such as hydroxycarbamide), diagnostic tests and surgical procedures. 
 
Incidence 
Incidence rate is a measure of morbidity based on the number of new cases or episodes of 
illness arising in a population over an estimated period. It is expressed in terms of persons 
with the disease or episodes of the disease per 1000 individuals at risk. 
 
Prevalence 
The proportion of individuals in a defined population with a disease. Prevalence rate is a 
statistical concept referring to the number of cases of a disease that are present in a 
particular population at a given time (point prevalence) or over a stated period (period 
prevalence). It is expressed either as persons or episodes of sickness per 1000 individuals 
at risk.
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Chapter 1: Overview of Sickle Cell Disease and 
Development of a Disease Registry. 
1.1 Introduction 
This chapter will describe the rationale for and aims of this thesis. It provides an 
introduction to sickle cell disease (SCD) and a history of medical progress in 
understanding and managing this serious chronic disorder in the UK. This is essential to 
understanding the origins of the SCD registry and the development of the research question 
to be answered by this study. The chapter sections are as follows: 1.2 describes the disease, 
1.3 the epidemiology (1.3.1 incidence and prevalence and 1.3.2 disease detection 
methods), 1.4 the pathophysiology, 1.5 clinical presentation, 1.6 current management and 
survival, and 1.7 current treatments, especially hydroxycarbamide. Hydroxycarbamide 
treatment efficacy is discussed in 1.7.1, evidence of effectiveness in 1.7.2 and mechanisms 
of action which result in disease modification in SCD in section 1.7.3. Motivation for the 
development of a SCD registry is covered in section 1.8 including the history of the 
European Haemoglobinopathy Registry (1.8.1), rationale for developing an SCD registry 
(1.8.2) and origins of the present registry, the North West London sector 
Haemoglobinopathy Registry (1.8.3). The final section (1.9) describes the rationale for, 
aims, objectives and focus of this PhD study. 
 
1.2 What is SCD? 
Sickle cell disease is the name given to a group of inherited conditions that affect 
haemoglobin (Hb) formation in the blood. It is caused by an alteration of the beta globin 
gene which results in abnormal haemoglobin production. Haemoglobin is the oxygen 
carrying protein found in the red blood cells (RBCs). Adult haemoglobin (HbA) is the 
normal and most common type of haemoglobin seen in adults while newborn infants have 
predominantly fetal haemoglobin (HbF) which is largely replaced by adult haemoglobin by 
the age of one year (Oni et al, 2006; Sickle Cell Society, 2008). SCD occurs when an 
infant inherits the gene for sickle haemoglobin (HbS) from both parents or the gene for 
sickle haemoglobin from one parent and another abnormal haemoglobin gene, such as HbC 
or HbβThal, from the other parent (Brawley et al, 2008). The homozygous condition 
(HbSS), known as sickle cell anaemia, is the most common and most severe type of SCD 
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seen in the UK but the following clinically significant SCD genotypes are also common; 
sickle haemoglobin C disease (HbSC), sickle beta zero thalassaemia (HbS/β0Thal), sickle 
beta plus thalassaemia (HbS/β+Thal) and less frequently sickle haemoglobin Dpunjab disease 
(HbSDpunjab) and sickle Oarab (HbSOarab) (Panchan and Howard, 2005; Oni et al, 2006). 
Individuals who inherit only one sickle (HbS) gene from one parent and the normal HbA 
gene from the other are sickle cell carriers (HbAS): they rarely have clinical symptoms and 
often do not know they are carrying the HbS gene. However individuals with sickle trait 
are at risk of having children with a clinically significant syndrome if their partner also 
carries the sickle gene or another significant abnormal haemoglobin gene (Oni et al, 2006). 
 
1.3 Epidemiology 
1.3.1 Incidence and prevalence 
The disorder occurs predominantly in individuals of African descent but these disorders are 
also prevalent throughout the Mediterranean, Middle East and parts of India, the 
Caribbean, and South and Central America (Sickle Cell Society, 2008). Due to population 
migration, there are people with SCD in most countries and because of the severity of the 
condition it forms an important part of health care practice. Early estimates suggested that 
sickle cell disease affected 1-2% (120,000) of infants in Africa annually but more recent 
data shows that there are more than 200,000 new cases per year (Davies and Oni, 1997; 
Strouse et al, 2008). About 50-60,000 people in the USA suffer from the disease and 2000 
babies are born annually (Brawley et al, 2008; Platt, 2008). 
 
There are at least 12,500 people living with the condition in England, where it is the most 
common and fastest growing genetic disorder (Hickman et al, 1999; NHS Sickle Cell and 
Thalassaemia Screening Programme, 2008). Recent data from the Newborn Screening 
Programme suggests that more than 300 babies with SCD and some 8,500 carriers are born 
each year (NHS Sickle Cell and Thalassaemia Screening Programme, 2008). Previous 
estimates by Hickman and colleagues (1999) reported that approximately 3000 babies 
(0.47%) born annually, in England, carried sickle cell trait, 2800 (0.44%) carried β 
thalassaemia trait and approximately 140-175 (0.22-0.28 per 1000) infants were born with 
SCD every year. Black ethnic minorities have comparatively high carrier rates of sickle 
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cell responsible for high rates of the disease: 5.6 per 1000 births among black Caribbeans 
and 14.7 among black Africans (Davies et al, 2000).  
1.3.2 Disease detection 
SCD is detectable from birth by a specialist blood test (Pancham and Howard, 2005; NHS 
Sickle Cell and Thalassaemia Screening Programme, 2006a). The test can be undertaken in 
the local haematology laboratory, provided it is CPA-accredited and takes part in quality 
control schemes for haemoglobin testing (NHS Sickle Cell and Thalassaemia Screening 
Programme, 2006a). Best practice in conducting and reporting screening tests are outlined 
in the ‘Sickle Cell and Thalassaemia: Handbook for laboratories’ (NHS Sickle Cell and 
Thalassaemia Screening Programme, 2006a). 
 
The NHS Sickle Cell and Thalassaemia Programme was set up in 2001 as a result of the 
commitment, in the ‘National Plan for England’, to introduce effective antenatal and 
neonatal screening programmes for sickle cell and thalassaemia (Department of Health, 
2000; NHS Sickle Cell and Thalassaemia Screening Programme, 2008). Consequently 
universal neonatal screening for sickle cell disease, using the Guthrie card system, was 
introduced in England in 2006. Antenatal screening programmes also identify a small 
proportion of adults with sickle cell. Individuals who have not been picked up by routine 
screening methods because they are immigrants or because they were born before 
screening was introduced are picked up in an ad hoc manner. Most common methods 
include family screening, presentation to the GP or local hospital with symptoms 
suggestive of SCD or during routine screening such as pre-operatively (Pancham and 
Howard, 2005). 
 
1.4 Pathophysiology 
There are two essential pathological processes: vaso-occlusion and haemolysis (Sickle Cell 
Society, 2008). Red blood cells (erythrocytes) are normally round and very flexible (see 
Figure 1.1) but when depleted of oxygen can become dehydrated and crescent shaped or 
‘sickled’ in people with SCD. These deformed inflexible sickled red blood cells (see 
Figure 1.2) may not be able to pass through small blood vessels, tending to clump together 
and stick to blood vessel walls causing blockages and damage to the red cell membrane. 
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This phenomenon is called ‘vaso-occlusion’ and it may happen in any part of the body’s 
microcirculation, resulting in extreme pain called a ‘vaso-occlusive crisis’ or ‘painful 
crisis’ in the affected part. The process prevents blood flow into the surrounding tissues 
and organs with deprivation of oxygen which may result in localised dying tissue and 
vascular damage leaving the organ permanently impaired. Large blood vessels are also 
damaged by this process, which may be the cause of such complications as stroke, acute 
chest syndrome (ACS) and pulmonary hypertension (Davies and Gilmore, 2003; Sickle 
Cell Society, 2008). Sickled RBCs have a shortened life span (16 – 20 days in contrast to 
120 days in normal RBCs) due to the constant injury caused by these processes, which 
results in a chronic haemolytic anaemia. Individuals with SCD have an increased risk of 
serious infections due to non functioning spleens (functional asplenia) from repeated 
infarcts (Pancham and Howard, 2005). 
 
Figure 1.1: Normal red blood cells 
 
Credit: David Gregory & Debbie Marshall 
Figure 1.2: Sickled and other red blood 
cells 
Credit: EM Unit/Royal Free Med. School 
 
1.5 Clinical presentation 
The clinical syndrome results from chronic haemolytic anaemia, increased susceptibility to 
infection and vaso-occlusion, which in turn can give rise to chronic organ damage (Davies, 
2003). The initial clinical presentation usually occurs in childhood but people with less 
severe SCD may not develop symptoms until later in life (Sickle Cell Society, 2008). The 
condition varies in severity from one person to the next for reasons that are not well 
understood (Oni et al, 2006). Known markers of severity include severe anaemia, a low 
haemoglobin F% (HbF%), dactylitis syndrome (hand/foot pain crisis) at a young age and 
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an increased white blood cell count (Davies, 2003). The most common clinical problem is 
painful crises which causes over 90% of acute hospital admissions and significant 
morbidity in the community (Brozovic et al, 1987; Fuggle et al, 1996; Ballas and Lusardi, 
2005). Other common clinical conditions include overwhelming infection, ACS, lung 
disease, chronic leg ulcer, eye disease, kidney and spleen dysfunction, priapism and 
cerebrovascular accident (stroke) (Day and Wynn, 2000; Sickle Cell Society, 2008). 
 
1.6 Clinical management and survival 
Like other chronic diseases SCD is a major source of morbidity, mortality and health 
service resource utilization (Kahn, 1999; Steinberg, 1999). Affected people suffer 
unpredictable, potentially life threatening, acute adverse events which require precision 
clinical management for optimal outcomes (Department of Health, 1993). The chronic 
manifestations of the disease often occur insidiously thus requiring close monitoring to 
identify and treat complications early to prevent or arrest disease progression (Jones, 
1998). Life expectancy is considerably reduced and death generally relates to SCD, caused 
either by chronic organ failure or as a result of an acute catastrophic event (Platt et al, 
1994; Wierenga et al, 2001; Davies and Gilmore, 2003). A recent national confidential 
inquiry of sickle cell patient deaths in England reported that the most common causes of 
death in adults were cerebrovascular accidents (CVAs) and pulmonary complications 
(NCEPOD, 2008). 
 
Up to 15 years ago management was, purely preventative and supportive, aimed at 
symptom control (Amrolia et al, 2003; Davies and Gilmore, 2003). Standard care involves 
lifelong infection prophylaxis and prevention of crisis. Treatment for acute uncomplicated 
pain crisis includes pain-killing medication, hydration and antibiotics (Davies and Gilmore, 
2003). Life threatening crisis such as ACS may require transfusion of red blood cells and 
inhaled oxygen. Many patients need emotional, psychological, educational, employment 
and social support to cope as SCD can impact on every facet of life (Fuggle et al, 1996; 
Lee et al, 1997; Anie, 2005; Pancham and Howard, 2005). It is essential to have a 
multidisciplinary team approach which involves both primary and secondary care health 
professionals so that holistic care is provided to patients and their families (Pancham and 
Howard, 2005). 
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1.7 Available therapies 
The only potential cure for SCD is stem cell transplantation, preferably from a matched 
sibling donor. There is still a sufficiently high risk of failure, complications and death from 
this procedure to preclude it as a mainstream therapy option in the UK (Davies and 
Gilmore, 2003; Chakrabarti, 2007; Darbyshire and Roberts, 2007). Long term red blood 
cell transfusion is the treatment of choice for secondary stroke prevention (Pancham and 
Howard, 2005; Sickle Cell Society, 2008). Due to the risks, complications and 
inconvenience of this therapy it is not widely used for other types of symptom control, for 
example pain crisis. Many drugs have been tested over the last 20 years but only 
hydroxycarbamide, previously known as hydroxyurea (HU), has proven efficacy in 
ameliorating the disease and improving life expectancy for most patients (Charache et al 
1995; Davies and Gilmore, 2003; Steinberg et al, 2003). 
 
1.7.1 Hydroxycarbamide: treatment efficacy 
Charache et al (1995) showed conclusively in a large multi-centre double-blind 
randomized clinical trial, called the Multi-centre Study of Hydroxyurea (MSH), that adult 
patients treated with HU had statistically significant lower pain crisis rates than the placebo 
group. There were also significantly fewer patients on HU therapy that suffered an ACS 
episode or needed a blood transfusion. Weaker evidence suggests children have similar 
clinical benefits while on HU (Ferster et al, 1996; Hankins et al, 2005). In addition a nine 
year longitudinal observational follow-up of the original patient cohort in the MSH study 
showed a 40 percent reduction in mortality for those treated with HU (Steinberg et al, 
2003). 
 
1.7.2 Hydroxycarbamide: evidence of effectiveness in clinical practice 
Despite this evidence there is still only a subset of potential patients who could benefit 
from HU being treated (Aliyu et al, 2005; Ballas and Lusardi, 2005; Lanzkron et al, 2006, 
Segal et al, 2008). A major problem is that the median length of follow-up is relatively 
short, thus weakening the evidence of long-term risk/benefit (Spell, 2003). Only a few 
studies have evaluated effectiveness of HU in everyday clinical practice. Ferster et al 
(2001) followed up a cohort of 91 children and young adults from the Belgium HU-treated 
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SCD registry for up to five years, with a median follow-up of 3.5 years. This prospective 
series was updated by Gulbis et al (2005), who reported the outcomes for 127 patients 
followed for up to eight years with a median of three yrs and 11 months. De Montalembert 
and colleagues (2006) followed up a French cohort of 225 SCD children and young adults 
with a mean duration of HU treatment of 3.8 years; ten had been on HU for over ten years. 
The other noteworthy study, by Steinberg et al (2003), followed-up the original MSH 
participants for up to nine years but most of the cohort received HU for less than 
37 months (Spell, 2003). 
 
Consequently little is known about the significance and magnitude of serious side effects 
with long term therapy. In particular the unquantified risk of patients developing leukaemia 
and the potential for HU to act as a teratogen has restricted usage (Davies and Gilmore, 
2003; Zumberg et al, 2005; Hankins et al, 2007; Platt, 2008). No data exists pertaining to 
the proportion of sickle patients treated with HU therefore the relative incidence of serious 
adverse events is unknown (Halsey and Roberts, 2003). In addition ambivalence exists 
about which patients will benefit from treatment and how optimum benefit versus least risk 
can be achieved in routine clinical practice, outside the controlled environment of a clinical 
trial (Halsey and Roberts, 2003; Platt, 2008). For instance uncertainty prevails about why 
some patients are non responders, whether maximum tolerated dose (MTD) or a set dosing 
schedule is best practice, should the strict monitoring schedule be relaxed, and if clinical 
benefits are sustained in the long term (Davies and Gilmore, 2003; Segal et al, 2008). 
 
Therefore insufficient evidence has made it impossible to convince the majority of 
patients, whom it could potentially benefit, to use it and their doctors to prescribe it. 
 
1.7.3 Hydroxycarbamide: mechanism of action in management of SCD 
The impact of HU was initially attributed to its ability to promote HbF synthesis, which is 
known to ameliorate the clinical symptoms of SCD. Recent research shows that it has 
many other beneficial effects which modify the clinical severity of the disease (Davies and 
Gilmore, 2003; Aliyu et al, 2005; Sickle Cell Society, 2008). These include improving red 
cell hydration, maintaining vascular tone, decreasing cytokine production and red cell 
adhesion. Davies and Gilmore (2003) provide a summary account of the reported 
mechanisms in which HU alleviates SCD symptoms. 
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1.8 Motivation to develop a sickle cell disease registry 
1.8.1 History of European Haemoglobinopathy Registry 
This ambivalence surrounding the long-term risks/ benefits of HU therapy led to close 
collaborations between the haematology department at Central Middlesex Hospital (CMH) 
and European partners which culminated in the development of a pilot European HU-
treated SCD registry in 1998 (Davies and Roberts- Harwood, 1998). However this registry, 
called the European Haemoglobinopathy Registry (EHR), was discontinued for a number 
of reasons including loss of the co-ordinator, lack of funding and organisational 
difficulties. Subsequently a disease registry for all SCD patients was set up in its place, in 
1999, with a special interest in monitoring the subgroup of patients treated with HU 
(Gilmore, 2001). 
 
1.8.2 Establishing a disease registry for sickle cell 
No other SCD registry existed and therefore this presented a unique opportunity to build 
upon the work and experience already gained from the original EU HU-treated SCD 
patient database. Furthermore recent government funded reviews of sickle cell services had 
advocated establishment of registries to help overcome the ongoing lack of accurate 
population based information and of research based evidence for effective patient 
management (Department of Health, 1993; Streetly et al, 1997). For example Zeuner and 
colleagues (1999) reported a virtual absence of UK epidemiological data for modelling 
predictions and estimations to determine the needs of a national screening programme for 
sickle cell disease. 
 
CMH was the preferred location due to the high disease incidence and prevalence in the 
locality, the position of CMH as a specialist centre for patients with this condition and the 
high level of local enthusiasm and motivation for this project. In addition CMH had 
amassed critical expertise and infrastructure to establish and run the registry. 
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1.8.3 Origin of the North West London Sector Haemoglobinopathy Registry 
The SCD registry was initiated at Central Middlesex hospital without any secure long-term 
funding therefore continual efforts were made, over the years, to attract funding in order to 
keep it viable. Survival depended on ad hoc streams of money to undertake various 
projects. Consequently, registry data collection and outputs were tailored to meet the 
requirements of the registry’s sponsors. Initially a three year research grant was secured 
from the Department of Health, in 1999, to evaluate the long-term risk benefit of HU for 
SCD patients. A registry co-ordinator (the author) was employed to develop the registry. A 
further three year research grant was awarded, in 2002, to continue this study. Other 
sources of funding included a small grant from the Washington University School of 
Medicine, St Louis, Missouri. In addition funding from local health authorities 
(subsequently reorganised into Primary Care Trusts) was secured, in 2001, for three 
additional local hospitals to join the registry thereby expanding coverage to three-quarters 
of the SCD patient population in the local North West London Health Sector geographical 
region. This project was for three years. Further funding was not acquired to enable the 
remaining hospitals, in the sector, to participate or for the existing hospitals to continue in 
the registry from 2004. However Brent Primary Care Trust (PCT) continued to contribute 
to the running of the registry for CMH patients. This registry is known as the North West 
London (NWL) Sector Haemoglobinopathy registry and operates under the umbrella of the 
EHR. 
 
1.9 Rationale for PhD 
1.9.1 Feasibility of a successful registry 
At this time there was plenty of debate about the desired components of a successful 
clinical registry (Thompson, 1989; Black, 1997) but little evidence or scrutiny of how they 
work in routine clinical practice settings. For instance many were still in their infancy, 
particularly in the UK, or had never been evaluated for reliability, efficiency and 
effectiveness (Rowan, 1996; Keogh et al, 1998; Black, 1999). This was not a trivial project 
as the opportunity cost of developing and maintaining a clinical registry is significant due 
to the complexity, resource requirements and longevity of the project (Thompson, 1989; 
Anionwu, 1997). The absence of evidence about the feasibility and utility of disease 
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registries led me, the researcher, to the conclusion that establishing and maintaining a 
sickle registry would need systematic investigation to identify the essential components to 
enable it to succeed. 
 
1.9.2 The Research Question 
The rationale for developing a sickle registry was to enhance the evidence base for SCD 
which in turn would benefit patient care. In particular urgent evaluation of the long-term 
effectiveness and safety of HU was required. Therefore it was necessary to test empirically 
if it was feasible to develop and sustain a ‘successful registry’. The following hypotheses 
were proposed: 
 
i. The development of a SCD registry for the dual purposes of patient clinical management 
and research is feasible. 
ii. A SCD registry will provide tangible benefits to SCD patients, their health care 
providers and the wider health community. 
 
1.9.3 The Aim 
The aim of this thesis is to evaluate the feasibility and utility of a SCD registry for clinical 
management of patients and research. 
 
1.9.4 The Objectives 
i. Develop an evidence based registry 
ii. Assure high quality data 
iii. Develop clinical management tools from the registry data 
iv. Demonstrate utility of the registry for SCD patient management and research 
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1.9.5 Focus of PhD study 
This evaluation will be focused, mainly, on the hydroxycarbamide sub-registry as it 
provides a distinct subsection where the topic and study population are easily defined and 
investigation of HU usage for SCD patients is critical.
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Chapter 2: Review of the Literature 
2.1 Introduction 
This literature review will identify the main issues to be considered when establishing a 
clinical database or disease registry. The phrases ‘clinical database’ and ‘disease registry’ 
are used interchangeably throughout as the literature does not tend to differentiate between 
the two and some electronic databases function as both disease registries and clinical 
databases. A model that serves as both a disease register and clinical database appears to be 
the most suitable for sickle cell disease (SCD). 
 
The North West London Sector Haemoglobinopathy registry is managed by National 
Health Service (NHS) employees, in an NHS facility, and participants receive their 
healthcare from the NHS. Studies that are conducted in environments with the same or 
similar health services are likely to identify relevant problems and provide better insight of 
the critical attributes necessary for a successful sickle cell disease registry in North West 
London. Therefore the focus will be on British and European literature and additional 
studies will be included if they add value to the review. 
 
2.1.1 Background 
Clinical database and disease registry outputs are increasingly used to assess quality of 
care and for epidemiological and health service research in the UK (Black, 1999; Brewster 
et al 2002). In addition database outputs can be utilized in routine clinical management to 
help patients and their clinicians decide on their best treatment and care options, however 
this function is unproven (Black, 2003a). Nevertheless they remain under utilized and often 
regarded with scepticism because until recently there was little known about which 
databases actually existed in the UK and even less about their scope, remit and quality 
(Black and Payne, 2002). 
 
In an attempt to address the paucity of information Black and colleagues developed a web 
based Directory of Clinical Databases called DoCDat, which aimed to list all UK multi-
centre clinical databases together with an independent assessment of their scope and 
quality (Black and Payne, 2003; Black et al, 2004). The directory was populated with 
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information on 105 databases and they found that the audit and research potential of most 
databases had not been realised (Black et al, 2004). This concurs with Raftery et al (2005) 
who evaluated English databases and found that their main use was for comparative audit. 
 
A major factor in this underutilization is likely to be due to uncertainty about the quality of 
data held in databases (Keogh et al, 1998; Black and Payne, 2003; Fine et al, 2003; Keogh 
et al, 2004). Contents of the database must be seen to be valid and reliable for confidence 
in its outputs and this assessment of quality will determine what uses can be made of it 
(Black and Payne, 2003; Fine et al, 2003). The most important dimensions when assessing 
quality are completeness and accuracy (Black and Payne, 2003). Black and Payne (2003) 
constructed and tested an instrument to objectively evaluate the quality of databases, which 
included the assessment of coverage, reliability and validity. The authors assert that these 
dimensions cover all methodological threats to the reliability, internal validity and external 
validity/generalisability of a database. 
 
Strict regulations govern the operation of clinical databases/ registries as they usually hold 
personal health data and therefore must comply with the Data Protection Act 1998, the 
Common Law of Confidentiality, Human Rights Act 1998 and Administrative Law 
(Department of Health, 2003). Custodians are obliged to ensure patient privacy and respect 
without jeopardising the methodological integrity of research and audit derived from the 
data (Al-Shahi and Warlow, 2000; Black, 2003b; Fraser, 2003; Lowrance, 2003; Willison, 
2003). 
 
This project already has multi-centre research ethics committee approval with the 
condition that informed written consent (opt-in consent process) will be gained from all 
patients prior to utilization of the data for research purposes. Acquiring consent is not a 
trivial matter and rates are affected by the cumulative effect of barriers to accessing and 
approaching eligible patients as well as gaining consent. The credibility and generalisibility 
of results from observational research may be affected if the excluded non-consented 
patients are systematically different to the consented cohort in characteristics that matter 
(Woolf et al, 2000; Verity and Nicoll, 2002; Tu et al, 2004; Al-Shahi et al, 2005). 
 
In addition the complexity of running a registry and sustained efforts and resources 
required to keep it viable often result in underutilization or termination (Thompson, 1989; 
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Donaldson, 1992). However there are some recent examples of successful databases where 
sustained efforts, resources and political drive have ensured their survival. For instance the 
long established cardiac surgery and cancer databases have thrived over the last decade due 
to support derived from government policy initiatives. These policies aimed to improve 
quality of health care and promote active involvement of patients in health care decision 
making processes. For instance the cardiac surgery databases have been greatly supported 
by the national service framework (NSF) for coronary artery disease, launched in 2000, 
and the Central Cardiac Audit Database (CCAD) project. CCAD is part of the National 
Clinical Audit Support Programme (NCASP) (Keogh et al, 2004). 
 
At the core of these initiatives were plans to ensure that information in the NHS could be 
transferred seamlessly across sectors; the task was designated to the NHS Information 
Authority (now known as NHS Connecting for Health). NCASP, a component of the NHS 
Information authority, was responsible for promoting clinical audit in cancer and coronary 
heart disease. The goal was to harmonise data collection between cardiology, cardiac 
surgery and other administrative systems so that everyone had ownership of, and was 
working from, the same base dataset and the same definitions (Keogh et al, 2004). 
 
The UK regional cancer registries are another example of how government influence and 
support helped to improve these registries. Reliable population based information derived 
from cancer registries were viewed as essential to the implementation and monitoring of 
‘the NHS Cancer Plan’, in 2000. This document was the driver to reforms in the UK cancer 
services. Integral to these reforms were schemes to improve the national cancer datasets, 
outlined in the 2000 Cancer Information Strategy (Department of Health, 2008). 
 
In conclusion the issues to be considered when developing a clinical database/ disease 
registry are the purpose, organisation and quality assurance processes involved. The 
literature will be appraised to identify and quantify these critical aspects of establishing a 
successful disease registry for SCD patients. Finally how do we know if the registry is 
effective? Registries are thought to benefit patients, their health care providers and 
government agencies involved in the planning and funding of health services. Therefore 
the utility of existing registries will be evaluated to determine how to maximise the 
potential of a SCD registry. 
 
Chapter 2  31 
2.1.2 Chapter structure 
The next section (2.2.) reviews the purposes and benefits of clinical registries/ databases. 
This is outlined as follows: Section 2.2.1 explores the properties and purpose of different 
types of clinical databases to identify a feasible model for SCD and Section 2.2.2 will 
evaluate the scope and usefulness of existing clinical registers. Section 2.2.3 reviews 
registries for chronic diseases; Section 2.2.4 databases set up to evaluate health 
technologies; and section 2.2.5 cancer registries. 
 
Section 2.3 covers the pertinent legal and ethical topics relating to clinical registries. These 
include data storage and use (section 2.3.1), personal identifiers (2.3.2), requirement for 
patient consent (2.3.3), consent process (2.3.4), consent bias in population health surveys 
(2.3.5) and consent bias in clinical registries (2.3.6). 
 
Section, 2.4, reviews the quality issues pertaining to registries. Section 2.4.1 summarises 
the origins of registry data, 2.4.2 examines the need for validation, 2.4.3 covers the 
reliability of data abstraction and 2.4.4 timing of data. The topics relevant to registry 
completeness are explored next: section 2.4.5 explains completeness in the context of a 
database, 2.4.6 examines completeness of follow-up, 2.4.7 completeness of case 
ascertainment, 2.4.8 timeliness of case ascertainment, 2.4.9 geographical coverage and the 
value of indirect quality indicators are reviewed in section 2.4.10. 
 
Findings are summarised in the discussion (section 2.5) and conclusions under 2.6. 
 
2.2 Purposes and benefits of clinical databases and disease 
registries 
2.2.1 Deciding on a model 
Raftery et al (2005) classified English databases in terms of their usefulness in health 
technology (HT) assessment. This classification system is useful in deciding the properties 
for a sickle cell disease registry. Their system distinguished between three groups of 
databases: those with both HT and patients’ characteristics, and those with one or the other 
of these. Their findings suggest that databases able to assess effectiveness, diffusion and 
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equity include information on both a HT and patient characteristics. Health state data must 
be collected at the level of individual patients to be useful. 
 
Clinical registries were considered the best source of data on HT and patient health states. 
These are either designed around gathering data on the recipients of a health technology, 
such as the databases concerned with a specific surgical intervention or a drug, or around 
an entire client or disease group. However registries that only cover a HT do not include all 
the patients with the health condition so their uses are limited to comparative audit. 
Registries that cover the entire client or disease group are the most effective at assessing 
effectiveness and equity because they include all individuals with the common factor (i.e. 
disease), whether they received the HT or not. 
 
In contrast clinical-administrative databases tend to have less depth but greater breadth of 
coverage than clinical registries as they were originally designed for administrative 
purposes. They contain some patient level information including identity, treatment and 
some health state or outcome data (Raftery et al, 2005). Examples include the Hospital 
Episode Statistics, the General Practice Research Database and cancer registers. They are 
of limited use in terms of measuring HT effectiveness except for the cancer registries, 
which can measure comparative mortality. These databases also have the potential to 
measure equity and diffusion because of their good coverage. Raftery and colleagues 
(2005) suggest that cancer registries have limited data on HTs but could include more 
variables to be clinically richer like disease registries. 
 
Clinical registries/ databases and cancer registries appear to have all the relevant properties 
and potential uses needed for sickle cell patients; therefore these types of registries will be 
the focus of this literature review. 
 
2.2.2. Scope and uses of clinical disease registries and health technology 
databases 
A wide range of clinical areas have databases but this review will focus on the categories 
of databases the author perceives could fit with the care and management of SCD patients. 
Section 2.2.3 will evaluate registries set up to monitor patients with serious and clinically 
significant chronic diseases, similar to SCD. Section 2.2.4 will explore databases set up to 
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evaluate health technologies as any registry will require the ability to evaluate the 
effectiveness of existing and future health technologies for SCD. As stated in chapter 1, 
hydroxycarbamide use in SCD requires monitoring and evaluation and therefore this will 
be a priority for the database. Section 2.2.5 will review cancer registries as they are the 
most prolific registries in the UK; are well established and funded; and mandated by 
national and European governments as an essential population based information resource. 
It is hoped the experiences of these registries will give valuable insight into how to use and 
manage a SCD registry. 
 
2.2.3 Chronic disease registries 
2.2.3.1 Cystic Fibrosis 
The chronic disease register for cystic fibrosis called the UK Cystic Fibrosis Database 
(UKCFD) commenced in 1992 as an audit project to establish the number and 
characteristics of the Scottish cystic fibrosis (CF) population and subsequently evolved 
into a clinical database by collecting additional variables on disease severity (Mehta et al, 
2004). It gradually expanded in terms of remit, mode of operation and coverage and now 
covers most of the UK cystic fibrosis population. Its multiple functions are purported to 
benefit CF sufferers, their health care providers and government agencies. For example 
participating clinics are able to produce individual patient reports from their registry data 
which support clinical management during patient consultations. These reports provide 
feedback to the patients on relevant aspects of their disease and care. Mehta et al (2004) 
purport that the benefit derived from this feature encourages clinicians to continue to 
collect data for the registry. Over time clinicians requested more detailed clinical reports 
which proved the derived benefit of the database as a clinical management tool (Mehta et 
al, 2004). 
 
Information from the UKCFD has been used by the Scottish NHS for budget planning as 
the registry can profile the current and future CF population. This information is purported 
to be useful for planning the location of new clinics, calculating staffing needs and disease 
burden in terms of lung disease. For example by constructing disease severity scores they 
have been able to band patients into ‘cost categories’. The aggregate data has also provided 
valuable information for national audit. Examples include profiling drug usage which has 
highlighted clinics that prescribe potentially toxic drug dosages and inter-clinic 
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comparisons that have identified the prevalence of poor nutritional status of children in CF 
clinics. These serious deviations from optimal care standards were fed back to individual 
clinics for remedial action and stimulated debate among clinicians and research initiatives 
to identify causal factors. Published studies from the database include investigation of 
clinical outcomes in CF disease such as reproductive prognosis (Boyd et al, 2004); risk 
factors for increased morbidity (Sims et al, 2005a); and evaluation of health programs such 
as newborn screening for CF (Sims et al, 2005b, c). 
 
In addition the registry can identify potential subjects for research into the CF gene. Mehta 
and colleagues (2004) suggest the registry already assists clinical trials by assigning 
controls for cluster case control studies and providing information on anticipated patient 
numbers for randomized trials. 
 
2.2.3.2 Diabetes 
Traditionally diabetic registers were used to assess incidence and prevalence of diabetic 
patients in local communities and were derived from aggregating diabetic patient records 
held in general practices (GPs) or by integrating GP registers with lists of patients who 
attended hospital diabetic clinics (Burnett et al, 1992; Morris et al, 1997; Gill et al, 2003). 
More recently some registers have expanded their remit and are used to conduct research. 
For example the ‘Diabetic Audit and Research in Tayside Scotland’ (DARTS) database has 
been used extensively to evaluate health technologies, the effects of the disease on 
morbidity, mortality and identification of risk factors (Evans et al 1999, Evans et al, 2002, 
Evans et al, 2005, Tan et al, 2004). DARTS data has also been combined with other 
validated health databases using cross sectional and cohort methodologies. For example 
Evans et al (1999) combined data from DARTS with the Medicines Monitoring Unit 
(MEMO) dispensed prescribing database to investigate patterns of self monitoring of blood 
glucose concentration in insulin dependent diabetic patients. Another study compared risks 
of cardiovascular outcomes between patients with type 2 diabetes and patients with 
established coronary heart disease using DARTS data in combination with inpatient 
hospital admissions and death certificate data (Evans et al, 2002). 
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2.2.3.3 Hepatitis C 
Another UK chronic disease registry, called the National Hepatitis C Virus (HCV) 
Register, aims to document the natural history of hepatitis C infection in a cohort of UK 
patients (Harris et al, 2000). To date the registry has proved useful in epidemiological and 
evaluative research and as a national audit tool in care provision. For example registry data 
has been used to document the clinical course of hepatitis C virus in the first 10 years 
following infection (Harris et al, 2002) and to describe survival rates and predictors of 
survival (Harris et al, 2006). Brant et al (2005) have used the data to demonstrate the care 
pathways for these patients and evaluate resource utilization. The authors were able to 
compare actual care with national policy recommendations. Findings highlighted 
deviations from recommended patient management and treatment and identified care 
providers not following the recommended care pathways. The authors also profiled the 
usage of antiviral drug treatments, in this cohort, assessed response rates and identified 
factors affecting effectiveness of treatment regimes. 
 
2.2.4 Health Technology Databases 
2.2.4.1 UK Cardiac Surgical Register 
The first UK cardiac surgical register was set up in 1977 with the aim of improving 
standards of care (English et al, 1984). It was the first attempt by any medical speciality in 
Britain to collect national activity and outcome data. It provided the first national 
information on trends in incidence of and mortality from cardiac surgery. The data was 
collected at the level of the ‘cardiac unit’ and all the information was presented in 
completely anonymous aggregate form in the annual report. Individual units and surgeons 
received an annual report. The objective was to enable each surgeon to compare his or her 
performance with the national trends and encourage local introspection and action (Keogh 
et al, 1998). Additionally this data provided the first analysis of regional workloads so 
policy makers were able to plan services and target resources where they were needed. 
 
2.2.4.2 UK Heart Valve Registry 
The establishment of other registries for cardiac surgery followed, including the ‘United 
Kingdom Heart Valve Registry’ (UKHVR), in 1986 (Taylor, 1997). The additional benefit 
of this registry was the ability to provide actuarial survival data for valve replacement 
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surgery as it was linked with the Office for National Statistics (ONS) for the provision of 
mortality data. If any UKHVR patient died the ONS sent a copy of the death certificate to 
the registry which enabled comprehensive and accurate data for early mortality (up to 30 
days post operative) and for longitudinal survival analysis. The UKHVR also provided an 
important regulatory role as it collected the serial number of each implanted valve which 
could be used for monitoring safety and evaluating performance of individual valves. 
 
2.2.4.3 UK National Adult Cardiac Surgical Database 
A major development was the establishment of the UK National Adult Cardiac Surgical 
Database (UKNACSD), in 1994, which ran in parallel with the UK Cardiac Surgical 
Register (Keogh et al, 1998). This database collected an expanded dataset including patient 
specific information on co-morbidity for case-mix analysis to enable comparative audit 
(Keogh et al, 1998; Keogh and Kinsman, 2001; Keogh et al, 2004). The first surgeon 
specific crude unadjusted mortality figures were published in 2004 (Keogh and Kinsman, 
2004). This data was of insufficient quality to compare each surgeon’s performance but it 
could assess safety by identifying any surgeon’s performance that lay outside a predefined 
mortality limit (Keogh et al, 2004). 
 
2.2.4.4 North West of England Regional Cardiac Database 
In contrast the North West of England Regional Cardiac Database managed to use their 
data for comparative audit of surgeon’s post operative mortality (Bridgewater, et al 2003; 
Bridgewater, 2005). These authors were able to use the data to compare death rates 
between individual surgeons following adult cardiac surgery, stratified by risk (low and 
high risk patients). Bridgewater (2005) was able to demonstrate that risk stratified data was 
a good and fair indicator of a surgeon’s performance. This was the first data analysis that 
could be used to monitor a surgeon’s performance and enable patients to make informed 
choices about their cardiac surgery. It was essential to produce good quality risk stratified 
information that had the confidence of surgeons to avoid risk adverse behaviour. For 
example surgeons would avoid operating on high risk patients for fear of bad outcomes, 
which are much more likely in high risk cases. If the analysis of outcomes could not 
adequately adjust for a surgeon’s case mix this could give an unfair assessment of the 
surgeon’s results and adversely affect their performance in the government ‘league tables’ 
(Keogh and Kinsman, 2001; Bridgewater et al, 2003). 
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2.2.4.5 Central Cardiac Audit Database 
Under the national service agreement for coronary heart disease (2000) data collection 
from the UK National Adult Cardiac Surgical Database shifted to the Central Cardiac 
Audit Database (CCAD) in 2003 (Keogh et al, 2004; Keogh and Kinsman, 2004). An 
added value from this move was the ability to track deaths from the ONS. According to 
Keogh and colleagues (2004) this would enable future analysis of factors that influence 
long-term survival in addition to the current focus on early post operative death. 
 
Since the move to CCAD the database has developed further and the data is now risk 
adjusted so that accurate comparisons can be made against national and international 
survival rates as well as between surgeons. Outputs from CCAD are now available for 
review via a public website (Healthcare Commission, 2008). The public can get current 
reliable information about the rates of post operative survival from cardiac surgery for 
individual surgeons and hospitals in the UK. The data has also been used to develop an 
interactive tool for the website which enables patients’ to calculate their predicted survival 
rate post surgery. 
 
Keogh and Kinsman (2004) suggested the current comprehensive dataset would enable 
other performance indicators to be measured including complication rates and length of 
stay. The aim was to move beyond the basic outcome measure of post operative hospital 
mortality rates to better and more sensitive outcomes and quality of practice indicators. For 
instance risk of stroke may be equally or even more important to the patient than risk of 
death following surgery (Keogh and Kinsman, 2004). 
 
2.2.4.6 Intensive Care National Audit & Research Centre Case Mix Programme 
Database 
The Intensive Care National Audit & Research Centre (ICNARC) coordinates a national 
comparative audit of patient outcomes from adult, general critical care units in England, 
Wales and Northern Ireland called the Case Mix Programme (CMP) (Rowan, 1996). Their 
database ‘The Case Mix Programme Database’ (CMPD) has been used extensively for 
research as well as audit purposes. Using the criteria of Raftery et al (2005) the database is 
classified as describing a health technology. Units submitting data receive comparative 
data analysis reports from which they can identify their own unit’s performance compared 
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with all other participating units. Clinicians and managers can also interrogate the CMPD 
directly by submitting requests for analyses to ICNARC (Harrison et al, 2004). 
 
Initial research from the CMPD provided reliable baseline information on the case mix, 
outcome and activity of patients admitted to intensive care units (ICUs) (Harrison et al, 
2004). Other studies looked at outcomes for specific patient groups including the influence 
of patient gender on admission to ICU (Raine et al, 2002), influence of night discharge 
from ICU on patient mortality (Goldfrad and Rowan, 2000), comparative outcome analysis 
of patients admitted with end stage renal failure (Hutchison et al, 2007) and epidemiology 
of severe sepsis in ICUs (Padkin et al, 2001; Padkin et al, 2003). Over time the utility of 
the CMPD has increased as comprehensive data has been collected, year on year, since 
1996 and more ICUs have joined thereby increasing national coverage. This enabled 
examination of yearly trends in the incidence of and mortality from severe sepsis (Harrison 
et al, 2006). 
 
The CMP database has also been used to identify potential ICUs for participation in further 
research studies (Wildman et al, 2007). The study by Wildman and colleagues (2007) is a 
practical example of the versatility of the database and also the potential cost efficiencies if 
this type of data repository is fully exploited. These researchers conducted independent 
research, involving interviews with ICU consultants, and then supplemented the 
information with routinely collected outcome data from the CMPD. 
 
The strength of the CMPD derives from its ability to collect information in an on going and 
systematic fashion and therefore the results reflect what is happening in actual clinical 
practice. Results identify issues for further action or investigation. This follow through is 
required if the database is to be of benefit to patient care. For example it is known that 
ICUs have been very slow to implement the results of clinical trials that have proven 
efficacy in reducing mortality in patients admitted with severe sepsis (Dellinger and 
Vincent, 2005; Harrison et al, 2006). Clinical guidelines and ‘care bundles’ were 
developed for this condition in an effort to implement changes to patient care and 
management. A care bundle is a group of interventions to help clinicians change practice in 
line with evidence based interventions (Dellinger and Vincent, 2005). Harrison and 
colleagues (2006) purport that the results of their study provides essential baseline 
information for future evaluation of the impact of these care bundles on patient outcomes. 
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The CMPD could also be used to test the generalisability of the results of randomized 
controlled trials (RCTs) and to assess the financial implications of introducing new 
treatments (Padkin et al, 2001). An example is the recombinant Human Activated Protein 
C Worldwide Evaluation in Severe Sepsis (PROWESS) trial which assessed the 
effectiveness of this treatment for severe sepsis. Randomized controlled trials are often 
preformed in atypical settings with atypical patients, making it difficult to assess the 
applicability of the results (Padkin et al, 2001). Therefore, even if the evaluated 
intervention provides significant benefit for the patients studied, clinicians have to make 
their own judgment about which patients will benefit, if any, in routine clinical practice. 
The authors suggest that the CMPD could follow-up patients which are prescribed new 
mediciations, such as recombinant Human Activated Protein C, longitudinally after clinical 
trials are completed. This would enable monitoring diffusion of the new drugs and 
assessment of their long-term effectiveness in clinical settings. The advantages of using a 
pre existing system like the CMPD are its wide coverage, high quality, data collection 
systems already exist and participating clinicians are familiar with the database systems 
(Padkin et al, 2001). 
 
2.2.4.7 European Vascular Surgery Registries 
The Nordic countries have had vascular surgery registries for the last 20 years and these 
have been operating on a national basis for the last 10-15 years. Data from the registries 
are utilized extensively for evaluative and epidemiological research and audit including 
national audits, to determine incidence of various vascular surgeries, to assess operative 
risk and incidence of surgical complications, and to compare national surgery outcomes 
with those achieved by randomized controlled trials (Bjorck et al, 1996; Kantonen et al, 
1997a; Kantonen et al, 1998; Kragsterman et al, 2004; Laustsen et al, 2004). For example 
Kragsterman et al (2004) used data from the Swedish Vascular Registry (Swedvasc) to 
audit complication rates after Carotid Endarterectomy (CEA) surgery. Using a combination 
of cohort and case-control designs the authors were able to identify risk factors for serious 
complications (i.e. death and permanent stroke), to quantify the complication rate and 
compare performance of the different types of centres performing CEA surgery. Findings 
showed university hospitals as an independent risk factor for serious post operative 
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complications but not enough information was collected to understand why outcomes were 
worse in this category of hospital. 
 
2.2.4.8 Belgium HU-treated Sickle Cell Disease Registry 
A national registry for hydroxycarbamide (HU) - treated sickle cell disease patients was 
established in Belgium in 1996 under the auspices of the Belgium Society of Hematology 
(Ferster et al, 2001). It was set up to collect prospective longitudinal clinical data on 
children and young adults treated with HU to evaluate the drug’s long-term efficacy and 
toxicity. The HU clinical benefits in adults with severe SCD had been confirmed by a large 
multi-centre RCT in 1995 (Charache et al, 1995) but evidence of the drug’s efficacy in 
children was weak (Ferster et al, 1996; Ferster et al, 2001). Furthermore the treatment’s 
effectiveness and safety in the median and long-term was unknown (Ferster et al, 2001). 
 
Registry findings were published after five and eight years follow-up (Ferster et al, 2001, 
Gulbis et al, 2005). This follow up of patients enabled the everyday clinical use of this 
treatment for sickle patients in Belgium to be profiled. Findings provided an insight into 
some of the problems with long-term therapy such as non-adherence to treatment regime 
and management protocol, long-term effectiveness, reported side effects and therapy 
attrition. In addition American researchers were able to compare outcomes of the Belgium 
cohort with their own to give better insight into the usability and sustainability of HU in 
the median to long-term (Zimmerman et al, 2004). 
 
2.2.4.9 Epidemiologic Registry of Cystic Fibrosis (ERCF) 
This was a European wide multicentre, longitudinal follow-up project of the long-term 
effectiveness and cost effectiveness of the drug ‘dornase alfa’ for cystic fibrosis patients 
(Strobl et al, 2003). A randomized control trial had observed a treatment benefit with up to 
96 weeks of use (Quan et al, 2001) and a Cochrane review showed that the drug seemed to 
be effective for up to six months (Jones et al, 2003). Longer term follow-up was required 
to undertake an economic evaluation of usage. Clinically rich data on the health technology 
and on patient health states were collected to make longitudinal comparisons between 
patients taking the drug and those not taking it. 
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2.2.5 Cancer registries 
2.2.5.1 UK Regional and National cancer registries 
In Great Britain national and regional cancer registries are the most prolific types of 
databases in operation, with 11 general and 14 specialized cancer databases included in 
DoCDat (Black et al, 2004). Cancer registration in England is conducted by nine regional 
registries and Scotland, Wales and Northern Ireland have their own registries (Micheli et 
al, 2003). Many of these regional registries were established in the 1950’s and have been 
supplying data to the Office of National Statistics (previously called the Office of 
Population and Census Surveys (OPCS)) since the early 1960’s, for the provision of 
national cancer statistics (Department of Health, 2008). Cancer registries are viewed as 
essential to the implementation and monitoring of key national initiatives, such as the NHS 
Cancer Plan (2000) and the more recent Cancer Reform Strategy (2007), which aim to 
improve the quality of care and survival for cancer patients. The aim is to enable timely, 
comparable, high-quality data for comparative audit and research. Trend data has shown 
the progress in cancer survival over the last decade so that the government is able to 
measure if reduction in mortality is in line with policy targets (Department of Health, 
2007a). Other findings show poorer outcomes for some groups of patients, suggesting 
inequalities in care and services. The results have enabled the Cancer Reform Strategy 
(2007) to target initiatives, funding and services where they are most needed to improve 
outcomes for patients (Department of Health, 2007a). Registry data has also been linked 
with other NHS services to evaluate their effectiveness. It is purported that feedback on 
service quality to service providers of the national breast and cervical screening 
programmes has resulted in year on year improvement in services (Department of Health, 
2007a). Cancer registries assist external research by supplying patient names to bona fide 
researchers for projects investigating causes of (and outcomes from) specific cancers. 
 
There is evidence that regional registries can utilize their own data to improve patient care 
and outcomes locally. For instance Silcocks et al (1999) used data from a UK regional 
prostate cancer registry to audit clinical care and investigate the possibility of identifying 
surrogate variables to assess quality of care. The results identified deficiencies in clinical 
practice and made recommendations for standardization and quality assurance in the 
content of pathology reports and for standard treatment protocols to assist with recording 
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and comparison of treatments. They also found that only 2% of patients were recruited to 
RCTs. 
 
In addition the majority of UK cancer registries contribute data to international 
publications and European studies such as EUROCARE. 
 
2.2.5.2 EUROCARE 
The European Cancer Registries (EUROCARE) co-operative project was set up in 1989 to 
measure and explain international differences in cancer survival in Europe (Coleman et al, 
2003). It is the largest population- based cancer registry study on survival in European 
cancer patients (Micheli et al, 2003). The initial project was developed further with the 
EUROCARE 2 study, then EUROCARE 3 and recently the results of EUROCARE 4 have 
been published (Berrino et al, 1998; Coleman et al, 2003; Berrino et al, 2007). By 2003 
this project had led to over 100 published papers exploring survival patterns for individual 
cancers (Coleman et al, 2003). An important outcome of EUROCARE is the ability to 
measure differences in survival from cancer over time and between and within European 
countries. (Berrino et al, 1998; Coleman et al, 2003; Richards, 2007). These results 
continue to be used as a reference point for individual countries to compare their relative 
survival rates for specific cancer sites (Angell-Andersen et al, 2003; Berrino et al, 2007; 
Department of Health, 2007a; Richards, 2007). 
 
The sustained efforts to improve the quality and range of data collected by the registries 
which populate the EUROCARE have enhanced the utility of this database. Analysis of 
data has progressed from identification of a problem to, in many cases, understanding why 
the problem occurred so that corrective action can be taken. For example the researchers 
were able to use the data in conjunction with macro-economic variables to assess the 
relationship between better cancer outcomes and each country’s wealth and level of health 
expenditure (Micheli et al, 2003). In addition ‘high resolution studies’ were conducted on 
subsets of patients to try and explain inter country differences in survival (Gatta et al, 
2000; Sant et al, 2003; Sant et al, 2007). This was achieved by gathering more detailed 
data on diagnostic and treatment procedures from a representative sample of incidence 
cases in areas where the analysis identified extremes in survival rates. 
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EUROCARE results were one of the major influences in shaping UK national policies and 
practices in cancer care subsequent to the Calman- Hine Report (1995)( Department of 
Health, 2007a; Richards, 2007). Results showed that while UK survival rates for most 
cancers were improving over time they persistently lagged behind other comparable 
developed European countries (Coleman et al, 2003, Micheli et al 2003). The high-
resolution studies indicated that UK outcomes were comparatively worse mainly due to 
patients being diagnosed at a more advanced stage of the disease. These results had a major 
influence on the development of the English NHS Cancer Plan (2000) (Richards, 2007). 
For example findings were able to inform policymakers that service changes were required 
to enable earlier cancer diagnosis. The latest results, from EUROCARE 4, were used as an 
indicator of NHS performance in cancer care and treatment and to measure the 
effectiveness of the NHS cancer plan reforms (Berrino et al, 2007; Department of Health, 
2007a; Richards, 2007; Verdecchia et al, 2007). 
 
EUROCARE has continued to be progressive, innovative and increasingly collaborative. 
For instance EUROCARE survival data has been compared with survival data from the 
cancer registries covered by the Surveillance, Epidemiology, and End Results (SEER) 
databases of the United States (Gatta et al, 2003; Verdecchia et al, 2007; Sant et al 2008). 
EUROCARE also collaborates with other cancer registries worldwide to expand 
comparisons to other populations in developed countries (the CONCORD project) 
(Berrino, 2003; Coleman et al, 2008). This project has enabled direct comparison of cancer 
survival between high-income and low-income countries and results may act as a stimulus 
for change. Coleman and colleagues (2008) suggest that these findings should eventually 
facilitate joint assessment of international trends in incidence, survival and mortality as 
indicators of cancer control. 
 
The longevity of the cancer registry datasets has enabled statistical methods to be 
developed and tested for making predictions and estimations. For example Brenner et al 
(2002) used the long-term series of the Finnish cancer registry to test the accuracy of a new 
method of predicting long-term survival called period-analysis. The method was applied to 
the EUROCARE-4 series to enable more up-to-date survival information to be reported 
then was previously available (Richards, 2007). The improved timeliness of the data made 
the findings more relevant for assessing the performance of current healthcare services and 
practices. Similarly cardiac datasets have enabled risk measurement instruments, such as 
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Parsonnet and EuroSCORE, to be developed and tested for accurate prediction of cardiac 
surgery outcome (Keogh and Kinsman, 2001). 
 
2.2.5.3 FinProg Breast Cancer Series 
Lundin et al (2003) report on an interactive web based decision support system that was 
developed to generate survival estimates, in real time, using existing cancer survival data. 
This case-match survival estimation system was applied to the FinProg breast cancer 
dataset of women diagnosed with breast cancer in Finland in 1991-2. This system allows 
clinicians to estimate survival based on actual data for the entire available follow-up 
period, in this case 10 years, and not just a single time point estimate. A clinician can 
obtain a prediction of survival for a new patient by matching her disease profile to that of 
all previous patients with the same profile whose outcome is known. The system can be 
applied to any clinical database that holds data on patient characteristics that affect 
outcome and time to event information. These techniques can promote patient centred care 
and enhance shared clinical decision making between clinician and patient (Black, 2003a). 
It is also purported to increase the accessibility of the anonymised datasets to clinicians and 
researchers creating a climate of openness and sharing. However the robustness and 
accuracy of the estimates depends on the quality of the underlying data set (Lundin et al, 
2003). Secondly clinical care changes over time therefore the data would need to be more 
contemporary to give an accurate prediction of survival (Black, 2003a). 
 
2.3 Legal and ethical perspectives 
Important issues relating to data confidentiality, security and consent have evolved with 
the increasing use of databases for managing patient care, audit and research. Custodians 
are obliged to ensure patient privacy and respect without jeopardising the methodological 
integrity of research and audit derived from the data (Al-Shahi and Warlow, 2000; Black, 
2003b; Fraser, 2003; Lowrance, 2003; Willison, 2003). In the first instance data security 
and patient confidentiality procedures are required for the physical processes of collection, 
transmission and storage of personal data. Then additional confidentiality measures are 
required to use it for research and audit. Finally there are the ethical, legal and practical 
implications of ensuring that patients know about and have consented to the secondary use 
of their health information for these purposes. 
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2.3.1 Patient data storage and use 
Health databases used for secondary research have two interrelated functions (Lowrance, 
2003). They receive, store and safeguard data and they are also the providers of data for 
research and audit to internal and/or external researchers. Lowrance (2003) suggests that 
‘stewardship’ adequately describes the responsibility of the custodians of a health database 
as it infers the notion of judicious protecting and sharing. In the UK the collection, storage 
and processing of identifiable patient information is governed by The Data Protection Act 
1998 which came into force on 1 March 2000. The purpose, content and length of storage 
of all personal data must be justified by all agencies holding personal data and the 
confidentiality of data held is paramount. The guiding principle is that if an item of 
personal data is not essential to the purpose then it should not be held. 
 
2.3.2 Patient identifiers 
A requirement of any longitudinal cohort study is the ability to link participant’s data over 
time. This facilitates completeness of recruitment; avoids duplicate entries; enables follow-
up; and analysis of trends over time (Black, 2003b). A range of procedures are used by 
registries to enable longitudinal linkage while maintaining patient privacy. In the UK 
Cystic Fibrosis Database model the patient information is anonymised before it is stored in 
the database (Mehta et al, 2004). The computer generates a unique personal identification 
number (PIN) for each new patient registered which cannot be reverse-engineered. This 
PIN is then used as the identifier for all data entered into the database concerning that 
patient. This serves to maintain patient privacy and at the same time tags all the patient’s 
records. Paper forms identifying patients are kept securely in a locked room centrally. 
Similarly national and regional cancer registries send datasets with an anonymous PIN for 
each case to EUROCARE. In addition the day of the month is removed from all dates 
attached to patient information which improves confidentiality without compromising the 
utility of the data (Berrino et al, 1998). Another example of compliance with patient 
privacy regulation is the method employed by the Finnish Vascular registry (Finnvasc). In 
this national registry the patient identification variables are permitted in the local site 
registries but removed prior to mailing to the central registry (Kantonen et al, 1997b). 
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However, clinical registries are increasingly tapping into existing computerized data 
repositories to source new cases and to improve the completeness of data collection and 
follow-up. Therefore it is vital to have patient identifiers that are able to track patients 
across multiple databases as well as longitudinally. The focus has changed to finding 
methods for ensuring patient data is held securely and confidentiality is maintained without 
total anonymisation. For example in Denmark every citizen has a unique identification 
number, which encodes sex and date of birth (Pedersen et al, 2002). Norwegian cancer 
registries also use a national personal identification number which makes record linkage 
easier, less resource intensive and avoids duplicate registrations (Harvie et al, 1996). In the 
DARTS database, cases are identified by a unique identifying number, called the 
‘community health number’, which is allocated to every patient who is registered with a 
GP in Scotland (Morris et al, 1997). 
 
Databases also need to collect patient identifiers such as age, gender and postcode to 
ensure comparisons of patient outcomes are meaningful and for investigation of the 
influences of socioeconomic and geographic factors on outcomes (Berrino et al, 1998; 
Black, 2003b). For instance EUROCARE reports relative survival rates, which requires the 
patient’s age, gender and geographical location to conduct this analysis. 
 
2.3.3 Requirement for patient consent 
Under the Data Protection Act 1998 all research involving patients requires the patient to 
give informed consent. However researchers can apply for exemption to use patient 
identifiable information for research without consent under section 60 of the Health and 
Social Care Act 2001. This provision is a temporary measure until anonymisation or 
consent can be put in place (Goldblatt, 2006). Most patients are willing to allow personal 
and clinical information from their medical records to be used for research, audit and 
health surveillance (Willison et al, 2003; McKinney et al, 2005; Barrett et al, 2006; Tate et 
al, 2006) but the limited evidence available indicates that they prefer to be asked for 
consent either verbally or in writing (Willison et al, 2003). 
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2.3.4 Consent process 
In practice the process of gaining consent presents major obstacles for some observational 
studies and clinical registries/databases. McKinney and colleagues (2005) had only partial 
success at obtaining individual signed consent in seven paediatric intensive care units 
(PICUs) to share patient identifiable information with an externally located national 
clinical audit database. Lack of staff resources led to one unit not participating and another 
not fully implementing the protocol. The overall consent rate was only 43% and ranged 
from 9% to 84% between units. Consent rates were significantly better for children who 
were more severely ill on admission and for hospital stays of six days or more. Children 
aged 12-16 yrs were not consented, probably due to confusion among staff over the 
separate consent documentation required for these patients. Most patient consents were 
taken by staff nurses, which makes sense as they have the most prolonged and repeated 
contact with patients and carers in ICU. 
 
Tu et al (2004) attempted to obtain written consent from consecutive patients admitted to 
stroke units in order to enrol them in the prospective Registry of the Canadian Stroke 
Network. The overall consent rate was 39% in Phase 1 which improved to 51% in phase 2, 
following extra staff training and “easing” of their workload. Again participation rates 
varied from an average of 72% in the best units to 17% in the worst. The consents were 
obtained by research co-ordinators rather than ward staff. The main obstacle was access to 
patients. Access issues included patients dying or having left hospital before being 
approached for consent or potential participants not being admitted at all. Additionally 
patient access was deterred due to the logistics involved in arranging interviews at a 
convenient time for the patient during their hospital stay. 
 
Al-Shabi and colleagues (2005) also had major problems accessing patients for consent to 
include them in a population based observational research study of intracranial vascular 
malformations. GPs and hospital consultants refused access to 30% of potential 
participants. Reasons for refusal were patient deceased, cognitively impaired or anxious 
about their diagnosis. In some cases the doctor did not respond to the request or did not 
give a reason for refusal. 
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Similarly Busby et al (2005) found that consent rates varied enormously between eight 
European congenital anomaly clinical registries that used opt-in informed consent 
procedures. One registry had 18% missing cases and another estimated a 4% consent rate 
in the year after implementation of the opt-in consent scheme. Another registry, which 
requested consent by post, estimated between 15-20% loss of cases due to non response 
and another was not fully operational due to low notification levels caused by the 
requirement for consent. Patient refusal was reported as less than 1% by all these registries. 
However, this group of registries also reported difficulty in persuading busy clinicians to 
take on the extra workload of gaining consent. In contrast the three other congenital 
anomaly registries surveyed did not appear to have any problems with gaining patient 
consent. In one registry consent was obtained at maternity booking to enable research staff 
to examine all newborns for abnormalities after birth; they reported only two refusals since 
1990. Another was a voluntary association of clinicians which obtained verbal consent for 
registration of data from parents. The third registry used information from interviews 
conducted with parents, of children with congenital anomalies (and controls), shortly after 
birth. 
 
2.3.5 Consent bias in population health surveys 
If patients are excluded because they have not consented selection bias may be introduced 
into the analysis and outcomes observed in observational research (Tu et al, 2004 Al Shahi 
et al, 2005; Tate et al, 2006). Most of the existing literature on consent bias has focused on 
large health surveys that involve data collection either by post or by interview with the 
participant. 
 
In a national cohort study 92% of mothers gave consent for linkage of their child’s health 
records with survey data (Tate et al, 2006). However the group that did not consent 
differed from those that consented in socioeconomic, educational, ethnicity and country of 
residence. Tate et al suggest that these sources of non-consent bias should be taken into 
account when analysing linked data from socially and ethnically mixed populations. Dunn 
et al (2004) analyzed consent patterns from seven UK general practice population surveys. 
They found that consent by patients to follow-up and GP medical records review were 
similar with males, younger people (under 50 yrs) and patients reporting the symptom 
under investigation being more likely to give consent. Consequently these groups may be 
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overrepresented in these types of studies. A similar study conducted by Woolf et al (2000) 
of family practitioners, in the USA, yielded some similar evidence but also dissimilar 
findings. They reported that older age, males and lower functional status were significant 
predictors of consent. 
 
2.3.6 Consent bias in clinical cohort studies and disease registries 
Non participation in clinical registries appears to alter the case mix of patients studied 
compared to the true patient population. Al-Shahi et al (2005) conducted a prospective 
follow-up study of a Scottish cohort of adults diagnosed with intracranial vascular 
malformation on or after 1 January 1999. When a newly diagnosed patient was notified to 
the study, the team endeavoured to gain patient consent for participation in the study via 
their GP or hospital consultant. The authors did not find any statistically significant 
differences between those who consented or not in terms of demographics (age, gender) 
and socioeconomic status but patients who gave consent to participate had a different and 
less severe disease profile to non-consenters at first presentation (with the illness). 
Consenters were significantly more likely to be alive and independent at presentation. 
These factors significantly changed the results in some important clinical outcomes 
measured. For example analysis of the whole cohort suggested that presentation with an 
intracranial haemorrhage conferred a higher risk of subsequent haemorrhage but this 
association disappeared when the analysis was restricted to consenters only. This 
prognostic variable, which partially influences treatment decisions, came up with different 
inferences depending on how the cohort was analysed. Some of the differences observed 
between non consenters and consenters were due to exclusion from the cohort of deceased 
patients. In England, , it is possible to include deceased patients in medical observational 
research without their consent (General Medical Council, 2004a,b). Including deceased 
patients, in this study, would have reduced selection bias and strengthened the 
methodological rigor in this instance. 
 
As a consequence of the low and variable consent rate the patients in a study by Tu et al 
(2004) were not representative of the typical patient with stroke at centres included in the 
study. In general those who participated were younger, more likely to be alert at admission 
and more likely to be alive at discharge and their preferred language was more likely to be 
English or French. Again, excluding patients who died skewed the data significantly as the 
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in-hospital mortality rate was much lower among patients who enrolled than those who 
were not enrolled (6.9% vs 21.7%). Selection bias persisted in hospitals with high 
participation rates and well as those with low participation rates. Tu et al (2004) reported 
that the data was similar to that collected by clinical trials. For example certain 
observational inferences could be made about risk factors and outcomes but they were 
uncertain about the generalisability of the results to the general population with stroke. The 
data was of limited use for monitoring and planning health care delivery. 
 
In contrast more severely ill ICU patients would be over represented and teenagers 
underrepresented in the clinical database study by McKinney et al (2005), due to the 
consent process. The authors suggest that even the 16% level of incompleteness from the 
best performing unit was too high and it would compromise the database’s ability to act as 
an instrument for monitoring care effectiveness and clinical governance. 
 
2.4 Validation of clinical databases/ registries 
2.4.1 Origins of registry data 
Clinical registries and databases are frequently populated with secondary data from 
medical records. Medical record review refers to any study that uses pre-recorded, patient-
focused data as the primary source of information to answer the research question (Worster 
and Haines, 2004). Clinical registries generally use a multiplicity of information sources to 
populate the patient record including patient notes, clinical and administrative databases, 
diagnostic test reports, GP records, and Accident and Emergency notes. 
 
The traditional method is for patient information to be abstracted from the patient records 
by hand and entered into the registry (e.g. the UK Cystic Fibrosis Registry). Modern and 
well funded registries often use computer linkage as the main system for data abstraction 
(DARTS database) or a combination of both methods such as employed by the UK cancer 
registries. Main sources of information for cancer registries are pathology databases and 
the NHS Patient Administration System (PAS). The hospital PAS records all patient 
discharges in electronic format using the World Health Organisation (WHO) International 
Classification of Diseases diagnostic codes (ICD). 
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2.4.2 Validation of registry data –definitions and scope 
Information in medical records is recorded at the point of care and for the purpose of 
patient care not research, audit or health surveillance. There is generally no protocol or 
systematic process for giving care or recording the process therefore the information is 
recorded in a casual manner by multiple providers and observers (Lowenstein, 2005). As a 
consequence of using these secondary data sources registries are faced with three potential 
problems which threaten the quality of their data irrespective of the methods used for 
abstraction. Firstly is the information valid for abstraction i.e. is the medical record a valid 
description of the patient episode of care? Secondly is the data abstraction process reliable? 
Finally is the register complete? The following sections will explore the problems with 
accuracy and completeness of registry data, how these issues can be addressed and their 
effect on the utility of database information. 
 
2.4.3 Reliability of data abstraction 
Data accuracy can be assessed by measuring the reliability or reproducibility of the data 
(internal validity). Studies identified for this review either measured the reliability of the 
medical record extraction process prospectively as part of the methodological rigor of 
conducting the study (Eder et al, 2005) or to ascertain, in retrospect, the reliability of 
registry data derived from medical records (Every et al, 1999; Fine et al, 2003; Strobl et al 
2003). Findings clarify the factors and types of data elements that influence the level of 
reliability achievable, the instruments and procedures that improve reliability and the 
impact of data reliability on the utility of a database. 
 
Reliability of data abstracted from medical notes is affected by the type of information 
abstracted (Eder et al, 2005). These authors reported that if variables were specific and 
objective in nature such as demographics, documentation of procedures and results, they 
were abstracted with a high degree of reliability. However clinical data elements that were 
open to subjective descriptions by clinicians and patients were found to have lower inter-
rater agreements between abstractors. For example the patient self-report of symptoms and 
the variety of terminology used by clinicians to describe clinical examination findings 
made it difficult for the abstractors to decipher and record these findings. Secondly the 
clinician’s diagnosis/ suspicion of cancer proved difficult to determine from the 
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documentation. A major source of inter-rater variance was the inconsistency in information 
obtained from more than one source within the record. Also there was inconsistency in 
where relevant data was documented because it was recorded by a variety of personnel 
during different patient visits, sometimes while the patient attended for a separate health 
problem. 
 
Assignment of a ‘final outcome’ was the most problematic data item because this required 
the abstractors to make a subjective decision about whether the patient care pathway 
followed recommended guidelines. This variable was susceptible to information bias 
because inter-rater variance was sometimes linked to over interpretation of information 
actually recorded. This judgement should have been based entirely on the information in 
the medical record but the abstractors were experienced clinical staff and they found it 
difficult not to substitute their own clinical assumptions when confronted with missing or 
inaccurate data. 
 
These researchers imposed a continual cycle of quality improvements which resulted in 
sustained high-quality information retrieval methods among multiple data abstractors over 
multiple sites (Eder et al, 2005). For instance an information-priority algorithm was created 
which listed the hierarchy of data sources that should be used for abstracting data elements. 
The researchers also developed a glossary that contained terms that were to be considered 
equivalent definitions of a single variable (examination outcome) from the qualitative 
descriptions found in the notes to describe clinical findings. This helped promote 
consistency in data coding of qualitative terms and provided standardisation to the medical 
record abstraction process. Arts et al (2003) also reported a significant improvement in 
overall accuracy of data abstraction following clinician training in data definitions and data 
extraction guidelines. 
 
2.4.3.1 Internal validity examples 
Every et al (1999) compared the internal validity of two large US clinical databases – the 
National Registry of Myocardial Infarction Two (NRMI 2) and the Cooperative 
Cardiovascular Project (CCP), which collect data on Acute Myocardial Infarction (AMI) 
by retrospective chart abstraction. Process of care variables and medication showed high 
agreement (kappa values = 0.75-0.97). Some past medical history variables were under 
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reported in the NRMI 2 database which would under identify co-morbidities if the results 
were generalized to population level. In addition identification of adverse events that 
occurred during hospitalization such as stroke and shock showed lower agreement (kappa 
= 0.57 and 0.63 respectively) while the clinical outcome variable ‘reinfarction’ had the 
lowest agreement (kappa 0.21). The authors suggest that these higher levels of 
disagreement may be due to differences in the definitions of these variables used by each 
database; clinicians may also use different definitions for these events which could lead to 
variation in chart documentation. Therefore these outcomes must be viewed with caution. 
 
Similarly Topp and colleagues (1997) reported that the reliability of data elements in the 
Danish Cerebral Palsy Register varied according to definition and significance of the 
specific variable. For instance variables with unambiguous definitions such as maternal 
diabetes, caesarean section and male sex were very reliable. However there was poor 
agreement between the medical record and registry entries for gestational age due to a 
systematic error in how the variable was defined. It was measured as one week higher in 
the registry then calculated from the raw data in the medical records. This occurred 
because of confusion among clinical staff over the correct measurement method. The 
registry relied on this information being reported in the discharge letters therefore this 
systematic error could not be avoided. The significance of the error depended on the 
accuracy required; if one week variance was allowed then 84% were registered correctly 
and if two weeks variance was acceptable then 93% were correct. 
 
In general variables involving calculations appear to be problematic (Arts et al, 2003). Arts 
and colleagues reported that, even after training, variables such as body temperature and 
mean alveolar-arterial oxygen difference were frequently incorrect. Body temperature was 
often incorrect because clinicians forgot to add 10C if measured from the groin. Incorrect 
selection of blood gas samples resulted in inaccuracy in all data calculated using this 
variable. The main cause of this problem was non adherence to data definitions. 
 
Laustsen et al (2004) assessed the reliability of data in the Danish National Vascular 
Registry by comparing re-abstracted data with the originals sent to the registry. Data forms 
were re-completed from the patient’s medical notes by each site and also by an 
independent member of the registry board. There was no difference in reproducibility 
between the three data sets for data on type of operation and indication for surgery/ 
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diagnosis. Reproducibility of coding for complications and risk factors was poorer and 
varied considerably between sites. For example in one department it was the primary data 
set that was poorly coded and in another department it was the re-coded data set that was 
substandard. Lack of improvement in reproducibility between the data sets from refilled 
forms and the independent observer was thought to result from weakness in the 
classification of the parameters under study. 
 
Kantonen et al (1997b) assessed the reliability of vascular surgery cases in the Finnvasc 
registry by requesting the surgeon responsible for data collection in each centre to resubmit 
the registry data for a sample of patients. Intra-rater reliability was measured by comparing 
the refilled forms with the corresponding primary data in the registry. An overall 
agreement rate of 93% was achieved, similar to that achieved by a previous study 
undertaken 13 years earlier. However, only 38% of all forms had no differences. The 
variables differing most were risk factors, with 15% differences, and operation code (10% 
differences). The problem with the operation codes were thought to be due to the surgeons’ 
lack of familiarity with these codes as they were developed for administrative systems and 
clinical staff would not use them routinely. 
 
In the follow-up registry form the surgeon states whether the treatment had resulted in an 
improvement or not. Kantonen et al (1997b) suggest that this could result in biased data as 
the objective measures used by the surgeons to assess outcome could be misleading and 
they were not available for all types of vascular surgery. Also follow-up was undertaken at 
one month which was too short a period to judge the success of some procedures. The 
authors recommended extending follow-up to one year to improve the evaluation of 
success/ failure rate. Linkage of the registry for national vital statistics was proposed for 
improved appraisal of long-term survival analysis. 
 
Pedersen et al (2004) found that the reliability of the data in the Danish Hip Arthroplasty 
Registry (DHR) was dependent on the type of variable and the ability of the data collection 
form to capture relevant and complete data. The overall positive predictive value (PPV) of 
registered diagnoses was 85% but the PPV varied between the different diagnoses. For 
example a low PPV (30%) was found for fresh fracture of the proximal femur due to 
confusion over the distinction of this diagnosis with another diagnosis. The authors 
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suggested this occurred because various definitions exist in clinical practice for this 
diagnosis, leading to diagnostic misclassification. 
 
The follow-up form did not correctly identify patients with and without postoperative 
complications. Post operative complications registered were confirmed in only two-thirds 
of the patients reviewed and specificity of postoperative complications was only 0.3. In 
addition, a variety of postoperative complications were identified in the medical records 
that were not registered with the DHR. 
 
Strobl et al (2003) assessed the accuracy of data entered into the Epidemiologic Registry of 
Cystic Fibrosis against original data in the medical record. The rate of disagreement 
between the database and medical record was generally low (range 0.4% - 3.7%) due to the 
routine automatic data checking procedures carried out on the database. Similar to other 
study results demographic data, test results and treatment data were very reliable. However 
variables used to measure outcomes were problematic. For example episodes of pulmonary 
exacerbation were difficult to identify and also verify as there was poor congruence 
between the different sources of information on exacerbations. Interviews revealed that 
sites were not consistent in how they interpreted some data recording rules. This was 
particularly relevant for lung function test, an important outcome measure. There was 
inconsistency between sites as to whether a good or poor lung function test result was 
selected for reporting to the registry, which could cause systematic differences between 
centres. 
 
An independent assessment of the UK National Adult Cardiac Surgical Database, by Fine 
et al (2003), found that the essential variables required to adjust for case mix were not 
reliable. Sampling of the registry data against re-abstracted data from medical notes found 
that mean reliability of all the centres studied was good (k= 0.67) but for each individual 
centre the average reliability score was only moderate, at 0.44. After a five month 
intervention of monitoring, validation and feedback to centres a prospective re-sampling of 
the database showed only slight improvement in reliability (0.53 vs 0.44). The variables 
targeted for validation were required to assign a preoperative severity (risk) score using the 
Parsonnet score and the EuroSCORE (European System for Cardiac Operative Risk 
Evaluation). The Parsonnet risk scores and EuroSCORE calculated from the original and 
re-abstracted data did not differ significantly. The authors did not discuss if the minimal 
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improvement in scores occurred because there was little change in data reliability. 
However, it is generally recommended that researchers strive for a minimum level of 
interobserver agreement of 60% beyond chance, a kappa value of 0.6 or greater (Worster 
and Haines, 2004). 
 
A small but significant difference in the Parsonnet risk score recalculated from the original 
data compared with the score the centres submitted was observed. After the intervention, to 
improve data quality, the submitted scores were more reliable in the prospective phase. 
However the reliability of the calculated EuroSCORE remained unchanged throughout 
because coding of some of the data elements required for this calculation remained 
problematic. Similarly Arts et al (2003) found no improvement in clinicians’ accuracy in 
calculating APACHE 11 (Acute Physiology and Chronic Health Evaluation) severity of 
illness scores after training. This was attributed to unreliability and incompleteness in the 
variables used for the calculations, even after training. 
 
2.4.3.2 Quality of data in cancer registries 
Brewster et al (2002) found that the overall quality of cancer registration data in the 
Scottish Cancer Registry was high. For instance reliability was generally high for 
demographic, diagnostic and fact of treatment data. However discrepancies in grade of 
differentiation, staging variables and oestrogen receptor status ranged from 1.5% to 20% 
between the registry and the re-abstracted data. This made the database less reliable for 
more specific information needed to assess case-mix. Major inaccuracies in cancer grade 
and staging is a frequently reported problem for cancer registries and is due to this 
information being poorly documented and/or missing in medical notes (Schouten et al, 
1997; Berrino et al, 1998; Silcocks et al,1999). Schouten et al (1997) reported that many of 
the disagreements in staging cancer were caused by missing and inconclusive information 
or from discovering additional investigative results from another source. Brewster et al 
(2002) recommended collecting the data prospectively on structured proformas in the 
context of clinical audit, because accurate recording of this information is essential for 
clinical care. 
 
Phekoo et al (2002) compared a specialist haematological malignancy database against 
data from the same area covered by the Thames Cancer Registry (ThCR). Discordant 
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diagnoses were recorded in 20% of the cases that were common to both databases. This 
was due to certain disease types being misclassified by the Thames Cancer Registry and 
some rare disorders being underreported. This seemed to be partially due to problems with 
assigning the correct ICD code for the disease. It was thought that the revised ICD codes 
for oncology (ICD-O) would enable more accurate and specific diagnosis as it had more 
refined coding for haematological malignancies. 
 
In addition haematological malignancies are complex to identify and a lack of diagnostic 
information/ investigations led to some cases being assigned an ‘unspecific diagnostic 
code’ or being completely missed. Diagnosis involves several investigations which are 
difficult to collate as they are performed in different locations and may not be recorded in 
the hospital’s pathology system. Also some diagnoses may be made by clinicians without 
undertaking all the relevant tests such as histopathology (Phekoo et al, 2002; Berrino, 
2003). Following the study a partnership was formed between both haematological 
malignancy registers. It was thought that actively involving the haematologists (the disease 
specialists) in collecting and validating data should enhance case ascertainment and 
diagnostic accuracy. 
 
Middleton and colleagues (2000) examined the accuracy of cancer registrations from an 
un-corroborated subset of hospital Patient Administration System data in the Northern 
Ireland Cancer Registry (NICR). This data received a validation check against patients’ 
medical records. Demographic data accuracy was high. However diagnostic data was less 
accurate and resulted in 19% of the PAS only notifications being excluded from the 
registry, which amounted to 7.5% of the total cases in the database. Errors included 7.4% 
of patients incorrectly coded as being diagnosed with cancer and a further 4% had tumour 
behaviour incorrectly coded as fully malignant instead of benign, in-situ or uncertain 
behaviour. This error could be partially explained by the fact that these patients had been 
investigated for ‘suspected’ cancer. Almost a third had some inaccuracy in coding tumour 
site. For instance about 27% of cases had a completely different system or organ recorded 
as tumour site in the case notes compared to that entered into PAS. Common errors 
occurred for sites that were anatomically close. Also the majority of cases that had been 
assigned a non specific cancer site in PAS were recoded to a specific cancer site following 
the notes review. In addition about 17% were prevalent cases. 
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Most of the errors were false positives therefore the effect of all errors would have been to 
inflate the overall incidence figures. Sub analysis of the incidence rates would have 
produced grossly inaccurate figures for some forms of tumour, such as cervical, which 
would have been inflated by almost 50%. This would have impacted adversely on the 
quality assurance assessment of the cervical screening program. 
 
2.4.3.3. Improving quality of cancer registries 
Middleton et al (2000) suggest that many of the errors in the PAS data, used to populate 
the NICR, could be reduced with better training for clinical coders and improving the 
quality of clinical information recorded by clinicians in medical notes. They concurred that 
PAS data is a valuable source of case identification but there would be an on-going need to 
undertake a target medical notes review of all uncorroborated PAS data supplied to the 
registry. According to Middleton and colleagues (2000) the best long-term solution is the 
development of clinical information systems in routine patient care with mandatory high 
quality data. 
 
Harvie and colleagues (1996) reported that the data in the Norwegian prostate cancer 
registry was very reliable. Six percent of the patients’ records sampled had one error per 
record. There were no errors in recording of demographic data. The majority of the errors 
were in coding of metastases and the ‘basis of diagnosis’ because several sources of data 
had to be reviewed to decide the correct code. The excellent reliability of the data was 
attributed to the high number of cases confirmed by histology (over 95%) and the multiple 
sources of information received on each case for consistency checks (average number of 
reports per patient was more than three). In addition, all coding was undertaken at the 
central registry by trained coders. The authors purport that these measures ensure a high 
level of internal validity and prevents bias. 
 
In Norway the organizational structure and legal obligations appear to ensure that cancer 
registry data is reliable and complete. Reporting of cancer cases to the registry is 
compulsory and since 1983 Norwegian registries have an explicit legal obligation to assess 
the quality of their own registrations. 
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2.4.4. Timing of data - is it important? 
Brewster et al (2002) found a 24.3% inconsistency in recording of diagnostic date but, in 
most cases, the re-abstracted incidence date was within six weeks of the registered date. 
Therefore this level of imprecision in diagnostic date would have minimal effect on 
incidence information. 
 
Accurate timing of outcome events is important in longitudinal data collection because 
without timing of data it may be difficult to distinguish between discrete episodes (Strobl 
et al, 2003). Due to imprecision in recorded medical information these researchers found it 
difficult to quantify the number of discrete pulmonary exacerbations events the patient 
experienced. This was due to the fact that fields from different files had to be cross-
referenced and assumptions made about realistic time gaps between distinct episodes. 
 
Some authors have reported a problem with data collectors and clinical staff selecting 
values of physiology variables, such as blood pressure, from outside the specified time 
frame (Chen et al, 1999; Arts et al, 2003). This led to poor data reliability and inaccurate 
calculations of severity of illness scores and probability of death predictions. These errors 
were caused by lack of staff training and non adherence to data definitions and data 
abstraction rules (Chen et al, 1999; Arts et al, 2003). 
 
In the quality assurance study by Brewster et al (2002) the date of first treatment for each 
modality was unreliable with between 15 to 25% disagreement between the registry and re-
abstracted data. These discrepancies happened because different information was available 
to the person making the original registration than to the person re-abstracting the data at a 
later date. Silcocks et al (1999) also reported this problem where relevant patient 
information becomes available after the case has been submitted to the registry. 
 
2.4.5. Completeness in clinical databases and registries 
Completeness is measured in terms of exhaustiveness of case ascertainment, completeness 
of coverage of the geographical area covered by the clinical database/ registry and 
completeness of variables collected (Black and Payne, 2003). Completeness of registration 
or case ascertainment is defined as the extent to which all the incident cases (cancers) 
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occurring in a target population are included in the registry’s database (Parkin et al (1994) 
cited in Lang et al, 2003). 
 
The research reviewed shows how to assess the completeness of a database, identify the 
critical issues in bolstering completeness and discusses the consequences of 
incompleteness on the validity of results derived from the data in the database. 
 
2.4.6 Completeness of follow-up 
The independent assessment of the UK National Adult Cardiac Surgical Database 
(UKNACSD) found deficiencies in completeness of variables as well as deficiencies in 
reliability. The significant difference between the completeness of data entered into the 
database and data available in the patients’ medical records (25% vs 1%), was largely 
because of failure to transfer information from patients’ notes into the database (Fine et al, 
2003). Following the validation check, database re-sampling showed that the proportion of 
missing data elements fell to 9 % but this was still significantly more than the 4% missing 
in the patient notes. 
 
2.4.6.1 Accurate survival rates require accurate staged diagnostic data 
A UK regional cancer registry investigated by Silcocks and colleagues (1999) could only 
report crude survival rates as an outcome because the database did not have information on 
case-mix at diagnosis. The registry relied on information extracted from the hospitals’ 
PAS. This data was extracted by clinical coders from discharge summaries or medical 
notes. Variables necessary to assess case-mix, such as tumour stage at diagnosis, were 
invariably not present in the medical notes therefore it was missing from the database. 
However trained non medical registry personnel were able to reliably impute the stage 
from the clinical information provided. This validated data then provided very good 
outcome data for age and stage adjusted survival rates. According to the investigators it 
was more costly to use trained registry staff to abstract the staged diagnostic data than it 
would be for clinicians to provide adequate data in the notes in the first place. The most 
efficient process was for clinicians to formally stage the tumour at diagnosis, in a 
standardized format, and record it in an accessible part of the notes or in a clinical 
database. 
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2.4.6.2 Incomplete treatment data due to time lag 
Silcocks et al (1999) reported that treatment data was incomplete in the cancer registry as it 
was based on the information available at the time of original coding and also on the ability 
of the coders to extract the relevant information from what was available in the notes. 
Silcocks and colleagues (1999) suggest that treatment information will be incomplete if it 
is submitted to the registry following the patients’ initial discharge from hospital. In 
practice there is often a large time lag between when the patient is first diagnosed by the 
clinician and when diagnostic tests are performed to verify diagnosis prior to commencing 
therapy. Treatment data will not be captured by the registry if the patient starts it as an 
outpatient because this information is not recorded on PAS. 
 
Du and colleagues (2006) reported the same problem with incomplete follow-up treatment 
data in the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) breast cancer registry. Incompleteness of chemotherapy and hormone therapy 
information was thought to arise because patients were not followed up for long enough 
after diagnosis to capture this data. Chemotherapy is started after surgery and hormone 
treatment may be started later. Secondly these treatments may be commenced in places 
where the registry do not collect data such as outpatient clinics or in the physician’s office. 
Also if patients received treatment in external states then this information may be missed 
altogether or severely delayed in being recorded in the registry. The authors suggest that 
underreporting of chemotherapy and hormone therapy use in breast cancer should be noted 
when using SEER data. Similarly Kantonen et al (1997b) deemed follow-up information 
difficult to collect for vascular surgery as some patients did not attend their follow-up 
appointments or their care was transferred elsewhere. This problem resulted in 30 day 
follow-up information missing for 18% of cases in the Finnish Vascular (Finnvasc) 
registry. Du et al (2006) conclude that it would be better to combine patient data from 
different sources to obtain more complete information. 
 
2.4.6.3 Under reporting and outcome variables 
Strobl et al (2003) reported that some outcome variables were under-reported in the cystic 
fibrosis registry. Hospital admissions were significantly under-reported by one centre, 
which would have caused systematic bias in the results. Similar to the findings of other 
studies recording of death data was incomplete, with deaths being under reported by 8%. In 
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addition 21 causes of death and 17 dates of deaths were missing from the database. The 
dates of deaths were entered as discontinuation dates in the registry. Strobl et al (2003) 
suggest that incomplete outcome data is problematic for economic evaluations. Neither 
resource use nor health outcomes can be estimated reliably without knowledge of the 
extent of under reporting. Variations in clinical practices between centres, such as local 
treatment protocols and shared care arrangements with local-non specialist clinicians, were 
not well recorded by the registry. The authors suggest that this risks misattributing 
variations in outcome to recorded variables when they may arise from unrecorded 
variables. 
 
Fine et al (2003) found that the number of total deaths originally submitted to the 
UKNACSD was under reported in some centres and these errors alter mortality 
calculations substantially due to the small numbers of total deaths. ‘In hospital mortality’ 
rate was the only outcome indicator measured therefore this would have a substantial effect 
on all results. Mortality records were uniformly poor in all centres studied and there were 
problems with computer software, particularly in transferring patient data between 
different software systems. In the future all deaths were going to be tracked via the ONS, 
which should improve completeness. 
 
2.4.6.4 Risk factors under reported 
Topp et al (1997) found that two risk factors were significantly underreported in the 
cerebral palsy registry. For example placenta abruption, an important predictor of risk, was 
underreported (sensitivity = 42%), possibly because this is a clinical diagnosis without 
clear cut criteria. Completeness of this variable would have been improved if obstetric 
discharge letters were sent to the registry. 
 
2.4.6.5 Missing data bias 
Missing values are usually managed by case deletion but if missing cases are not random 
then the impact of exclusion will be non random which may produce biases in any analyses 
(Norris et al, 2000; Worster and Haines, 2004). Case deletion also reduces the sample size 
therefore even if missing data is random it may impact on the utility of the database. For 
example investigators may not have enough information to adjust for case mix or to report 
outcomes reliably. The second method of managing missing data is to impute the result, 
Chapter 2  63 
typically by assuming the absence of the variable if the field is left blank or, thirdly, find 
alternative data sources to improve completeness (Norris et al, 2000). 
 
These investigators compared the impact of these three methods for managing missing 
variables needed for risk adjustment in a cardiac surgery clinical registry. The data were 
missing in non random patterns with a higher level missing in one site, more data missing 
earlier in the year under study then later and variables were often missing in clusters. The 
database with improved completeness preformed best for predicting risk and the database 
which excluded cases with missing variables was second best. They found that imputing a 
negative or zero value for missing predictor variables underestimated the true prevalence 
of risk factors. However, the database with improved completeness was only marginally 
better than the other two models. The authors suggest that the extra cost involved in 
improving completeness was worthwhile as the enhanced database had clinical face 
validity and the results were more generalisable because one quarter of the patients would 
have been excluded if cases with missing variables were deleted. 
 
2.4.7. Completeness of case ascertainment 
In the comparison study conducted by Phekoo et al (2002) only 28% of incidence cases 
were recorded in both databases, 42% were recorded only in the Thames Cancer Registry 
(ThCR) and 30% were recorded only in the haematology malignancy database. The 
Thames Cancer Registry obtained records on haematological malignancies from 30 
different specialities and haematology accounted for 35% of these cases. This illustrates 
how difficult it is for a specialist database to achieve completeness as the haematologists 
were only submitting data on their own patients and therefore patients treated by other 
types of clinical specialists were missed. Even the ThCR was only 70% complete and of 
these 31% were identified through death certificate only (DCO). 
 
The high level of DCOs is a strong indicator that case ascertainment is very incomplete 
and case identification methods inadequate (Berrino et al 1998; Berrino, 2003). This 
suggests a bias in survival estimates but does not indicate the direction of the bias. For 
example missing cases, in a cancer registry, will include patients who do not die, for 
instance patients who are cured and cancer will not appear on the death certificate 
(Capocaccia et al, 2003). This has the effect of underestimating survival rates. Omitting 
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DCO cases may introduce a selection bias if cases are systematically different to registered 
cases. For instance DCO cases may be very ill patients with short survival and exclusion of 
these cases tend to overestimate survival rates (Scotter et al, 2000; Capocaccia et al, 2003). 
 
DCO cases cannot be included in survival data unless a date of diagnosis is found therefore 
some registries, including English regional cancer registries, track back DCOs to find a 
diagnosis date so patients can be included. This increases the completeness rate but causes 
selection bias and can result in underestimates of survival due to the non random case 
ascertainment of lethal cases (Berrino, 2003). This bias may affect survival estimates of 
registries with a high proportion of DCOs to start with but only a small proportion 
remaining after the track back exercise (Stotter et al, 2000; Phekoo et al, 2002; Berrino, 
2003). 
 
 In a similar study Stotter et al (2000) reconciled incident breast cancer cases in the Trent 
Cancer Registry (TCR) with Glenfield Hospital’s breast cancer clinical database. This 
process improved the completeness of the registry by 12% and changed the characteristics 
of patients registered. The missed cases were not typical of the cohort as a whole but 
consisted of a subset of older women with a shorter life expectancy. In addition 25 (of 62) 
cases identified through DCO in the TCR, had a diagnosis date identified in the Glenfield 
database; these patients had a median survival of only 11 months. None of the patients who 
received private health care were in the TCR. 
 
The improved case ascertainment had the effect of increasing breast cancer incidence rates 
and the five year survival rate decreased from 62% to 59%. Older women were 
systematically underrepresented in the registry because the main source of registration was 
through the hospitals’ Patient Administration System. Therefore patients managed as 
outpatients only, without surgical intervention, were likely to be omitted. The median age 
for those who underwent surgery was 56yrs compared with 77 for those without surgical 
intervention; consequently older women were systematically omitted. Similar to Phekoo et 
al (2002) amalgamating the two sources of information improved both the rate and 
representativeness of breast cancer cases registered thus increasing the credibility of any 
outcome information derived from the data. 
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Another British study by Pobereskin (2001) examined the completeness of brain tumour 
registration in a Regional Cancer Intelligence Unit with a clinical database called the 
Devon and Cornwall database (DCDB). The DCDB was taken as the gold standard 
because it was developed as part of the Devon and Cornwall brain tumour incidence study 
which had exhaustive methods of case ascertainment (Pobereskin and Chadduck, 2001; 
quoted in Pobereskin, 2001). Only 52% of cases ascertained in the DCDB appeared in the 
registry and certain tumours were systematically under reported such as benign tumours in 
younger patients, without surgery. Under ascertainment of cases occurred because most 
notifications to the regional cancer registry were through the hospital PAS, which would be 
likely to only identify patients with surgical interventions. Again there was no mechanism 
for registering patients if they were treated through the outpatient department. However 
only 64% of patients admitted to hospital for operation were notified to the registry via 
PAS and no explanation was given why so many inpatients were missed by this system. 
 
Incidence data from this registry would be particularly unreliable as incidence rates would 
be underestimated and survival rates overly pessimistic as younger people with better 
prognosis were undercounted. 
 
Stefoski Mikeljevic et al (2003) evaluated the completeness of skin cancer registrations in 
the Northern and Yorkshire Cancer Registry and Information Services (NYCRIS) during 
1994. The proportion of under ascertainment of malignant melanoma (MM) was 12% and 
non-melanoma skin cancer (NMSC) was 17%. The effect of including the additional 
missing cases increased the regional estimated incidence rate, for that period, from 7.5 per 
100 000 per annum to 8.4-9.3 for MM. 
 
2.4.7.1 Completeness of reporting and pathology data 
Furthermore, completeness of reporting rates to the NYCRIS varied considerably between 
pathology laboratories (from 32% to 98%). A likely cause was the absence of quality 
control mechanisms in any of the laboratories to ensure skin cancer cases were notified to 
the registry. Investigation of the PAS data showed that it was not sufficiently complete or 
reliable to act as a primary notification source because there was considerable variation 
between hospitals in the quality of information extracted, especially with respect to under 
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reporting of skin cancers. Only half of cases identified from GP practices were in the 
registry. 
 
The primary routine means of notification of new cases to NYCRIS were pathology 
laboratory reports and this was supplemented by data from PAS. PAS and the pathology 
information together increased the matching rate in comparison to either source alone. For 
example 95% of all patients identified through pathology laboratories and PAS had a 
matching record in the registry compared to 80% if identified by either source alone. 
According to Stefoski Mikeljevic and colleagues (2003) the most effective strategy to 
enhance case registration would be the routine linkage with PAS information 
supplementary to that from pathology laboratories. The authors suggested that it would not 
be cost effective or efficient to link to GP computer systems as a source of case 
identification because GP practices only accounted for a small proportion of total cases and 
each GP practice only had a few cases per year. It was recommended that clinicians and 
GPs send biopsies for histopathology verification on all suspected skin cancer patients. 
This would improve case ascertainment as well as being considered good clinical care. 
 
Brewster et al (1996) reported that ascertainment of cases by the Scottish cancer registry 
was very efficient for most sites with an overall completeness rate of 94%. Missed cases 
were not equally distributed and some cancers (e.g. non-melanoma skin cancer) had a 
higher percentage of cases not registered. Estimates of completeness were also lower for 
some rarer cancers. The effect of missing cases is more dramatic on estimates of incidence 
where small numbers are involved; therefore data from pathology databases would be very 
beneficial for identifying rarer cancers. However using the ‘pathology only’ to identify 
cases would have led to a large proportion of false positives because 36 percent of ‘missed 
cases’ identified by this source were ineligible for registration. Overall computerised 
pathology databases were seen as a useful additional source for case ascertainment but 
needed to be collaborated with additional sources of patient information. 
 
2.4.7.2 Scandinavian databases and completeness rate 
Harvie et al (1996) reported the deficiency of reporting incidence cases of prostate cancer 
to the Norwegian cancer registry as less than 1%. The high completeness rate was 
attributed to their system of complementary acquisition of data from three different sources 
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(hospital departments, histopathological laboratories and National Death Register). 
However they found that a large number of patients in the registry were not found on 
hospital lists reflecting incomplete recording of diagnosis in hospitals. Therefore hospital 
lists or diagnostic indices were not reliable sources of information at that time period. 
Pedersen et al (2004) reported that the overall completeness of the Danish Hip 
Arthroplasty Registry (DHR) for registration of primary total hip arthroplasties (THAs) 
and/or revisions was 94%. There was a lower degree of completeness for revisions than for 
THAs (81% vs. 94%), for university hospitals than for other hospitals (91% vs. 95%) and 
for low-volume hospitals (87%) compared to medium (92%) and large volume hospitals 
(96%). 
 
The authors found that some operations were misclassified as revisions in the reference 
database (the Danish National Register of Patients (NRP)) but were correctly classified as 
primary THAs in the DHR, which could explain why there appeared to be a lower level of 
completeness for revisions. The higher rate of incompleteness of registrations from some 
of the university hospitals was attributed to the large number of temporary trainee surgeons 
who might not be informed about the registry by the permanent orthopaedic surgeons. 
Reporting cases to the registry is compulsory so that might explain why there was such a 
good overall level of completeness. 
 
Kantonen et al (1997b) reported that the mean percentage of missing cases in the Finnvasc 
registry were 19% (range 0-47%) and completeness varied considerably between 
participating centres. Emergency operations and endovascular surgery were the most 
common missing cases. The authors suggest that centres with low registration may not be 
registering cases with unfavourable outcomes. Also problematic procedures that occur at 
night and those undertaken in the angiography suite needed further investigation. 
 
These results showed a lack of improvement in case ascertainment rates from a previous 
validity study conducted 13 years earlier. Kantonen and colleagues (1997b) suggest that 
lack of improvement over time may be because some centres are less interested in 
participating in the registry due to the time consuming task of filling in the forms properly, 
checking and mailing the data. No monetary compensation was given to centres. The only 
benefit was the feedback of their centre results and the overall results of the whole country 
for comparison. Similar to Pedersen et al (2004) some of the hospital databases, used as the 
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reference database, had missing cases therefore hospital registers should not be the 
absolute reference. The authors believed that accuracy of hospital records might improve 
in the future because charging would be based on the surgical procedural code for the 
patient. 
 
Topp et al (1997) estimated that the completeness of the Cerebral Palsy Register in 
Denmark was 85% but missing cases had similar characteristics to enrolled cases therefore 
the under ascertainment did not create selection bias in the data. However, the improved 
completeness of the register, following the validation study, could introduce a potential 
bias when estimating prevalence rates over time as any change in rate might be due to the 
improved completeness rather then a real change in the rate. 
 
The study also found that the reference database used for the validation (the Danish NRP) 
was systematically missing mild cases because these patients were not hospitalised. 
Consequently, using this database alone for prevalence estimates would have lead to 
selection bias in the results. There were also a significant number of false positives in the 
NRP, which were attributed to non specialist clinical staff mis-diagnosing cases. Topp and 
colleagues (1997) suggest that cerebral palsy is difficult to diagnose in practice due to 
vague diagnostic criteria and a possible low diagnostic agreement even between specialist 
clinicians. They recommend that explicit criteria be used for making the diagnosis and, 
preferably, the same specialist take responsibility for diagnosing cases. 
 
2.4.8 Timeliness of case ascertainment 
In the study by Phekoo et al (2002) only 39% of incident cases were reported to the 
regional registry during the year of diagnosis, 44% were reported after one year and 17% 
two to three years later. Harvie et al (1996) also reported that completeness of case 
ascertainment improved with the number of years following diagnosis from 95% after one 
year to 99% after five years and after 10 years, registration was near 100%. 
 
Delays in identification of cases and completing relevant follow-up, results in significant 
time lags in reporting of registry data such that it can be considered out of date when made 
public (Black, 2003a; Berrino, 2003). The problem is compounded by the additional time 
required to check, analyse and publish the information (Berrino, 2003). Patient care 
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changes over time therefore publishing results that relate to the last decade may not be that 
useful for current clinical management and planning services (Berrino, 2003; Black, 
2003a; Richards, 2007). Statistical methods have been developed and registry procedures 
modified to reduce time delays in reporting cancer survival rates for the EUROCARE 
studies (Brenner et al, 2002; Berrino, 2003). Even with these measures the last publications 
related to patients that were diagnosed five to seven years previously; therefore further 
improvements in timeliness are required (Richards, 2007). The Diabetic Audit and 
Research in Tayside Scotland database appears to have current data because it is regularly 
updated with patients by automatic computer linkage to multiple sources for case 
ascertainment (Morris et al, 1997). Applying some of the principles and practices from this 
model might help improve timeliness. 
 
2.4.9 Geographical coverage 
Coverage per country varies from 100% to less then 10% in the EUROCARE population-
based cancer studies (Capocaccia et al, 2003). Countries with low coverage are included in 
estimating European wide survival rates by using weightings proportional to the reciprocal 
of the registry’s coverage for that country (Berrino et al, 1998). 
 
However study results from registries with low coverage may or may not be representative 
of the country as a whole so caution is needed if the data is used to compare inter country 
differences (Berrino et al, 1998; Capocaccia et al, 2003). There is evidence to suggest that 
countries with low coverage can be representative. For instance four countries in 
EUROCARE-3 had increased their national coverage substantially from the previous 
EUROCARE-2 study but the overall cancer survival rankings did not change for any of 
them (Capocaccia et al, 2003). 
 
However Berrino and colleagues (1998) did find outlier values for some high lethality 
cancers in countries where the registries had a low proportion of coverage. In this situation 
survival rate estimates will be subject to large random variability. Also ‘case selection’ is 
likely to occur during the early years of a population-wide collection if a registry 
previously operated as a clinical database/registry (Capocaccia et al, 2003). For example 
the Munich registry was omitted from aggregate analysis with the other German registries 
in EUROCARE 3 because the researchers were worried about the representativeness of the 
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results. This was a new-population based registry which used to be a clinical registry. The 
authors suggested that the registry required a longer period of incidence data collection and 
more health state information (disease stage) to determine if the high survival rates 
observed were real or due to case selection. 
 
Indeed Strobl et al (2003) stated that complete geographical coverage of any geographical 
region by the Epidemiologic Registry of Cystic Fibrosis was unlikely even in participating 
centres where registration was complete. This was because specialist centres do not draw 
patients from clearly demarcated regions and not all patients whose care was shared with 
local hospitals were registered in the database. Therefore they did not know if their patient 
sample was representative of the UK cystic fibrosis population. 
 
Every et al (1999) reported higher hospital mortality in the NRMI 2 database due to 
inclusion of non-insured older patients, which were excluded from the CCP database 
because it was exclusive to Medicare beneficiaries. The authors did not comment on the 
impact of this finding but exclusion of this group may cause selection bias in the CCP, for 
example leading to skewed mortality outcome data. 
 
These examples highlight the importance of knowing the purpose of a database and its 
methods of case ascertainment in order to assess if reported results are generalisable to the 
total population or to specific subgroups only. 
 
2.4.10 Indirect quality indicators 
A range of routine quality checks can be performed on clinical data repositories to assess 
their accuracy and completeness (Berrrino et al, 1998; Strobl et al, 2003; Harrison et al, 
2004). The EUROCARE studies used indirect indicators, based on cross-validation 
analysis of consistency of the relevant variables (Berrino et al, 1998). Data queries were 
sent back to the registries for checking and correction if possible. Records returned after 
review were rechecked and included for analysis if they passed the quality checks. Records 
characterised as having ‘major’ errors were excluded but not deleted from the database in 
case they were corrected in the future. All changes to data were logged for future 
reference. Comparable procedures were employed by the NRMI 2 database which proved 
effective at maintaining reliable and complete data (Every et al, 1999). Arts et al (2003) 
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also reported a much lower error rate following automatic data checks compared to data 
that was not subject to this form of checking. 
 
Other indirect quality indicators used by EUROCARE included assessment of the 
proportion of cases ascertained through death certificate only (DCO), microscopically 
verified cases and cases lost to follow-up by country (Berrino et al, 1998). In addition 
unexpectedly high survival for cancers known to have very poor prognosis may indicate 
inaccurate diagnosis and/or deaths not known to the registry (Berrino et al, 1998). 
 
2.5 Discussion 
2.5.1 Registry uses 
The strength of clinical registries and databases is that information reflects what is 
happening in routine clinical practice. They provide rigorous scientific evidence about 
what is and is not clinically effective. Over recent years their utility has evolved from 
providing basic information that allowed only descriptive comparisons of levels of activity 
and crude outcomes. Current registries are capable of achieving much more because they 
use expanded datasets and sophisticated statistical methods. Their results identify problems 
and often the source of the problem for further action. Registry information has been used 
to document the natural history of diseases, map the care pathways for patients and 
demonstrate if patient care followed recommended guidelines. Accurate prognostic models 
have been developed for performance monitoring and to enable accurate predictions of 
outcomes of care and treatments. Health technology databases are ideal for evaluating the 
medium and long-term effectiveness and safety of treatments where efficacy has been 
proved by clinical trials (Ferster et al, 2001; Padkin et al, 2001; Strobl et al, 2003). 
However to assess diffusion and equity the registry should include the entire client group 
not just the cohort that had the intervention/ treatment (Raftery et al, 2005). In addition 
utilizing registry data in local clinical settings, such as for individualized patient reports, 
helps clinical management. 
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2.5.2 Benefit to patients 
The overall objective of better information on services and outcomes is to benefit the 
patient. The Department of Health wants this information to be the driver for enhanced 
patient choice, improved service quality and to underpin stronger commissioning 
(Department of Health, 2007a). Therefore the ultimate test of whether registries lead to 
health benefit depends on how the information is used to change and improve practice. 
Registry outputs provide the stimulus and evidence to initiate action and the instrument to 
monitor progress (Keogh and Kinsman, 2004; Harrison et al, 2006; Department of Health, 
2007a). Translating this information into effective action is required if a registry is to 
ultimately benefit the patient (Keogh and Kinsman, 2004). 
 
However affecting change in clinical practice is complicated and difficult to achieve 
(Dellinger and Vincent, 2005; Harrison et al, 2006). For example cancer registry 
information, especially EUROCARE results, have led to government initiatives to improve 
cancer outcomes, including the NHS Cancer Plan (2000) and the Cancer Reform Strategy 
(2007). Unfortunately the evidence demonstrated that while cancer outcomes are 
improving in the UK, relative survival still lagged behind comparable European countries 
rates (Department of Health, 2007a, Richards, 2007). Therefore cancer care has not 
improved enough to eliminate the deficiencies identified by the EUROCARE studies and 
cancer patients in parts of the UK are still receiving sub-optimal cancer care. 
 
In contrast UK adult cardiac surgery outcomes are comparable with outcomes 
internationally, which is, at least partially, attributed to the success of the UK National 
Adult Cardiac Surgical Database for its role in national comparative audit and performance 
monitoring. This database is an integral part of the society for Cardiothoracic Surgery of 
Great Britain and Ireland (SCTS) (Society of Cardiothoracic Surgery of Great Britain & 
Ireland, 2008). Now incorporated into the Central Cardiac Audit Database, it is an essential 
source of data on cardiac surgical outcomes which feeds into their quality improvements 
programme. This model, where practicing clinicians take ownership and responsibility for 
improving patient care appears to be more successful then top down interventions by 
government agencies. An equally important incentive was the exposure created by 
comparative audit where the performance of individual cardiac surgeons and units were 
directly compared with other local, national and international services (Keogh et al, 2004). 
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2.5.3 Determinants of utility 
The fundamental requirement for a registry to be valuable is the availability of high 
quality, usable and relevant information (Department of Health, 2007a). However there 
appears to be a trade off between quality and depth of data collection. The more variables 
collected the more questions can be answered with registry information but one has to 
balance this with the cost and risk to data quality of enlarging the data set (Raftery et al, 
2005). For example, in comparative audit the information is often detailed enough to 
identify both good and poor performance and even isolate risk factors but more detailed 
patient and institutional information is often needed to tease out the cause of the problem. 
This is perfectly reasonable as a single method of enquiry is often not sufficient to study 
complex issues such as healthcare and disease processes (Spiegelhalter, 2002). Conducting 
targeted smaller studies on a subset of the registry population allows more in-depth data 
collection and analysis to answer specific questions such as why differences in outcomes 
occur between countries, units or patient groups (Berrino, 2003). 
 
2.5.4 Registry methodology 
Greatest benefit is derived from a registry if the entire patient population for the designed 
geographical area is included and comprehensive health data is collected at the level of the 
individual patient. Patient level data should include demographics, diagnostic and 
treatment variables, health states and outcomes. This will ensure the registry can answer 
questions on effectiveness, equity and diffusion (Raftery et al, 2005) and be used locally 
for clinical management and audit (Metha et al 2004). Length of follow-up influences the 
outcomes that can be measured. 
 
Ensuring the registry is set up and adheres to these principles requires rigorous quality 
procedures and standards. There are several processes that enhance the quality and 
efficiency of a database such as electronic linkage and individual patient identifiers. 
Registries/ databases use observational research methods therefore they are susceptible to 
the methodological difficulties inherent in this form of research. Major categories that were 
identified as possible threats to the validity of any analysis undertaken are data validity, 
reliability, completeness and timeliness. Processes and procedures used for gaining patient 
consent and for data collection determine how vulnerable the registry is to such 
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methodological weaknesses. The impact on registry outputs of these methodological 
deficiencies depend on the scale and type of inaccuracy and/or bias introduced. This in turn 
can limit how the data is analysed thereby limiting its usefulness. Routine internal validity 
checks and external validation procedures will help prevent these difficulties. The research 
reviewed here suggests that current registries are of patchy quality. In an effort to tackle 
this problem various government policies have been initiated in recent years, with varying 
degrees of success (Keogh et al, 2004; Department of Health, 2007a; Richards, 2007). 
 
2.5.5 Electronic computer linkage 
Electronic linkage with other sources of relevant patient data improves the efficiency and 
effectiveness of registries. It decreases the burden of data collection, reduces transcription 
errors, and improves timeliness and reliability by cross validation of data from several 
sources. Most modern registry models use a combination of manual and electronic data 
collection methods but with increasing computerization in healthcare the shift is towards 
fully automated facilities. This functionality is essential in the long-term to enable the 
registry to attain its maximum potential and should be considered in the design. Therefore 
introducing automated enhancements on an incremental basis should be considered as a 
medium to long-term goal for the sickle cell disease registry. However implementing 
automated registry processes is complicated and expensive therefore this option requires 
further investigation in terms of feasibility, cost, and IT specialist requirements and 
equipment. 
 
2.5.6 Record linkage 
A national personal identification number (PIN) such as that used in Scotland and the 
Nordic countries is the most efficient and effective for tracking patient records but these 
PINs are not completely secure as they encode date of birth and gender. A better option 
would be to use the NHS number, introduced in England and Wales, which is a secure 
unique patient identifier. All newborns are now issued with a NHS number and there is a 
national drive to ensure every UK citizen has an NHS number (NHS Information 
Authority, 2001; Department of Health, 2007b). However, it is not yet universally used as 
the principal patient identifier in healthcare facilities, including NHS trusts (Department of 
Health, 2007b; NHS National Patient Safety Agency, 2008). Therefore, for the foreseeable 
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future, English registries will continue to require other traditional patient identifiers in 
conjunction with the NHS number to facilitate lateral and longitudinal linkage of patient 
records (NHS National Patient Safety Agency, 2008). 
 
2.5.7 Efficiency and effectiveness of consent process 
Consent procedures for databases need to be decided on a case by case basis. Problems 
with the consent process have resulted in very variable consent rates between registries and 
clinical databases and between different sites within the same registry/database (Verity and 
Nicoll, 2002; Tu et al, 2004; Al-Shahi et al, 2005; Busby et al, 2005; McKinney et al 
2005). Success rates depend on the type of disease and patient under study, logistics of the 
process, resources involved and the enthusiasm, training and experience of all the 
personnel involved in gaining consent (Woolf et al, 2000; Tu et al, 2004; Al-Shahi et al, 
2005; Busby et al, 2005;McKinney et al 2005). The predictors of consent for clinical 
registries appear to be the ability to have good access to the patient, pro-longed or repeated 
contact and the health status of the patient. In addition staff must be motivated, competent, 
have the time and be supported to ensure high consent rates. Patients with cognitive 
impairment and where there are language barriers are more challenging. Therefore to be 
successful registries must monitor consent rates and identify factors that influence whether 
patients consent or not. Deficiencies in the process can be targeted for improvement though 
an audit cycle framework. 
 
2.5.8 Deceased patients 
Patients that die are less likely to be consented (Tu et al, 2004; Al-Shahi et al, 2005). There 
is provision, under the English information governance regulations, for researchers to use 
deceased patients’ medical notes for medical research, without consent as long as patient 
confidentiality is maintained and there is no risk of harm to surviving relatives (General 
Medical Council, 2004a, b; Singleton and Wadsworth, 2006). The pertinent statutes 
governing access to the health records of deceased patients are Access to Health Records 
Act 1990 and section 251 of the National Health Service Act 2006 (The Stationery Office 
Ltd, 1990, 2006). Increasingly, the Freedom of Information Act 2000 is being used to 
support requests for access to such records (Bonnici and Choong, 2009). However, this 
regulatory framework is complicated and gaining access is difficult to achieve (Kalra et al, 
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2006; Bonnici and Choong, 2009). Researchers may need expert advice on interpretation 
of the statutes before making a request for data (Kalra et al, 2006; Bonnici and Choong, 
2009). 
 
Locating medical notes for patients, are their death, is a major problem as they are often 
archived off-site or missing (Middleton et al, 2000). Du et al (2006) found that where 
retrieval was possible is took time and often involved a fee because of offsite storage. In 
addition the retrieved files were frequently incomplete as they had been thinned. Excluding 
deceased patients because of incomplete or missing information may cause systematic bias 
in results if these subjects are not typical of the rest of the cohort. 
 
2.5.9 Effect of non consent 
Despite the best efforts not everyone will consent to longitudinal studies or research 
involving their medical records (Dunn et al, 2004). Therefore it is important to compare the 
characteristics of patients who consent and those that do not to identify if there are 
systematic differences between the groups. Selection bias may compromise the validity of 
some analysis and may alter interpretation of results (Dunn et al, 2004). It may be 
necessary to assess the impact of bias on outcomes by conducting sensitivity analysis 
between consenters and the whole cohort. This will not be very fruitful for clinical 
registries if clinical variables are not available for non consenters. Ensuring large sample 
sizes to take account of non consenters will reduce the potential effect of bias (Dunn et al, 
2004). 
 
2.5.10 Data reliability 
The onus is on the abstractor to extract the data reliably and in an unbiased manner from 
the medical record. Problems arise because of missing data, conflicting or inconclusive 
information, interpreting the information due to non standardisation of recording, 
ambiguous definitions of data variables or complexity of the variables being measured. For 
example clinical data elements that were open to subjective descriptions by clinicians and 
patients were found to have lower inter-rater and intra-rater agreements. Adverse events 
which occur in hospital and complications seem to be particularly problematic. This 
possibly is because of their unpredictable nature where abstractors are not looking for 
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them. In addition they might occur after the follow-up cut off date or the data collection 
proforma is not good enough to capture this information reliably. The cancer registry 
research suggests that mistakes frequently occur where tumour sites are anatomically close, 
where there is no histological verification and because stage and grade information is 
missing or inaccurate. Inconclusive information such as ‘suspected cancer’ or suspected 
disease progression is invariably coded incorrectly, usually leading to false positives. 
Mortality data appears to be universally inaccurate due to poor hospital mortality records 
and registries not having adequate follow-up procedures to identify if a patient has died. 
 
Variances occur in recording if the abstractors are required to make a subjective decision 
about a variable. This happens if the information in the record is ambiguous or conflicting 
leaving abstractors with three options: deduce the correct answer, leave it blank or be non 
committal (e.g. non-specific cancer site). A further problem is introduced if data collectors 
are required to make a judgement about the outcome of an intervention especially if there 
is any room for subjectivity. For example Eder et al (2005) found that experienced clinical 
staff substituted their own assessments where data was lacking. Lack of reliability occurs 
because these data types are difficult to extract from the medical record and information 
bias may be introduced when abstractors have to make subjective decisions about the data. 
 
2.5.11 Impact of data reliability on the utility of the database 
The impact of imprecision in a data element depends on the significance of the error for 
analysis, its magnitude and whether it is random or not. Systematic errors can arise if 
variables are interpreted differently by groups of clinical staff or different registry sites 
(Topp et al, 1997; Strobl et al, 2003). As the error is not random this can lead to misleading 
results and the significance of the error depends on its magnitude. For example in the study 
by Stobl et al (2003) some centres were reporting the poorest lung function results for 
patients while others were reporting the best. This was an important outcome measure of 
the intervention under study therefore this would make comparative analysis between 
centres unreliable. However if the measurement error lies within the parameters permitted 
for that variable then it will not compromise the results (Topp et al 1997; Brewster et al, 
2002). 
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Bias and unreliability is frequently introduced where abstractors/ clinicians have to make 
judgement about data and report this as a final score or outcome. The probability of error is 
reduced where scoring systems or decision making processes are objective so there is less 
opportunity for personnel to be influenced by their own opinions about the patient or 
outcome (Eder et al, 2005). However, even objective systems can be unreliable. For 
example if each site uses a slightly different measurement method, or due to the variance 
introduced by different staff with variable expertise and training doing the calculations or 
due to the calculation being inappropriately applied (Kantonen et al, 1997b ; Arts et al, 
2003; Fine et al, 2003; Harrison et al, 2004). Furthermore if the variables used for the 
calculations are unreliable or incomplete then the scores themselves will be inaccurate 
irrespective of the skill of the person doing the calculations (Chen et al, 1999; Arts et al, 
2003; Fine et al, 2003). These errors can effect outcome measurement by over or under 
estimating benefit depending on the direction of the error and therefore make comparative 
analysis unreliable. 
 
Inconclusive information about a diagnosis or disease progression often leads to false 
positives and is common where it is difficult to confirm diagnosis by objective measures 
such as histology. This can have the effect of inflating incidence rates, which would be 
misleading in subgroup analysis where numbers are small. If this information is used for 
evaluation of interventions, such as screening programmes, then it would underestimate 
beneficial outcomes. However, if it is known with certainty that a systematic error has 
occurred then it can be accounted for in the analysis or explained in the results. 
 
The degree of accuracy of the data determines how it can be used or the level of analysis 
achievable. In principle the more accurate the data the fewer limits on its uses. For 
example minor errors in the last three digits of the patients’ address postcode could prove 
problematic if postcode was relied upon for linking patient data to other sources or for 
subgroup analysis at the postcode sector level (Middleton et al, 2000; Brewster et al, 
2002). In the UK Cardiac Surgical Database the degree to which the data can be stratified 
depends on its reliability (Spiegelhalter, 2002; Keogh et al, 2004). If the objective of this 
database is to facilitate patient choice about cardiac surgery then the public and clinicians 
require detailed risk adjusted tables of outcomes published in a comparative fashion (Fine 
et al, 2003; Keogh et al, 2004). This task necessitates reliable information on well defined 
prognostic factors such as severity and co-morbidity for case mix adjustment so that fair 
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comparisons between surgeons and units can be undertaken (Keogh et al, 1998; Fine et al, 
2003). However if the objective is to show that a surgeon is safe for quality assurance 
purposes then the data demands are slightly different. The method used by the UK Cardiac 
Surgical Database was to agree a threshold level for the outcome of interest (i.e. 
unacceptable mortality) and then show where each individual surgeon’s results lay relative 
to that threshold. The database initially presented its results in this format because 
variables needed for full risk adjustment were unreliable and incomplete (Fine et al, 2003). 
This level of information was sufficient to identify outliers for further investigation (Keogh 
et al, 2004) and proved sufficient to show (in retrospect) that Bristol Royal Infirmary had 
excess mortality for paediatric open heart surgery during 1991-1995 (Spiegelhalter, 2002). 
 
This is similar to the problems encountered by the UK cancer registers and EUROCARE. 
Inaccuracies in case mix can cause important biases in survival data. For example where 
there is a different case mix of tumours with a different prognosis in the same ICD 
category (Berrino et al, 1998). These deficiencies do not prevent analysis and publication 
of data from cancer registries but it can limit the level of analysis undertaken. For example 
cancer registries usually only undertake basic analysis to identify and report differences 
(and the scale of differences) in relative cancer survival between groups and geographical 
regions (Berrino, 2003). In the case of the EUROCARE project, outlier data are 
investigated by further in depth analysis which involves smaller studies where extra 
clinical and pathological information is collected on random samples of patients. 
 
2.5.12 Processes to improve data reliability 
This review highlights the need for robust data collection forms to capture all essential data 
with clear evidence based definitions of all data elements for use by all data collectors. 
Furthermore it is critical that different databases on the same topic share the same dataset, 
definitions and data collection methods to ensure comparability of results and 
amalgamation of data if required (Berrino et al, 1998; Magnani et al, 2001; Arts et al, 
2003). Checking multiple sources of information for consistency in clinical variables 
improves reliability of individual patient data (Harvie et al, 1996). Factors which increase 
accuracy include adequate staff training, standard rules for the data abstraction process and 
for reporting of variables, familiarity with the coding system and ease of data completion 
(Berrino et al, 1998; Chen et al, 1999; Arts et al, 2003; Harrison et al, 2004; Eder et al, 
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2005). Linking registries to national vital statistics is the best method of insuring accurate 
mortality information for both short and long-term survival analysis. A good example is 
the UK regional cancer registries which have a uniform process for registering every new 
case of cancer diagnosed in the registry’s population and a standard dataset on each 
registration is submitted to the Office of National Statistics (Department of Health, 2007a). 
 
However, regular monitoring systems are needed to ensure staff adherence to registry 
protocols especially data definitions and data abstraction rules (Chen et al, 1999; Arts et al, 
2003; Fine et al, 2003). Other measures which have improved data quality include 
imposing a legal obligation on registries to produce high quality information and linking 
hospital reimbursement to activity data so there is an incentive to code patient activity 
accurately (Harvie et al, 1996; Kantonen et al, 1997b). 
 
2.5.13 Coding principles 
Coding for disease must be comprehensive and ‘exclusive’ so that each data element can 
be captured accurately (Stein et al, 2000; Young et al, 2001). To be able to develop a 
reliable coding system there has to be agreed definitions for all variables, especially 
difficult data elements such as some diagnoses (Chen et al, 1999; Keogh and Kinsman, 
2004). Coding aids can be developed to assist classification and coding of qualitative terms 
(Eder et al, 2005). A prerequisite of any system is that it is compatible with other systems 
in common use such as Read codes and International Classification of Diseases (ICD -
9/10) (Young, et al, 2001). A good example is the Intensive Care National Audit & 
Research Centre coding method which was developed empirically for coding the reason for 
intensive care admissions (Young et al, 2001; Harrison et al, 2004). 
 
2.5.14 Data appraisal – local verses central measurement 
It is preferable that the central database has responsibility for measuring outcomes, 
calculating scores and making judgements about data, to avoid information bias and 
improve data reliability. For instance the Intensive Care National Audit & Research Centre 
database requires all raw physiology data to be submitted to the database and all scores and 
probabilities are calculated centrally using standard algorithms to avoid any bias (Harrison 
et al, 2004). This data enables risk adjustment models to be derived using standard 
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algorithms across all units, allowing better comparability of risk adjusted outcomes 
between units. Additionally this method has the advantage of improving the utility of the 
database. For example if the data needs to be reanalysed to compare or complement other 
studies’ results (i.e. a clinical trial) then having the raw data ensures it can be manipulated 
to fit the methods, definitions and scales used by other researchers (Padkin et al, 2003). 
Therefore because of the longevity and importance of databases/registries it is imperative 
they possess this compatibility and flexibility for optimal utility. 
 
2.5.15 Sources of incomplete follow-up 
Incomplete follow-up often happens because patient information is not accessed from 
sections of the health care system for example in outpatient departments, GP surgeries or 
for deceased patients. Therefore certain types of information such as drug treatment, timing 
of treatment and outpatient investigations may be systematically missed. Other variables 
may also be incomplete because follow-up is too short to capture all the relevant 
information or the abstractors have left the field blank because of problems interpreting the 
data due to poor documentation. Typical examples include staging disease, co-morbidity 
variables and diagnosis of late complications. 
 
2.5.16 Impact of incomplete follow-up 
Missing data can lead to non response bias because the patients with fields missing may be 
different to those included, for example the cohort with advanced disease or with mild 
disease (Worster and Haines, 2004). Therefore missing data, unless trivial, can threaten the 
validity of outcome analysis and results are not generalisable to the population. It may be 
possible to undertake statistical analysis to assess if non response bias has affected the 
results (Worster and Haines, 2004). For example a study reported by Wuerz (2001) 
conducted sensitivity analyses to test the effect of non-response bias on their results. 
Worster and Haines (2004) suggest comparing subjects not included in the analysis with 
those that are included to determine if they appear to differ systematically, such as by age 
or gender. These are not sufficient checks as participants who are included may differ in 
significant ways to non-participants even if they have a similar demographic profile (Al-
Shahi et al, 2005; Tate et al, 2006). 
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Missing variables may limit the utility of the database if case-mix adjusted outcomes are 
prohibited. Norris et al (2000) found that improved completeness enhanced the 
performance of a clinical registry for predicting risk but it was only marginally better then 
when the analysis was conducted without the subjects with missing variables. 
 
2.5.17 Methods to improve completeness of follow-up 
The research shows that patients are treated in various health care facilities from diagnosis 
to end of treatment or death. The facility used by the patient depends on multiple factors 
including the type and severity of illness, therapy prescribed, residence and age. Therefore 
to capture complete and accurate follow-up multiple sources of relevant data need to be 
combined with sufficient length of follow-up. Developing a model of the likely patient 
journey through the health system will identify where essential data variables can be 
sourced. These may differ between sites therefore information on local clinical practices, 
such as shared care arrangements, should be recorded (Phekoo et al, 2002; Strobl et al, 
2003). It is highly probable that it will not be possible to access data from all these sources 
due to logistical and resource constraints. However, if a primary source of data is not 
accessible, such as GP records, then it might be possible to collect the data from a 
secondary source. If underreporting of some information is known then it should be noted 
when reporting results (to assist readers with interpreting validity of results) (Du et al, 
2006). 
 
2.5.18 Effect of incomplete case ascertainment 
Under ascertainment of cases leads to erroneously low estimates of incidence making it 
difficult to assess true risk or compare incidence rates between geographical regions 
(Berrino, 2003; Stefoski Mikeljevic et al, 2003). Additionally if completeness changes over 
time, for example after a quality audit, this can invalidate trend analysis in incidence or 
prevalence rates and should be acknowledged and adjusted for in the analysis, if possible 
(Topp et al, 1997; Bower et al, 2000). 
 
The impact of under ascertainment on estimating outcomes is more complex. If missing 
cases are not representative of the population as a whole this introduces selection bias. In 
the case of cancer outcomes survival estimates can be over or under estimated, depending 
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on the severity of disease in the cohort excluded. For example if patients with advanced 
disease and poor prognosis are excluded then this would over estimate survival. This can 
invalidate comparisons between populations (Berrino, 2003). The effect of selection bias is 
more pronounced in subgroup analysis because of the small number of cases available for 
analysis. This may result in miscalculation in evaluation of the effectiveness of health 
programmes or lead to over or under provision of services for the population 
misrepresented. In contrast if cases are missing completely at random then the research and 
audit capacity of a clinical database in not unduly impaired (Every et al, 1999; Norris et al, 
2000). Overall it is best to strive for a high degree of completeness of registration to have 
confidence in the registry. Any analysis published from registries should report the extent 
of incompleteness and its effect on incidence calculations or prevalence calculations, if 
appropriate. 
 
Some statistical methods have been shown to reduce selection bias. For instance cancer 
survival rates are reported by age groups and the technique of age adjustment reduces the 
effect of selection bias on results (Brenner and Hakulinen, 2005). External validation 
studies can identify and quantify the probable extent of under-reporting and estimate the 
effect on reported incidence rates. There are also indirect quality indicators that can be 
applied to assess the completeness of a registry, such as the proportion of cases ascertained 
by death certificate only (Berrino et al, 1998). Stotter et al (2000) suggest that one should 
take into account how registry data was collected to assess validity of results. 
 
2.5.19 Maximising case ascertainment 
Multiple sources of information are the most efficient method of improving case 
ascertainment and verification to prevent false positives (Brewster et al, 1996; Stefoski 
Mikeljevic et al, 2003). Developing patient care pathways/scenarios of how affected 
patients are likely to be identified and treated can aid understanding of how to capture 
cases. This will be different for each disease therefore the best sources of information will 
differ for each clinical registry. For example a flagging system used by all radiologists 
reporting scans of the brain would identify virtually all cases of brain tumours (Pobereskin, 
2001). In sickle cell disease this could be achieved by filtering patients by blood test results 
that are indicative of the disease. Another method is to get lists of all patients who attend 
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hospital clinics that are likely to have SCD patients and cross check the patients on the list 
with their blood test results. 
 
Patients with mild disease are likely to have a different care pathway to moderate and 
severe cases and are often missed by registries because they might never be referred to 
hospital and/or admitted as an inpatient. Therefore for diseases with variable severity if 
outpatient and/or GP information are not captured this group of patients are likely to be 
under reported. Similarly severely ill patients who die shortly after diagnosis have a greater 
chance off not being identified because of their short utilization of health services. For 
other diseases, such as haematological malignancies, diagnosis is complicated and patients 
may be treated by a range of health professionals and therefore multiple internal sources of 
hospital information have to be amalgamated in order to identify and verify cases. 
Developing patient care pathways will also identify which health care professionals should 
be actively involved in the registry to ensure accurate diagnosis and improve case 
ascertainment and follow-up (Phekoo et al, 2002). Finally it is imperative to have 
knowledge of local clinical and reporting practices to maximise recruitment and interpret 
multi-centre data (Strobl et al, 2003). 
 
2.5.20 Generalisability 
Population based registries with low coverage can be included in aggregate (national, 
European wide) analysis provided the appropriate statistical methods are used to adjust for 
percentage of coverage. In the EUROCARE studies, countries that have less than 100 
percent coverage are included in European cancer survival estimates by assigning 
weightings proportional to the reciprocal of the cancer registry’s coverage in each country 
(Berrino et al, 1998, 2003). However if registries with low coverage are used in 
comparative analysis appropriate caution is needed with interpretation of the results, for 
example the likelihood of the data being representative of the geographical region 
(Berrino, 2003). While the results from the EUROCARE cancer studies suggest that 
registries with low coverage can be representative there is more confidence in the data the 
greater the coverage (Capocaccia et al, 2003). In addition clinical databases are prone to 
case selection and may not be representative of the underlying population (Capocaccia et 
al, 2003). Scrutiny of the exclusion/inclusion criteria will help identify if results are 
generalisable to the general population (Every et al, 1999). Overall it is better if all 
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potential participants in the targeted population have the opportunity of being included in 
the registry to avoid sampling and selection bias. 
 
2.5.21 Quality assurance processes 
Quality assurance programmes should involve both internal routine data quality 
procedures, to identify inconsistencies and missing data, and external validation checks of 
data reliability and completeness of registrations (Berrino et al, 1998; Fine et al, 2003; 
Pedersen et al, 2004). For example good reliability and completeness of cancer registries is 
indicated where a low proportion of cases have been identified by death certificate only; 
that the diagnoses where reliable is indicated by a high proportion of the cases confirmed 
by histological examination; and that follow-up was complete (Berrino et al, 1998). 
 
In addition inter-rater and intra-rater reliability checks will identify problems with data 
abstraction such as ambiguous variable definitions and data elements or events difficult to 
identify in medical records (Chen et al, 1999; Eder et al, 2005). A pilot study at the outset 
should identify these problems for correction. However it would be prudent to carry out 
external validation checks periodically because over the lifetime of the database there will 
be staff changes, organisational setup may change and the dataset may be changed – all 
these things can have an adverse affect on data reliability. 
 
Efforts should be made to improve the timeliness of data collection, processing and 
reporting so that registry results are more contemporary and relevant. 
 
2.5.22 Government initiatives 
Registry data in some of the Nordic countries is very complete and reliable and this is most 
probably influenced by the fact that registration of cases is mandatory and registries have a 
legal obligation to ensure that their data is complete and accurate. A similar climate of 
regulation and accountability for registry data is developing in the UK. Clinical registries 
and databases were recognised for their role in health surveillance, performance 
monitoring and facilitating patient choice when policymakers realised that improvements 
in health care could only be achieved when underpinned with good clinical information 
systems (Department of Health, 2000, 2007a). Some registries, such as the cancer registries 
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and the cardiac surgical databases, have already been mandated by the Department of 
Health and consequently became an integral part of the NHS development plans. This gave 
these registries the government support and resources needed to improve. 
 
Registries are now expected to collect better quality and more comprehensive and timely 
information so they are capable of more than ‘basic analysis’ (Keogh et al, 2004; 
Department of Health, 2007a). This involves routinely collecting variables that have 
proved difficult in the past (e.g. staging of cancer, co-morbidity, complications of 
treatment) together with comprehensive Quality Accreditation Programmes to ensure high 
quality data (Society for Cardiothoracic Surgery in Great Britain & Ireland, 2005, 2008). 
The focus of current policy initiatives is to make it the responsibility of all clinical staff 
and agencies involved in patient care to ensure disease registries achieve this level of 
reliable information. For example the NHS Cancer Plan (2007) stipulated that 
multidisciplinary teams will have an important role to play in collecting all relevant 
clinical information for cancer patients and for making this data available for cancer 
registries and national audits (Department of Health, 2007a). Catalysts for change in the 
UK Cardiac Surgery Database were the recommendations of the Bristol Royal Infirmary 
Inquiry into paediatric cardiac deaths and growing government pressure, for public release 
of individual surgeon outcomes (Keogh et al, 2004). This was a powerful incentive to 
ensure information collected was comprehensive and reliable so that outcome and 
performance measurements were fair and accurate. 
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2.6 Conclusions 
Population based registry information is now recognised as the linchpin to improvements 
in patient care. There is clear evidence that registry outputs can result in benefit to patients, 
health care providers and policy makers provided that their findings and recommendations 
result in local and national initiatives to improve patient care. A registry is a long-term 
investment and will result in increased benefits as the data collection period grows. 
However, registries are only as good as their data, which has proved to be of highly 
variable quality in the past. Therefore registries need to operate with the same scientific 
rigour as any other type of research study and report results and methodological 
deficiencies to ensure accurate interpretation. A clinical registry which functions as a 
clinical information system, in the context of clinical audit, is the best model for research, 
audit, health surveillance and routine patient management. This appears to be the only 
feasible method of collecting data for patients with chronic diseases, such as sickle cell 
disease, where outcomes, such as survival, cannot be related to a single intervention but to 
the efforts of a multidisciplinary team over a lifetime. 
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Chapter 3: Methodology 
3.1 Introduction 
This chapter will provide a brief history about the establishment of the sickle cell disease 
(SCD) registry at Central Middlesex Hospital (CMH) (section 3.1.1), the geographical 
coverage of the registry (3.1.2), local prevalence (3.1.3 and 3.1.4) and incidence of sickle 
cell disease (3.1.5). Section 3.2 provides an overview of the registry’s function and 
organisation. Section 3.2.1 reiterates the aims and objectives of this thesis, section 3.2.2 
describes the function of the registry and section 3.2.3 the registry properties. Section 3.2.4 
provides an overview of the organisational set-up, section 3.2.5 covers ethical and data 
governance issues, section 3.2.6 the consent process and section 3.2.7 reports a procedure 
set up to overcome problems with access to patients’ clinical information. The processes 
established for identification of SCD cases in the registry’s catchment area are described 
under section 3.3, including the Newborn Screening Programme (3.3.1) and other 
screening methods (3.3.2). Potential and feasible methods of case ascertainment are 
described in sections 3.3.3 and 3.3.4. Development of a high quality registry is covered in 
section 3.4. The characteristics of high quality data are summarised under section 3.4.1, the 
proposed quality framework in section 3.4.2 and an overview of the data collection process 
in section 3.4.3. Methods for evaluating the utility of the registry are covered in the last 
section 3.5, including hydroxcarbamide (HU) measurable outcomes (3.5.1), monitoring 
HU adverse effects (3.5.2), patient eligibility and treatment schedule (3.5.3), data 
collection methods (3.5.4), data manipulation (3.5.5) and statistical methods and analysis 
(3.5.6). 
 
3.1.1 Historical perspective 
As stated in Chapter 1, the North West London (NWL) sector registry was established and 
curated at CMH. The registry initially covered the sickle cell patient population attending 
CMH and in 2001 three additional local hospitals joined (Hammersmith, Ealing and West 
Middlesex) thereby expanding coverage to three-quarters of the target SCD population. 
The care of SCD patients attending Northwick Park hospital was gradually moved to CMH 
in 2003, after rationalisation of services, when the hospitals merged to form the North 
West London Hospitals NHS Trust. 
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3.1.2 Geographical coverage 
This geographical area encompasses the current NWL Sector Health Authority, which is 
the health district covered by the local Managed Clinical Network (MCN) for 
Haemoglobinopathies (Figure 3.1). This health district covers eight local authority 
boroughs and is serviced by nine acute hospital NHS trusts including CMH, Charing Cross 
(ChX), Chelsea and Westminster (C&W), Ealing (EGH), Hammersmith (Hamm), 
Hillingdon, Northwick Park (NPH), Saint Mary’s (SMH), and West Middlesex University 
hospital (WMUH). Sickle cell patients who reside in NWL are expected to attend one or 
more of these hospitals for outpatient and inpatient care of their disease. Figure 3.2 shows 
the hospitals and the local authority boroughs these hospitals serve, the borough 
population, proportion of the population at significant risk of inheriting SCD and the 
estimated number of SCD patients attending each hospital. The Brent Sickle Cell & 
Thalassaemia Centre (BSCTC), located at the department of Haematology in Central 
Middlesex Hospital is a specialist centre for treating SCD patients. The centre serves the 
local population of Brent and Harrow and also receives patient referrals from other local 
hospitals and GPs in the sector as well as national and international referrals. 
 
Figure 3.1: North West London Sector SCD Registry Catchment Area (London Boroughs) 
 
The sector population is 1,731,019 and there are high rates of ethnic minority groups in 
each borough (ONS, 2003). Ethnic groups at greatest risk of inheriting the sickle cell gene, 
the black and black British, range from 20% in Brent to 3.3% in Hillingdon (Figure 3.2). 
Chapter 3  90 
These groups include black Africans, black Caribbean and black Other minorities 
(Department of Health, 1993; Davies et al, 2000). In addition 45% of the sector’s total 
population consists of ethnic minority groups that have varying degrees of risk of carrying 
the sickle or thalassaemia gene (Davies et al, 2000; ONS, 2003). For instance Brent scored 
as the most ethnically diverse local authority area in England and Wales in the 2001 
Census, with an 85% chance that two people chosen at random would be from different 
ethnic groups. 
 
Sources: *2001 Census for England and Wales 
*At Risk Population = Black African, Black Caribbean and Black Other Ethnic Groups 
#Alli M (2002) Haemoglobinopathy MCN for NWL: 3 Year Delivery Plan 2003-06 
 
Figure 3.2: NWL Sector SCD Registry Catchment Area (London Boroughs) Population 
Estimates and % at Risk of SCD (Trait or Disease*) NHS Acute Hospital Trusts Located in 
Each Borough (Est. No. SCD Patients#) 
 
3.1.3 Prevalence 
Due to the local concentration of ethnic groups at risk of inheriting this disease, it is 
reasonable to expect that high numbers of people with sickle cell reside in the NWL health 
district and use the health services therein. Disease prevalence arises from both migrants 
that have the disease and from affected births in the settled immigrant ‘at risk’ populations. 
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Most immigration into Brent occurred during the 1950s and was from the Caribbean and 
Pakistan (Davies et al, 2000). Immigration from Africa occurred later and continues to the 
present day. Therefore Brent would be expected to have a mixture of first, second and third 
generation migrants with the disease. 
 
There are no reliable estimates of the number of people with sickle cell in NWL. The best 
information was derived from a questionnaire survey of all haematologists and 
paediatricians looking after haemoglobinopathy patients in the nine acute NHS hospital 
trusts in NWL (Figure 3.2). This data suggests that in 2002 there were approximately 
1113-1172 patients with SCD attending the local hospitals, of which 530 attended Central 
Middlesex (Alli, 2002). These figures lack precision because they were derived from the 
clinician’s best guesstimate of patient numbers in their clinics. Also only patients who are 
known to the haematologist or paediatrician were included so patients who have not been 
referred by their GPs to a clinician for care of their sickle cell would be missed as would 
those who have never been diagnosed with the disease. 
 
3.1.4 Derivation of SCD prevalence statistics for NWL 
In order to get a more precise estimate of prevalence rates I have derived a population 
based estimate from the 2001 census statistics using the rates of disease among ethnic 
minority groups calculated by Davies et al (2000). This estimate, shown in Table 3.1, is 
more comprehensive than Alli (2002) but it also has deficiencies. For example it has not 
been age adjusted to take account of the declining rate of disease with age due to premature 
death in SCD. Conversely rates of disease could be higher than expected in NWL because 
people with the disease are more likely to come to a country (and area) which provides 
good health care for their condition and these individuals are also more likely to be granted 
permanent residency due to their medical needs. In addition a few cases will be missed 
because the rate of disease in other ethnic groups has not been considered in the estimate, 
though this number is very small. Overall the expected number of sufferers in NWL is 
between 1172 and 1468, probably closer to the higher estimate. Using the population 
estimates from Table 3.1 the prevalence is between 1172/151,671 and 1468/151,671 
[between 0.0077 = 7.7 per 1000 at risk population and 0.0097 = 9.7 per 1000 at risk 
population]. To simplify and round up between 0.8% and 1% of the at risk population have 
SCD. 
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Table 3.1: North West London Sector Sickle Cell Disease Registry: Population at risk, 
estimated prevalence of SCD and current estimate of patients attending hospitals in NWL 
Census 2001 
Local Authority Total % Black Pop. Bl *Estimate % Black Pop. Bl *Estimate % Black Pop. Bl *Estimate Total Acute Estimate
Borough pop. African African SCD pop. Carib Caribbean SCD pop. Other Other SCD pop. SCD pop. hospital SCD pts 
bean attending
Brent 263,464 7.83 20,629 303 10.47 27,585    154 1.56 4,110  23 481 CMH 553
Ealing 300,948 3.68 11,075 163 4.49 13,513    76 0.62 1,866  10 249 Ealing 67
Hammersmith & Fulham 165,242 4.88 8,064   119 5.16 8,526      48 1.08 1,785  10 176 Hamm 132
Charing X 57
Harrow 206,814 2.73 5,646   83 2.96 6,122      34 0.45 931     5 122 NPH 90
Hillingdon 243,006 1.74 4,228   62 1.35 3,281      18 0.21 510     3 83 Hillingdon 22
Hounslow 212,341 2.7 5,733   84 1.33 2,824      16 0.32 679     4 104 WMiddx 30
Kensington & Chelsea 158,919 3.78 6,007   88 2.58 4,100      23 0.61 969     5 117 C&W 56
Westminster 181,286 3.68 6,671   98 3.1 5,620      31 0.66 1,196  7 136 SMH 114
Not known 59
Total at risk of SCD: 68,054 1,000 71,570 401 12,047 67 1,469 1,172
Alli, 2002
 
Population statistics from 2001 Census (ONS, 2003). 
Numbers of patients attending acute hospitals in the sector are from Alli (2002) 
* Estimates of SCD population are calculated using the rates of disease derived by Davies et al, 2000 
 
Estimating rates of disease: (Source Davies et al (2000) 
1. High carrier rates are responsible for high rates of disease among black ethnic minorities:  
0.11 Carrier rate S and 0.04 carrier rate C leads to 5.6 per 1000 births among black Caribbeans 
0.20 Carrier rate S and 0.03 carrier rate C leads to 14.7 per 1000 births among black Africans 
0.11 carrier rate S and 0.04 Carrier rate C leads to 5.6 per 1000 births among black Other 
 
3.1.5 Incidence 
The North West Thames Regional Neonatal Screening Programme figures, for the period 
1990 to 1994, show that there was an annual mean rate of 25.5 SCD births in the whole 
region with a mean of seven for Brent (Davies et al, 2000). The geographical area covered 
by the programme is wider then the NWL health sector but most of the affected births 
occurred within the sector. The majority of these babies will be cared for by their local 
hospital within NWL or referred to a specialist centre within the region. The few children 
born outside the sector boundary (Barnet and Bedford) are likely to be looked after by their 
local hospital but referred to a specialist centre in NWL, such as Central Middlesex 
Hospital, for annual monitoring or specialist advice. These informal shared care 
arrangements between hospitals will be formalised in the future as the national standards 
for caring for sickle patients recommend that all sickle patients should have their care 
overseen by specialist sickle centres and have access to specialist centre services as 
required (NHS Sickle Cell and Thalassaemia Screening Programme, 2006b; Sickle Cell 
Society, 2008). 
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In addition people with sickle cell move into the sector each year due to the migration 
pattern of ethnic minorities; they tend to move into areas where there are people from the 
same background and to be near relatives (Sanchez, 2004). There is no available estimate 
of these numbers or of the stability of these population groups within the sector. However 
comparison of the 1991 and 2001 census statistics shows that both the number of people at 
significant risk of sickle cell is increasing in NWL and they are an increasing proportion of 
the total population (Table 3.2). Brent had the biggest increase (3.5%) where the ‘at risk’ 
group rose by 12,594. The ‘at risk population’ also rose considerably in the London 
borough of Harrow by 5294 (2.44%). 
 
Table 3.2: North West London Sector Sickle Cell Disease Registry: Estimated population at 
risk of SCD in 1991 and 2001 
Local Authority Total * % pop. Total pop. Total * % pop. Total pop.
Borough population at risk at risk population at risk at risk
1991 1991 1991 2001 2001 2001
Brent 243,025 16.5 40,099 263,464 19.86 52,324
Ealing 275,257 7.1 19,543 300,948 8.79 26,453
Hammersmith & Fulham 148,502 10.2 15,147 165,242 11.12 18,375
Harrow 200,100 3.7 7,404 206,814 6.14 12,698
Hillingdon 231,602 1.7 3,937 243,006 3.3 8,019
Hounslow 204,397 2.7 5,519 212,341 4.35 9,237
Kensington & Chelsea 138,394 5.8 8,027 158,919 6.97 11,077
Westminster 174,814 7.6 13,286 181,286 7.44 13,488
Total: 1,616,091 0.07 112,962 1,732,020 0.088 151,671
% of total population: 7% 8.8%  
* The main population groups at significant risk of SCD are black African, black Caribbean and black Other 
ethnic minorities. 
Sources: 1991 Census (ONS); 2001 Census (ONS, 2003); Davies et al (2000) 
 
3.2 Method of Evaluation 
3.2.1 Aims and objectives 
To reiterate, the aim of this study is to evaluate the feasibility and utility of the SCD 
database or registry for clinical management and research. The specific objectives are to: 
 
i. Develop an evidence based registry 
ii. Ensure high quality data 
iii. Identify and develop clinical management tools from the registry data 
iv. Demonstrate utility of the registry for SCD patient management and research 
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3.2.2 Registry function 
The review of the literature, in Chapter 2, suggests that the role of a clinical 
registry/database is to describe the health and health care of the population under study. It 
is an essential information source which should act as a catalyst for change and 
improvement or as proof that a service or treatment is effective. To be of value a registry 
needs high quality, usable and relevant information (Department of Health, 2007a). The 
intended use(s) of the sickle registry should be decided a priori as this determines the 
necessary properties of the data to be collected (Arts et al, 2002). In addition the quality of 
the data determines how well the registry may be utilized. As discussed in Chapter 2, 
section 2.5.11, paragraph 4, the degree of data accuracy influences the level and type of 
analyses that can be conducted; the better the data the fewer the constraints (Middleton et 
al, 2000; Brewster et al, 2002; Fine et al, 2003; Keogh et al, 2004). 
 
3.2.3 Registry properties 
All patients with SCD in the target population should be included for measuring 
prevalence and incidence rates. SCD is an inherited chronic disease and therefore the 
database should have the ability to follow-up patients over their lifetime in order to 
describe the natural history of the disorder. It should also be able to monitor and follow-up 
sub-groups of patients prescribed new treatments to assess long-term benefit versus risks. 
Patients on hydroxycarbamide treatment will populate the HU sub-registry. To illustrate 
the natural history of SCD and/or evaluate the effectiveness of a health technology the 
dataset should include all the patient characteristics that affect outcome. Complete case 
ascertainment is of lesser importance for these uses (Sørensen et al, 1996). 
 
3.2.4 Organisational principles of the SCD Registry 
In order to establish and maintain a successful SCD registry the following organisational 
structures and processes were developed. 
 
i. Overseen by a NWL sector steering/management group. 
ii. Involvement of the multidisciplinary team. 
iii. Continuous efforts to maintain funding streams. 
 
Chapter 3  95 
3.2.5 Ethical Approval and data governance 
As stated in Chapter 1 the registry has research ethics committee (previously known as 
multi-centre research ethics committee (MREC)) approval to conduct research on the data 
collected. The approval number is MREC/99/2/4. In addition the project is registered under 
the UK Data Protection Act (registration number: Z5730583) for the purpose of collecting 
patient demographic and clinical information for research. 
 
3.2.6 Consent procedure 
The research ethics committee (REC) approval requires that the patient gives informed 
written consent prior to utilization of their data for research purposes. The practical 
obstacles to gaining consent and the methodological implications for the research caused 
by exclusion of non consenting patients were described in Chapter 2. The following 
strategy was implemented to maximise consent rates: 
 
i. Obtain consent from patient/carer during designated sickle cell outpatient clinic 
visit. 
ii. Involve multidisciplinary sickle cell team to obtain patient consent (doctors, 
nurses, researchers). 
iii. Develop tools to assist with the consent process (for example list of consented 
patients, label to mark notes when patient has consented). 
iv. Monitor consent rates. 
v. Identify factors that influence whether patients consent or not. 
vi. Utilize an audit cycle to improve process by targeting deficiencies in the 
process. 
 
A regularly updated excel list was created to monitor rates of consent, factors that 
influence the rate of consent such as mean numbers of visits required to gain consent and 
reasons for non consent. 
 
3.2.7 Clinical information retrieval 
In retrospective study designs there are problems accessing deceased patients’ medical 
records. Indeed this also applies to living SCD patients as they are likely to accumulate 
numerous volumes of notes throughout their lifetime. Therefore a separate archive system 
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was established to have easy access to all SCD deceased patients’ medical notes and non-
current (closed) notes for surviving patients. 
 
3.3 Disease detection in North West London Health Sector 
3.3.1 Newborn Screening Program 
As stated in Chapter 1 sickle cell disease is detectable from birth using a specialist blood 
test. Universal neonatal screening for sickle cell and thalassaemia was introduced in North 
West London in 1988 and covered the old North West Thames Regional Health Authority 
(Davies et al, 2000). Initially both first and second line screening tests were undertaken in 
the Regional Haemoglobinopathy Laboratory at Central Middlesex Hospital. After the 
establishment of the national SCD newborn screening programme first line screening 
moved to Great Ormond Street Hospital, in September 2003, and second line testing 
remained at CMH. The positive test results (both trait and disease) are sent to the Specialist 
Community Nurses in BSCTC for follow-up. This geographical area encompasses the 
current NWL Sector Health Sector and the NWL SCD registry. 
 
All neonates born in the district have been screened for sickle cell disease since the 
programme began in 1988. All affected babies have been referred by the BSCTC to the 
haematologist or paediatrician in their local hospital for follow-up clinical care. The baby’s 
GP, health visitor and the child health department are sent written confirmation of the 
diagnosis. The CMH haemoglobinopathy laboratory services have changed since the 
introduction of the national SCD newborn screening programme but this has not affected 
the identification of and follow-up care programmes for local babies born with sickle cell. 
 
3.3.2 Other screening modes 
Local universal and targeted antenatal screening programmes in the health district identify 
a small proportion of adults with sickle cell. Other individuals are picked up, as discussed 
in Chapter 1, by family screening, symptomatic presentation to local health services or 
during routine screening such as pre-operatively. Individuals are also detected if they self 
present for a screening test to the GP or to the local specialist haemoglobinopathy 
community nurses. All screening blood tests, apart from those undertaken as part of the 
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neonatal screening program, are undertaken in the haematology laboratory of a local 
hospital. If the local laboratory is unable to undertake the test then it is sent to another 
laboratory in the area and results are sent back to the referring laboratory. 
 
3.3.3 Potential modes of case ascertainment 
Figure 3.3 shows the patient screening pathways where cases with sickle cell disease, in 
NWL, are diagnosed. The screening laboratories are the primary source for identifying 
cases because definitive diagnosis is made by a specialist blood screening test. The test 
preformed is haemoglobin electrophoresis or high performance liquid chromatography 
(HPLC). The newborn screening programme uses both tests to confirm diagnosis; HPLC 
for first line testing and haemoglobin electrophoresis for second line testing (Old, 2007). 
Additional information, such as family studies and DNA analysis, is required for some 
types of sickle cell disease diagnoses. Testing for thalassaemia also involves review of the 
person’s full blood count (FBC) indices and evaluation of clinical symptoms (Old, 2007). 
 
As shown in Figure 3.3 the screening tests for all newborn babies in the region are 
undertaken by the Regional Haemoglobinopathy Laboratory at CMH and therefore this is 
the best source for identifying babies, born in the district, with SCD. All other cases will be 
diagnosed by the local haemoglobinopathy or haematology laboratories in the region. For 
example the cases in Brent and Harrow will be diagnosed by CMH because it is the local 
laboratory where blood specimens are sent from resident GPs, hospital departments and the 
BSCTC Community nurses. 
 
Unfortunately it is not possible to use this method as the primary source of case 
ascertainment to populate the NWL SCD registry primarily because of the financial cost 
and IT expertise required to extract the data efficiently and securely. The aim, in the long 
term, should be to include this data source to enhance the completeness of case 
ascertainment. 
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Paed. / Adult Patients
(Self Referral)
Sickle Cell & Thal. 
Specialist Centre /
SP Community Nurse *
GP *
Inpatient
Admission *
GP
Referral
Local Hospital *
OPD Clinic
Haematologist / Paediatrician
Consultant
Referral
Newborn Screening
(Since 1988)
Paed. / Adult Patients
(Self Referral)
A&E *
Discharge
(No Referral)
SP Community
Nurse
Referral
Other Clinics: *
Antenatal,
General Surgery,
Ophthalmologist,
etc.
Consultant
Referral
No Referral
Private Care / 
No NHS Contact
NS Regional Haemoglobinopathy Lab
@ CMH
Confirm Diagnosis by Blood Test
* Patient may have a blood test to confirm diagnosis at any of these points of care.
NS = Newborn Screening
SP = Specialist
Local Haemoglobinopathy Screening Lab
Confirm Diagnosis by Blood Test
Antenatal Screening
Antenatal
Positive
Screening
Results
Primary Sources = Blue (dark shade)
Lost Cases = Red (light shade)  
Figure 3.3: Sickle Cell Disease Patients in North West London Sector: Primary Information 
Sources for Case Ascertainment 
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3.3.4 Primary method of case ascertainment for the NWL SCD registry 
In the case of chronic diseases, such as sickle cell, there is frequent repeat contact between 
health care providers and the individual. Figure 3.3 describes all the potential pathways 
where SCD cases come in contact with the NHS. When a patient has been identified with 
the disease they should be referred to the haematologist or paediatrician in their local 
hospital or local specialist SCD centre for outpatient follow-up care. Patients with sickle 
cell disease have stable conditions with intermittent acute exacerbations. The majority 
regularly attend designated outpatient clinics for monitoring. Consequently the local sickle 
cell clinics in each hospital, within the health sector, are the next most efficient sites for 
identification of cases. Patients are generally well/ in steady state condition when they 
attend outpatients therefore this is the best time to inform them of the registry, gain their 
consent and initiate data collection. 
 
A small minority are missed if they are not referred to the SCD clinic or are referred and 
do not turn up. Patients that use private healthcare exclusively will also be missed but they 
are likely to be non UK residents and are therefore ineligible to join the registry. 
 
3.4 Development of evidence based high quality registry 
The major threat to the viability and utility of a registry/database is the quality and 
‘perceived’ quality of the data. Clinicians and users of the data must have confidence in the 
quality of the registry both to make use of registry outputs and to be motivated to collect 
data for inclusion in the registry (Black and Payne, 2003; Raftery et al, 2005). Therefore 
the quality of the data plays a central role in determining the feasibility and utility of the 
database for the benefit of sickle cell patients. According to the literature (see chapter 2, 
section 2.5.11, paragraph 4) the proposed purpose of the specific data collection dictates 
the quality attributes that must be achieved. Abate et al (1998) suggest that an acceptable 
level of data quality is achieved if it conforms to a defined specification and the 
specification correctly reflects the intended use. If the data satisfies these quality 
indicators, called conformance and utility, then the data agrees with international and 
traditional standards for data quality and is ‘fit for purpose’ or ‘fit for use’ (Abate et al, 
1998). 
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3.4.1 Data quality characteristics for a SCD registry 
Assuring data quality requires establishing quality assurance procedures and quality 
control processes (Arts et al, 2002). Quality assurance consists of activities undertaken 
before data collection to ensure that the data collection is optimised. Quality control occurs 
during data collection to identify and correct substandard and/or erroneous data (Whitney 
et al, 1998). The data quality attributes that constitute a high quality SCD registry must be 
defined in order to develop quality assurance and quality control processes (Arts et al, 
2002). The literature identified the following data quality characteristics that infer high 
quality: 
 
• complete coverage of the target population 
• complete case ascertainment 
• complete and accurate data variables collected for each case 
• outputs that are relevant, timely and usable 
• adds value (beneficial to patients, health care providers and service planners) 
 
3.4.2 Quality assurance framework 
An operational framework has been developed to optimise quality of data collected by the 
registry. The framework, outlined in Table 3.3, describes the quality attributes that are 
required in relation to the purpose of the registry data (1st column). Column 2 defines the 
methods and processes established to enable the quality criteria to be achieved and the 
third column outlines the methods for evaluating if they are achieved. The outcome 
measures selected are objective, feasible, and can be repeated to monitor progress over 
time. Table 3.4 is a plan of the operational procedures implemented and tools developed to 
achieve the goals outlined in Table 3.3. 
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Table 3.4: SCD Registry Quality Assurance Methods 
Sampling Method
● Create comprehensive list of all known eligible patients (with sickle cell disease diagnosis)
● All consecutive cases selected after site joins registry 
● Inclusion criteria:
     ○ All patients with a significant SCD diagnosis (SS, SC, SBthal, SD, SO)      
     ○ Patient attends participating hospital as an outpatient or inpatient
● Exclusion criteria:
     ○ Failure to obtain consent
Hydroxycarbamide (HU) sub-registry
● Inclusion criteria:
    ○ All children and adults with SCD treated with HU
Quality Assurance Procedures
● Develop evidence based datasets for data collection
● Develop guidelines for proforma completion 
● Develop glossary of study definitions for clinical events
● Data extraction: blinding to hypotheses and/or objective outcome measures
● Abstractors are health professionals or health care employees
● Abstractors receive training, ongoing supervision and support
● Consensus management of conflicting and 'difficult to interpret' data
● Easy access to data collection tools for all sites and personal - via registry website
● Ongoing communication with sites and staff involved in registry
Quality Control Procedures: Internal
● Second check of data collected/ or sample of each patients data rechecked
● Automated data validation and processing
● Return draft patient report and log to abstractor for verification and completion of missing and/or conflicting information
● Produce descriptive statistic reports of data quality (e.g. % missing data for selected variables and cases)
Quality Control Procedures: External
● Conduct reproducibility studies ( to assess inter and intra-observer reliability)  
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3.4.3 Principles of Data collection 
I. The data collection set included patient demographics, diagnosis and disease stage data, 
co-morbidities, risk factors, treatment details and outcomes of interest. These were the 
fields identified in Chapter 2 as critical for data collection. A supplementary set of data 
variables were collected in the HU sub-registry. This data set will be described in the next 
section. 
 
II. Triangulation of data sources is the most reliable method of increasing data reliability 
and data completion rates. A hierarchy of data sources were developed, shown in 
Table 3.5, to identify the primary and secondary supplies of valid data. This was based on 
the systems available at CMH but it can be applied to any hospital in the area. In situations 
where the registry was unable to access the best source of data due to physical, financial or 
other barriers then lower levels of data were used. In addition there were some localised 
differences between hospitals in how to access some information. 
 
III. The extra workload was reduced by spreading the data collection among all relevant 
health care team members and electronic record retrieval, where feasible. Care pathways 
identified which health care professionals should be actively involved to ensure accurate 
diagnosis, improved case ascertainment and follow-up (Figure 3.4 and Figure 3.5). Data 
collection was initiated in outpatients during regular or annual clinic review. The medical 
team were primarily responsible for gaining patient consent and collecting the prospective 
data. The nurses and registry co-ordinators were also involved. The registry co-ordinators 
managed the registration of patients and data collection processes and collected 
retrospective data where required.
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* Annual clinical review undertaken at local and specialist centre. Patient may be referred to specialist centre 
more frequently as required. 
SP = Specialist 
 
Figure 3.4: Sickle Cell Disease Paediatric Care Pathway 
Adult Patient
SCD & Thal Community 
Services / Centre
SP Community Nurse
Psychologist
OPD
Clinic
Primary Care Secondary Care
Acute Hospital
Inpatient
CareGP
Haematologist
SP Community Nurse
Psychologist
SP Clinic Referrals
SP Joint Clinics
SP Acute Nurse
Regular
Clinical Review
Annual
Clinical Review*
Community Adult
Management
Community
Primary Care
Haematologist
SP Community Nurse ±
SP Clinic Referrals ±
Specialist CentreLocal Centre
 
* Annual clinical review undertaken at local and specialist centre. Patient may be referred to specialist centre 
more frequently as required. 
SP = Specialist 
 
Figure 3.5: Sickle Cell Disease Adult Care Pathway 
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3.5 Utility of the SCD Registry 
The hydroxycarbamide (HU) sub-registry was used to evaluate the utility of the database 
for research and clinical care purposes. This study evaluated the long term effectiveness 
and safety of hydroxycarbamide treatment for SCD patients. In addition this data was 
utilized for clinical management by the production of patient reports for monitoring 
treatment. 
 
3.5.1 Hydroxycarbamide: measurable outcome indicators from therapy 
The measurement parameters used in this study have been defined from existing research 
for monitoring HU treatment efficacy. In particular the indicators used by the Multicentre 
Study of Hydroxyurea (MSH) (Charache et al, 1995) continue to be used for estimating 
haematological and clinical response both in research studies and for clinical monitoring 
during therapy (Ohene-Fremprong and Smith-Whitley, 1997; Davies and Gilmore, 2003; 
Halsey and Roberts, 2003). Other research studies, especially in children have evaluated 
additional clinical outcomes. Using the same outcomes as other studies facilitates 
comparison. A further criterion for inclusion of a variable was the ability to collect and 
measure the variable in routine clinical practice. The same parameters were used for 
clinical monitoring during therapy therefore the database could function as a clinical 
management tool as well as a research resource. Table 3.6 describes the biologic variables 
measured, the rationale for using the variable and how the change induced by HU benefits 
the patient. Table 3.7 outlines the clinical outcome variables evaluated and the rationale for 
their inclusion. 
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Table 3.7: Clinical outcome parameters 
↓ frequency of hospitalized pain crises events MSH found significant reduction in adults and a
↓ was observed in children studies. 14,19,21
↓ frequency of ACS events Significant reduction observed in MSH and 
in some studies of children. 14,19,21,22,23
↓ in annual number of inpatient days ↓ found in childrens studies. 14,19
↓ in annual number of inpatient admissions ↓ found in childrens studies. 14,19,22
↓ Blood transfusion (Tx) requirement In MSH significantly fewer patients on HU required a Tx. 21
Some childrens' studies report ↓ in patient's Tx requirements. 14,19
Parameter* Rationale for evaluation
 
* The evaluation will measure the annual change in clinical outcome from baseline value 
 
3.5.2 Monitoring hydoxycarbamide adverse effects 
Hydroxycarbamide is a potent chemotherapeutic agent, normally used in the treatment of 
haematological malignancies (Davies and Gilmore, 2003). It inhibits DNA synthesis and is 
therefore cytostatic and cytotoxic (Ohene-Frempong and Smith-Whitley, 1997). The 
known and potential side effects are thought to be caused by the drug’s interference with 
rapidly dividing cells (Kennedy et al, 1975; Brawley et al, 2008). Various actual and 
potential toxicities have been described in the literature; several are expected due to the 
mechanism of action of the drug. Evidence of other possible adverse effects is emerging 
but it is still not possible to prove causality, in most cases, due to the paucity of good 
quality long-term follow-up studies. 
 
Monitoring the incidence and severity of side effects is an essential function of the HU 
registry. The drug’s short and long-term safety profile will determine the feasibility of 
future usage for SCD patients. A critique of the adverse effects of treatment described in 
the literature has been undertaken in order to define the parameters that should be 
monitored by the registry. 
 
3.5.2.1 Bone marrow, kidney, liver and spleen function 
HU causes bone marrow suppression and may result in cytopenias therefore patients need 
regular haematological and clinical monitoring during treatment (Davies and Gilmore, 
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2003). Myelosuppression is usually dose related and transient. The common toxic effects 
include a decrease in the patient’s white blood cells, neutrophils, platelets, erythrocytes and 
reticulocytes. Careful regular monitoring of the patient’s full blood count (FBC) and 
clinical wellbeing with appropriate dose adjustments will usually prevent or control these 
side effects (Davies and Gilmore, 2003). Renal function is monitored routinely for signs of 
renal toxicity because the drug is excreted through the kidneys and small increases in 
creatinine are sometimes seen while on treatment (Ohene-Frempong and Smith-Whitley, 
1997; Halsey and Roberts, 2003). Special care and reduced dosage is required if used in 
patients with renal dysfunction (Aliyu et al, 2005). Liver function is also monitored but the 
rationale behind this is unclear. HU has been reported to cause elevations in liver enzymes 
but this is also seen in SCD patients not on HU therapy (Ohene-Frempong and Smith-
Whitley, 1997). Limited evidence shows that HU can preserve and improve splenic 
function in some SCD patients (Claster and Vichinsky, 1996; Wang et al, 2001; Santos et 
al, 2002). However, some subjects have developed hypersplenism and splenic 
sequestration during treatment and patients with a past history of spleen problems appear 
to be at increased risk of these complications (Wang et al, 2001; Gulbis et al, 2005; de 
Montalembert et al, 2006). Due to the high risk of death from acute splenic sequestration 
crisis careful regular monitoring of spleen size and blood parameters in patients with a 
prior history of splenic complications is advised (de Montalembert et al, 2006). 
 
3.5.2.2 Cutaneous side effects, gastrointestinal upsets and headache 
Cutaneous side effects with therapy are increasingly recognised. Melanonychia (nail 
hyperpigmentation) and increased skin pigmentation or darkening are commonly reported 
(Kennedy et al, 1975; de Montalembert et al, 1999; Zimmerman et al, 2004). Incidents of 
hair loss, skin rash and gastrointestinal upsets have also been reported (Kennedy et al, 
1975; Najean and Rain, 1997; de Montalembert et al, 1999) but in the MSH clinical trial 
these problems were no more frequent in the treatment group than in the placebo arm 
(Charache et al, 1995). Headaches have rarely been reported as a side effect but if 
attributed to HU they can be a substantial impediment to treatment. For example in one 
sickle cell patient HU treatment was stopped because of headaches and this was thought to 
be the source of non compliance with HU in another (Scott et al, 1996; Kinney et al, 1999; 
de Montalembert et al, 1999). Therapy does not appear to increase the incidence of leg 
ulcers in SCD except in patients with a history of previous ulcers (Charache et al, 1995; 
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Chaine et al, 2001; Mendpara et al, 2004). In contrast an increased incidence of late onset 
leg ulcers have been reported in patients treated for other diseases (Najean and Rain, 1997; 
Best et al, 1998). 
 
3.5.2.3 Pregnancy and risk of teratogenicity 
The safety of HU therapy during pregnancy remains unclear. Teratogenicity has been 
shown in experimental animals given very high doses of the drug; between 10 -100 times 
greater than therapeutic doses (Diav-Citrin et al, 1999; Thauvin-Robinet et al, 2001). The 
largest case series of 32 pregnancies in 31 women, with various diseases, reported no fetal 
anomalies ascribed to HU treatment but the incidence of interuterine growth restriction, 
fetal death in utero and preterm delivery were greater than expected (Thauvin-Robinet et 
al, 2001). However, causality could not be attributed to drug exposure and may be due to 
maternal underlying disease because these women suffered from SCD (1 case), chronic 
myeloid leukaemia (6 cases), chronic myeloid splenomegaly (2 cases) and essential 
thrombocythaemia (22 cases). Thauvin-Robinet et al (2001) reviewed the published cases 
of HU exposure in expectant mothers and these authors did not find any reports of infant 
birth defects. Diav-Citrin et al (1999) suggest that the risk to the human fetus associated 
with maternal exposure to HU may be overestimated. However, there is no routine follow-
up of children exposed to HU in utero, therefore any long-term adverse effects on these 
children is unknown (Brawley et al, 2008). As a result of the lack of good research 
evidence it is recommended that pregnancy should be avoided during therapy but drug 
exposure is not an absolute indication for medical termination (Thauvin-Robinet, 2001; 
Davies and Gilmore, 2003). 
 
3.5.2.4 Spermatogenesis 
Hydroxycarbamide has been reported to impair spermatogenesis in male mice (Evenson 
and Jost, 1993 cited in Davies and Gilmore, 2003) and recent evidence suggests that it 
probably reduces sperm counts and motility and alters sperm morphology at therapeutic 
doses in men with SCD (Grigg, 2007; Berthaut et al, 2008; Lukusa and Vermylen, 2008). 
Despite this limited evidence, of toxicity, it is suggested that male fertility is conserved and 
pregnancy and birth outcomes are within the normal range (Berthaut et al, 2008). 
Nevertheless, uncertainties remain regarding the risk to pregnancy and therefore it is 
routine practice to advise both male and female patients to stop treatment for at least three 
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months before they or their partner try to conceive (Davies and Gilmore, 2003; Halsey and 
Roberts, 2003). Some research supports offering male patients sperm cryopreservation 
prior to HU treatment to preserve their fertility potential (Berthaut et al, 2008; Lukusa and 
Vermylen, 2008). 
 
3.5.2.5 Risk of malignancy 
There appears to be an increased risk of leukaemia after treatment with HU in patients with 
essential thrombocythaemia and polycythaemia rubra vera (Najean and Rain, 1997; 
Sterkers et al, 1998; Finazzi et al, 2000 and 2005). Polycythaemia rubra vera can progress 
spontaneously to leukaemia and it is thought that the leukemogenic potential of HU is 
observed only in preleukaemic myeloproliferative syndromes (Najean and Rain, 1997). In 
contrast a study of patients with cyanotic congenital heart disease on long-term HU 
reported no cases of malignancy (Triadou et al, 1994 cited in de Montalemant et al, 1997). 
There is also evidence of an increased risk of skin carcinomas after prolonged use in 
patients with myeloproliferative disorders (Callot-Mellot et al, 1996; Najean and Rain, 
1997; Best and Petitt, 1998). 
 
Leukaemia and other cancers have been reported in sickle cell patients exposed to HU but 
there is no evidence that the incidence is higher compared with the general population 
(Schultz and Ware, 2003; Steinberg et al, 2003; Gulbis et al, 2005; Brawley et al, 2008). 
There is no evidence that patients with sickle cell disease have an increased tendency to 
develop leukaemia compared with the general population (Davies and Gilmore, 2003). 
However the risk of malignancy, due to therapy, is a major concern for patients and 
clinicians and is a recognised barrier to usage (Zumberg et al, 2005; Brawley et al, 2008). 
 
3.5.2.6 Monitoring toxicity and adverse effects in the SCD HU database 
Information is collected on adverse events for both routine clinical monitoring purposes 
and research. Episodes of myelosuppression and liver and kidney function are monitored 
routinely at every outpatient clinic attendance by appropriate blood tests, recording of 
clinical history and physical examination of the patient. Date of last menstrual period 
(LMP) is recorded to assist with managing pregnancy risk. Cutaneous side effects, hair 
loss, gastrointestinal disturbances and headache have been recorded annually on a separate 
HU proforma because this information is not systematically collected as part of normal 
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clinical management. Pregnancies and birth outcomes have also been recorded on the 
annual HU proforma. Male patients are not offered sperm cryopreservation prior to starting 
treatment therefore evaluation of spermatogenesis is not possible. Leg ulcer events have 
been collected as part of the patient’s medical history. Episodes of acute splenic 
sequestration crisis are identified from inpatient admission data, which have been collected 
for evaluation of clinical outcomes. Information about the patients’ past history of 
malignancy has been documented at start of treatment and collected annually thereafter. 
The HU protocol for patient monitoring and data collection at CMH is in Appendix I. 
 
3.5.3 Patient cohort and HU dosing schedule 
Patients from four centres, treated with HU for severe SCD, were entered in the sickle cell 
HU registry. Eligibility criteria and treatment schedule were decided by the patients’ 
clinician. The dosing and clinic monitoring schedule are described in Figure 3.6. The 
dosing schedule was changed, in 2002, from a starting dose of 20mg/kg/day to 
15mg/kg/day and increased every four weeks instead of every two weeks. The aim of 
treatment was to reach a maximum tolerated dose (MTD) or a maximum of 30mg/kg/day 
whichever is lower. MTD was achieved by increasing the dose until the patient developed 
haematological toxicity and then reducing the dose by 2.5 mg/kg/day. This lower dose was 
considered the patient’s MTD. Haematological toxicity was defined by absolute neutrophil 
count (ANC) < 2 x 106/ml, platelets < 80 x 106/ml, reticulocytes < 1% or 100 x 109/l and/or 
drop of 3g/dl in haemoglobin (Hb) below the patient’s baseline value. 
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Figure 3.6: Schedule for Monitoring Sickle Cell Disease Patients on Hydroxycarbamide (HU) 
Treatment 
 
3.5.4 HU data collection methods 
Retrospective and prospective clinical and laboratory data were collected on all patients 
from the start of their treatment. Therefore each patient had a different starting date for 
data collection. Data was collected on specially developed proformas. A manual with 
definitions of clinical events was developed to ensure standardization in recording between 
data collectors (copy shown in Appendix II). A registration form was completed when the 
patient started HU (Proforma 1) and then a single page follow-up form (Proforma 2) was 
completed for each outpatient clinic visit thereafter. These proformas captured the clinical 
and haematological data described in Tables 3.6 and 3.7. The registration form collected 
clinical data on the patient for the 12 months prior to start of treatment. This provided the 
baseline patient values for the study. Reason for starting therapy, treatment objective 
(maximum tolerated dose or set dose) and daily dose given were also collected at 
registration. An inpatient admission proforma was developed for systematic capture of 
inpatient admission episodes prior to HU therapy (Proforma 4). The follow up proforma 
included a question about compliance with treatment and menses (date of last menstrual 
period). The form was revised in September 2004 and the updated version collected 
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information about contraceptive use to assist in monitoring the risk of pregnancy during 
therapy. In addition, a single page annual follow-up form was completed which captured 
further data on side effects of therapy, vital status of the patient, status of HU treatment, 
reasons for HU withdrawal, treatment objective (MTD or set dose), history of malignancy, 
information about pregnancy and birth outcome (Proforma 3). These proformas are 
included in Appendix III. Patients on HU therapy also had the standard SCD proformas 
completed at registration and annually, although this data was not analysed as part of this 
study. These proformas were in use to capture demographic and clinical data for all SCD 
patients regardless of treatment type. 
 
All the data collection tools could be downloaded from the registry website at 
www.hbregistry.org.uk. Participants were issued with usernames and passwords to access 
the members’ area. The data collection proformas were introduced in August 2001 and 
therefore data was entered retrospectively for those patients who commenced HU prior to 
that date. Data collection was undertaken by the registry co-ordinator at three hospital sites 
and by the doctors, nurse specialist and registry co-ordinator at the fourth site. The 
information was double checked by a registry co-ordinator against the medical records for 
missing or inaccurate data. 
 
3.5.5 Data management 
The laboratory and clinical variables were summarised at two monthly intervals for clinical 
management purposes and annually for research analysis. Patients were expected to be 
reviewed in clinic at least every two months when their treatment was stable. Therefore 
two monthly aggregates of data provided a review of the patient in the previous two 
months. 
 
Annual clinical evaluation included the following: status of patient (alive/dead), treatment 
status, number of inpatient admissions and days in hospital, inpatient admission diagnosis, 
number of transfusion events, pregnancies, incidence of serious adverse events and 
haematological toxicity events, treatment objective (e.g. MTD or set dosing schedule) and 
whether the latter was achieved, and mean HU dose per kilogram prescribed daily. 
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Annual blood investigations included total haemoglobin (Hbg/dl), haemoglobin F% 
(HbF%), mean cell volume (MCV fl), absolute neutrophil count (ANC x109/l), 
reticulocytes (retics x109/l), and serum total bilirubin (umol/L). Other variables were 
collected to assist with clinical management but are excluded from the analysis. In 
addition, contraceptive use, menses and data regarding side effects were evaluated at one 
site. 
 
3.5.6 Statistical methods and analysis 
The objective was to compare the changes in variables over time to measure 
haematological and clinical benefit from treatment. Changes from baseline (yr 0), to each 
of the yrs 1,2,5,7, and 9 were analysed to identify significant changes associated with HU 
usage. Baseline year consisted of data collected for the year prior to the patient starting HU 
and the subsequent data consisted of data collected for the specific year being measured. 
 
The statistical package used for the analysis was Stata, Version 9.0., by StataCorp, Texas, 
USA. For changes over time, that were normally distributed numerical variables, the paired 
t-test was used to compare the paired sets of data. The Wilcoxon matched pairs test was 
used if a variable was not normally distributed and the Fishers Exact for small numbers. 
The number of subjects in each analysis was reported to aid interpretation of results. For 
example it was expected that there would be fewer patients on treatment in the long-term 
therefore the results would be less robust for years 7 and 9 than for the earlier years’ 
analysis, which had larger numbers of patients included. 
 
For normally distributed continuous variables the mean and standard deviation (SD) was 
calculated at each time point. The mean change over time (and 95% confidence interval) 
was calculated for the same time point (the mean difference from pre-treatment values to 
yr 1,2,5,7,9). Finally the statistical significance (p-value) of the change in the value of the 
variable from baseline to each year assessed was calculated. If variables were not normally 
distributed the median and inter-quartile range (IQR) at each time point was calculated. 
The median (and 95% confidence interval) change over time was reported and the p-value 
indicating the statistical significance of each result was calculated. For categorical 
variables the numbers and percentages were reported. 
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Chapter 4: Utility of a High Quality Sickle Cell 
Disease Registry/ Clinical Database for Clinical 
Care and Research 
4.1 Introduction 
It was hypothesised that registry information would play a dual role in patient benefit with 
outputs being utilized for direct patient care and audit as well as utilisation of data for 
research purposes. The geographical coverage and case ascertainment attained is reported 
in section 4.2.1. Section 4.2.2 describes the contribution of registry information for 
purchasers and service providers. This thesis utilized the data from the hydroxycarbamide 
(HU) sub-registry to demonstrate the value of a clinical database for clinical patient 
management and health service research in sickle cell disease (SCD). Sections 4.2.3 and 
4.2.4 provide examples of how registry outputs were used for routine patient management 
and the final section (4.3) reports the outcomes of long-term HU treatment in a cohort of 
sickle patients managed in routine clinical care settings. 
 
4.2 Benefits to patients and service providers 
The registry provided aggregated data reports to the local Managed Clinical Network 
(MCN) for haemoglobinopathies to support equitable and effective provision of health 
services for sickle cell disorder and thalassaemia patients within the local health 
community. The sickle cell clinical database directly supported clinicians at the point of 
care provision to improve patient treatment and outcomes. This was achieved by provision 
of data for local clinical audits and developing individualized patient reports for patient 
management. 
 
4.2.1. NWL sickle registry: geographical coverage and completeness of case 
ascertainment 
Four of the nine hospitals in the North West London (NWL) Health Sector participated. As 
stated earlier Northwick Park (NPH) and Central Middlesex (CMH) hospitals amalgamated 
to form the North West London Hospitals NHS Trust. Sickle cell disorder and thalassaemia 
patients attending NPH were gradually transferred to CMH and entered into the registry at 
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the CMH site. Consequently patients from five of the nine hospitals populated the registry 
over time. Alli (2002) reported 1113 known SCD patients in NWL, of which 872 attended 
these five hospitals, therefore it was estimated that 78 percent of the total SCD population 
was covered by the registry. 
 
SS 53%
SC 21%
SBThal 10%
Other 6%
Missing 
Diagnosis 3%
Thal 
Syndromes 7%
 
Figure 4.1:CMH, Ealing, Hammersmith, West Middx. Hospitals - 828 Patients by Hb Type 
 
Figure 4.1 shows the number and proportions of patients with clinically significant 
haemoglobinopathies attending these hospitals. At the 31/03/2004 there were 828 patients 
identified by the registry of which the vast majority (695 or 84%) suffered with sickle cell 
disease. The data from Figure 4.1 was compared with the data presented in Table 3.1, 
Chapter 1, to estimate the effectiveness of case ascertainment. The prevalence figures 
reported by Alli (2002) were used as the reference. This data suggested that the registry 
had identified 62 percent (695/1113*100) of the sectors’ known SCD population and 89% 
of those attending the four participating hospitals (695/782*100). If NPH is included than 
80 percent (695/872*100) of the potential patients were identified. However, a poorer 
result was achieved when the population prevalence estimate derived with the Davies et al 
(2000) method was used for the reference/ gold standard. This method estimated a SCD 
population of 1468 in NWL (see Table 3.1). Therefore the registry identified 47 percent of 
potential cases (695/1468*100) by the 31st of March 2004 if this estimate is indeed the true 
prevalence. Due to funding restrictions only cases from CMH were ascertained after the 
end of March 2004. 
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4.2.2 Patient characteristics and implications for service provision 
Aggregated anonymised demographic and diagnostic information was collected for all 
haemoglobinopathy patients attending these hospitals, including those with thalassaemia 
syndromes. This information provided the core dataset for quantifying prevalence of sickle 
cell and thalassaemia and mapping local hospital workloads and types of service provision 
required. Figures 4.1, 4.2, 4.3 and 4.4 describe the diagnostic and demographic profile of 
haemoglobinopathy patients attending the participating hospitals. 
 
227
27%
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Figure 4.2: Ealing, Hammersmith, West Middx. Hospitals - 828 Patients by Age Group 
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Figure 4.3: CMH, Ealing, Hammersmith, West Middx. Hospitals - 828 Patients by Age Group 
 
While the majority suffered from SCD, as shown in Figure 4.1, there were significant 
numbers of patients with thalassaemia syndromes. Both conditions have complicated and 
lifelong health care needs therefore the Primary Care Trusts (PCTs) and MCN required 
basic demography on both conditions for adequate needs assessment. Figure 4.2 
demonstrates that approximately three fifths of all patients were adults and another quarter 
were teenagers or young adults. A disproportionately high number of adults attended 
Central Middlesex (CMH) and Hammersmith hospitals (Figure 4.3). Figure 4.4 describes 
the PCT of residence of patients attending each site. Results suggested that many patients 
accessed services outside their resident health boundaries. For example the majority of 
patients resident in Brent and Harrow PCTs attended CMH but half of Ealing patients 
attended hospitals outside their PCT of residence with especially large numbers attending 
CMH and Hammersmith Hospital. Furthermore it was evident from Figure 4.4 that CMH 
and Hammersmith attracted patients from across the whole sector and also large numbers 
from outside the health district. 
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Figure 4.4: CMH, Ealing, Hammersmith, West Middx. Hospitals Haemoglobinopathy Patients 
(828) by PCT of Residence 
 
Data from the registry was able to provide an assessment of the uptake of HU treatment 
within participating hospitals. Table 4.1 shows the prevalence of HU use among HbSS 
adult patients in each hospital and overall at 31/03/2004. 
 
Table 4.1: Proportion of adult HbSS patients on HU therapy on 31/03/2004 
Hospital Total adults 
with HbSS
No. on HU % of total on 
HU
A 164 22 13%
B 14 2 14%
C 77 10 13%
D 5 0 0%
Total 260 34 13%
 
Adults = ≥ 16 years 
 
These are examples of the data reports that were provided to health professionals, the local 
PCTs and the North West London (NWL) Haemoglobinopathy MCN to assist with local 
clinical audits, service planning and management and needs assessment for 
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haemoglobinopathy patients in the health sector. Table 4.1 demonstrates the utility of the 
registry for evaluating diffusion of health technologies (HT). This information was 
presented at the local annual MCN conferences, which were attended by health 
professionals, purchasers and service users. Written reports were also provided to 
stakeholders and the presentations were uploaded to the registry website, which could be 
accessed by health professionals and the public. An example of an annual report is 
included in Appendix V. Appendix VI is an example of a research manuscript published in 
a peer review medical journal using patient data from the CMH registry. 
 
4.2.3 Data quality assurance 
The registry identified patients to populate the SCD clinical database. Sickle cell disorder 
patients gave consent for their clinical information to be entered into the database and used 
for research. The clinical database did not include patients with thalassaemia syndrome or 
those with non-clinically significant haemoglobin variants, for example HbCC. 
 
Clinical and demographic information was collected at registration and annually thereafter. 
Patients on HU treatment had additional information gathered as described previously in 
Chapter 3. The following methods were used to ensure data entry was accurate and 
complete: 
 
i. Diagnostic criteria; All patients entered into the registry had their diagnosis verified by 
blood tests. The laboratory tests used for diagnosis were haemoglobin electrophoresis (e.g 
iso-electric focusing (IEF) or cellulose acetate electrophoresis) and/or high performance 
liquid chromatography (HPLC). The full blood count (FBC) indices were used to 
corroborate the result. These tests were conducted in quality assured/ accredited 
laboratories, as specified in Chapter 1. Where appropriate, making a diagnosis involved 
additional information including family studies, DNA analysis and evaluation of clinical 
symptoms. 
 
ii. Data collection tools were developed, as described in Chapter 3, to ensure consistency 
and reliability of data between sites and data collectors. These tools included the Glossary 
of SCD study definitions and grading tables, as shown in Appendix II and standardised 
proformas for data collection across sites (Appendix III). 
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iii. Collected data was second checked against the patient's medical record by a member of 
the registry team at one site. 
 
iv. Disagreement between the data elements collected by different data collectors were 
resolved by arriving at a consensus as to the true value of the variable. The consultant or 
other experts were consulted to verify the true value of a variable if there was doubt about 
a data item. For example diagnosing an acute chest syndrome event (ACS) was often 
difficult. The discharge letter sometimes did not record the event but scrutiny of the 
inpatient admission notes, chest x-ray results and physiologic data indicated that the patient 
did suffer an ACS event (using the criteria for diagnosis defined by the Registry). 
 
v. Manual and automated internal consistency checks were implemented. A draft copy of 
an electronic patient record (EPR) was created for each patient from the inputted data. This 
record included a summary or the entire patient's data and a log file, which identified 
missing and inconsistent information. This EPR was sent back to the registry co-ordinator 
for verification, completion of missing fields and correction of inaccurate data. The 
database was then updated with the corrected data. This data was then used to produce the 
patient's EPR and for research and audit purposes. 
 
vi. Other internal consistency checks included visual and automated checking for values 
outside the normal ranges, for example blood test results. Data elements entered in 
different parts of the electronic patient record were automatically cross checked for 
consistency. For example blood transfusion events were checked against the inpatient 
admission records and the past medical history record. In addition visual inspection of the 
EPR proved to be an effective and quick method of identifying illogical and/or inconsistent 
data. 
 
vii. It was not possible to conduct a formal inter-rater and intra-rater reliability study as 
part of the quality assurance procedures. 
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4.2.4 Automated patient record for SCD patients 
Automated reporting systems produced succinct but comprehensive individualized patient 
reports for clinical management. A second individualized patient report was developed for 
the sub-set of patients taking HU therapy (see Appendix IV for a sample of the HU report). 
These reports were developed in Microsoft Excel and print copies were put in the patients’ 
medical notes for use during outpatient clinic consultations. 
 
This HU report was presented in both tabular and graphical format. Figure 4.5 is an 
example of the graphical report which formed part of the patient’s health record. It 
summarised key haematological and clinical information essential for monitoring a 
patient’s response to HU. As discussed in Chapter 3 the blood results and clinical data 
were summarised every two months for clinical management purposes. The annual 
summary was used to evaluate the patient’s clinical progress and for research. For example 
the HU study conducted as part of this thesis utilized this information; the results are 
reported in the next section (4.3). 
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Figure 4.5: Sample Patient Graph 
 
Figure 4.5 reports the patient’s mean cell volume (MCV fl) and Hb F% with the daily HU 
dose from start of treatment (13/05/1994) to the end of follow-up. The right axis is the 
daily prescribed dose of HU and the patient’s actual dose is represented by the shaded area 
in the graph. This patient stopped treatment twice, as shown by the absence of shading, 
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after eight months and 136 months. It can be seen from the data that the rise in MCV and 
HbF% was dependent on the HU dose. The vertical bars delineate each year of treatment. 
The numbers on the top of the vertical bars represent the annual number of inpatient days. 
In this example the patient had 11 inpatient days in the baseline year, prior to starting HU, 
no inpatient days after 12 months and three during the second year of treatment (from 12 to 
24 months). The triangles identify when the patient suffered a myelosuppressive episode 
and the total number of toxic episodes per year were displayed. In this example the patient 
continued to suffer toxicity until the daily dose was reduced to approximately 24- 25 
mg/kg/day after four years. 
 
The HU response graphs provide a succinct visual summary of the patient’s journey on 
treatment. Figure 4.5 is a good example of the value of these graphs in clinical practice. It 
is now possible to monitor the patient’s response to treatment more accurately and rapidly 
identify when dose changes are required. This graph is also very useful for explaining the 
benefits and difficulties of HU treatment. In this instance the patient journey to a stable 
treatment regime took four years. Treatment benefit for this patient is evident from looking 
at the graph. 
 
4.2.5. Utility of patient record 
Patients with complicated disease and care requirements accrued most benefit from the 
patient reports. They were useful for actively involving the patient in their care and 
treatment decisions. Specific examples of where the individualized patient reports have 
proven beneficial to patient care are described. 
 
Case A: 
A teenager wanted to stop HU treatment, after six years, because his/her health improved 
and it was thought that the therapy was no longer required. The HU report was used to 
discuss with the patient their pattern of clinical and haematological response with treatment 
adherence compared with non adherence. In this instance the patient’s report enabled the 
doctor to demonstrate that during treatment the severity of their disease was diminished 
with associated improvement in quality of life, measured by reduction in annual inpatient 
admission days, pain crisis events and other sickle cell disease complications. 
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Case B: 
It was proving difficult to adequately reduce the frequency and severity of an adult 
patient’s painful crises with HU because chronic medical problems unrelated to SCD 
compounded and aggravated the patient’s sickle cell symptoms. The graphs of HU clinical 
and haematological response were used to explore, with the patient, the possibility of small 
incremental dose increases to help symptom relief and at the same time avoid toxicity. It 
proved possible to increase the daily dose with strict monitoring. In addition the patient 
had improved understanding and appreciation of the dose limitation due to toxicity. 
 
The main drawback of the patient record was the restricted access due to the limitations of 
the hospitals IT systems. The reports were kept on a single computer and could be printed 
and put in the patient’s medical notes. Clinicians would have preferred the reports to be 
held on a central server where they had unlimited direct access to the data and reports. 
They also wished to be able to make more use of the data to save time and avoid 
duplication of information. A typical example was the desire to integrate relevant 
information from the reports into patient correspondence such as outpatient clinic letters to 
GPs. 
 
4.3 Feasibility and benefit of hydroxycarbamide as a long-term 
treatment for sickle cell disease patients: experience of the North 
West London Sickle Cell Disease Clinical Database. 
The focus of this study was the cohort of registry patients treated with HU. The aim was to 
evaluate the long-term feasibility and benefit for SCD patients treated with HU in routine 
clinical care. Results are presented in sections 4.3.1 to 4.3.7. 
 
4.3.1 Patient and data characteristics 
Eighty patients started HU therapy but 18 were excluded. Outcomes were evaluated after a 
full year on treatment therefore those patients taking HU for less than 1 year were 
excluded. Likewise if patients stopped using the drug in the early part or middle of a 
treatment year their data was censored at the end of the last full year on therapy. If nine 
months or more HU treatment was taken it was considered a full year for analysis 
purposes. Only patients with the most severe forms of SCD were included to enable 
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comparison of results with other studies, which have been mainly exclusive to HbSS and 
HbS/β0thal phenotypes. Consequently fourteen patients were omitted because they 
received HU for less than one year and four because they were either HbSC or HBS/β+thal 
phenotype. The remaining cohort of 62 patients included 51 adults and 11 children. There 
were 38 males and 24 females of which 55(89%) were HbSS, six HbS/β0thal and one 
SDPunjab. Mean age at start of treatment was 28 years (range, 16-44yrs) for the adults and 
10 (range, 1-14) for the children. Thirteen were switched from blood transfusion 
programmes to HU therapy. Follow-up ranged from 1-13years. Data was censored after 
nine years because there were too few patients for analysis beyond this time point. This 
totalled 249 person-years of data with a median follow-up of three years (IQR, 1-6yrs). 
 
Table 4.2 shows the reasons for commencing HU. The majority of patients started 
treatment for frequent inpatient pain crisis events or pain crises with another sickle 
complication. The second most common indication of HU was acute chest syndrome 
(ACS) events or ACS with another medical problem, usually pain crises. Eight patients 
commenced treatment for other indications including having symptoms in the community 
which were disruptive to activities of daily living such as frequent school absences. In 
eight cases it was not known why HU was started. 
 
Table 4.2: Reason for initiating HU therapy 
Indication No. of patients
Recurrent IP pain crisis events 21
IP pain crisis events and ACS 11
IP pain crisis events with additional complication 6
ACS 4
ACS with additional complication 4
Symptomatic in the community 4
Severe anaemia 1
Chronic sickle lung and alloantibodies 1
Chronic chest/sternum pain 1
Alternative to Tx programme (primary reason not known) 1
Not known 8  
IP = inpatient, Tx = blood transfusion 
The additional complications included 3 with chronic sickle lung (CSL), 2 avascular necrosis, 1 priaprism,1 
symptomatic in the community, 1 mesenteric syndrome, 1 salmonella septicaemia and 1 transient ischaemic 
attacks 
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4.3.2 Laboratory parameters 
The pattern of haematological response is shown in Tables 4.3 and 4.4. For haemoglobin 
(Hb) there was a statistically significant increase in mean annual value between baseline 
and each of years 1, 2, 5 and 7 of treatment. The biggest difference was after seven years, 
where values were, on average, 1.2 g/dl higher than at baseline. There was no difference 
between years zero and nine, but the number of patients in this analysis was possibly too 
small to achieve statistical significance as the mean increase was similar to what was 
attained in earlier years. As expected a statistically significant increase occurred between 
baseline mean cell volume (MCV) and each subsequent time point measured. The 
difference from baseline to year one and two was 18 fl which increased to 23 fl after five 
years. The Hb F percent analyses showed patients achieved statistically significant higher 
mean annual values for each year on HU compared to pre-therapy, with a mean annual 
increase of between 9-13 percent approximately. A statistically significant drop in absolute 
neutrophil count (ANC) was observed between baseline and each subsequent year, with 
mean values being at least 3 x 109/l lower than baseline. The median annual percentage 
reticulocyte (retic) count was reduced throughout HU use but the reduction was 
statistically significant after one and five years only. There was some evidence of a 
difference for year seven as well, although this result was only of borderline statistical 
significance (p=0.05). Median annual total bilirubin was statistically significantly 
decreased from baseline for years 1, 2 and 7 on treatment, with a median reduction of 
between 10-18 umol/L. 
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Table 4.3: Clinical and biologic outcomes achieved with HU treatment (a) 
Variable Year N Year 0 Mean 
(SD)
Last Year 
Mean (SD)
Difference Mean 
(95% CI)
P-value
Dose 1 62 15.2 (4.9) 18.1 (8.4) 2.9 (0.4, 5.4) 0.02
(mg/kg/day) 2 46 15.7 (5.2) 19.3 (8.1) 3.5 (0.7, 6.4) 0.02
5 21 16.5 (4.7) 18.7 (7.5) 2.2 (-1.8, 6.3) 0.26
7 14 16.7 (4.3) 20.3 (5.6) 3.6 (-1.4, 8.5) 0.14
9 8 16.5 (2.5) 18.8 (4.9) 2.3 (-1.0, 5.5) 0.14
HB (g/dl) 1 60 9.0 (1.6) 9.7 (1.7) 0.8 (0.4, 1.1) <0.001
2 42 9.1 (1.6) 9.7 (1.4) 0.7 (0.3, 1.1) 0.002
5 20 9.1 (1.6) 9.9 (1.3) 0.7 (0.2, 1.3) 0.01
7 14 9.1 (1.4) 10.3 (1.3) 1.2 (0.5, 1.8) 0.002
9 8 9.0 (1.3) 9.7 (1.2) 0.7 (-0.7, 2.0) 0.28
MCV (fl) 1 60 86 (10) 104 (17) 18 (14, 21) <0.001
2 41 86 (10) 104 (18) 18 (14, 21) <0.001
5 20 91 (8) 113 (13) 23 (18, 27) <0.001
7 14 93 (8) 115 (16) 22 (15, 29) <0.001
9 8 95 (8) 116 (14) 20 (13, 28) <0.001
HB F% 1 59 5.9 (5.0) 18.7 (11.6) 12.8 (10.2, 15.4) <0.001
2 42 6.2 (4.8) 18.3 (11.0) 12.2 (9.3, 15.1) <0.001
5 19 5.4 (4.4) 17.8 (9.4) 12.4 (8.7, 16.2) <0.001
7 13 5.9 (4.9) 18.8 (9.1) 12.9 (8.7, 17.1) <0.001
9 8 7.1 (4.3) 16.3 (6.5) 9.2 (5.0, 13.4) 0.001
ANC (109/l) 1 55 7.4 (3.4) 4.4 (2.2) -3.0 (-4.1, -1.9) <0.001
2 39 7.5 (3.2) 4.5 (2.2) -3.0 (-4.3, -1.7) <0.001
5 20 8.4 (3.5) 4.6 (1.7) -3.8 (5.7, -1.9) <0.001
7 14 8.5 (3.3) 4.4 (1.9) -4.1 (-6.6, -1.7) 0.003
9 8 8.5 (3.5) 4.9 (2.4) -3.6 (-6.8, -0.4) 0.03
Pain crisis 1 43 2.05 (2.56) 1.33 (1.82) -0.72 (-1.20, -0.24) 0.004
(IP events) 2 31 1.90 (2.07) 1.03 (1.72) -0.87 (-1.60, -0.15) 0.02
5 17 1.18 (1.38) 0.59 (1.28) -0.59 (-1.60, 0.42) 0.24
7 13 1.23 (1.54) 1.00 (1.78) -0.23 (-1.83, 1.37) 0.76
9 8 1.13 (1.55) 0.63 (1.06) -0.50 (-2.34, 1.34) 0.54
 
The data is paired therefore for a subject to be included in the analysis, values are required at both time 
points. Consequently, there are a different number of subjects in each of the analyses. (The figures reported 
are the number of subjects on which the analysis was based, the mean (standard deviation) at each time, 
along with the mean (95% confidence interval) change over time, and p-value indicating the significance of 
each result. 
Abbreviations: IP = inpatient, ANC = absolute neutrophil count 
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Table 4.4: Clinical and biologic outcomes achieved with HU treatment (b) 
Variable Year N Year 0 
Median 
(IQR)
Last Year 
Median 
(IQR)
Difference 
Median (95% CI)
P-value
Retics% 1 37 9.2 (5.3, 136) 6.3 (4.6, 9.5) -2.2 (-2.0, -0.2) 0.04
2 23 9.3 (5.6, 13.7) 7.5 (5.6, 9.9) -2.2 (-4.3, 1.2) 0.25
5 10 13.5 (8.0, 18.1) 7.0 (3.5, 10.7) -8.5 (-10.3, -0.1) 0.01
7 9 13.0 (5.3, 17.2) 7.1 (4.4, 8.1) -7.9 (-10.8, 1.0) 0.05
9 5 17.4 (4.1, 29.5) 6.5 (5.6, 8.9) -11.2 (-21.7, 3.0) 0.22
Total 1 59 41 (23, 82) 30 (20, 46) -10 (-22, -8) <0.001
Bilirubin 2 43 41 (24, 89) 29 (20, 49) -10 (-22, -5) <0.001
(umol/L) 5 19 59 (30, 89) 36 (28, 73) -10 (-31, 4) 0.08
7 14 59 (30, 80) 38 (31, 58) -18 (-38, 8) 0.04
9 8 47 (29, 68) 32 (29, 49) -15 (-47, 11) 0.12
IP Days 1 46 18 (9, 33) 8 (0, 22) -8 (-14, -5) <0.001
(annual no.) 2 31 14 (7, 29) 0 (0, 8) -10 (-21, -6) <0.001
5 17 12 (7, 32) 2 (0, 12) -10 (-17, 2) 0.02
7 13 11 (4, 32) 0 (0, 14) -10 (-25, 0) 0.01
9 8 10 (0, 33) 0 (0, 15) -5 (-50, 37) 0.62
Chest 1 43 1 (0, 2) 0 (0, 0) -1 (-1, 0) <0.001
Syndrome 2 31 0 (0, 2) 0 (0, 0) 0 (-1, 0) <0.001
(IP events) 5 17 1 (0, 2) 0 (0, 0) -1 (-2, 0) 0.009
7 13 1 (0, 2) 0 (0, 0) -1 (-2, 0) 0.009
9 8 1 (0, 2) 0 (0, 0) -1 (-3, 0) 0.03
Blood 1 51 2 (0, 7) 0 (0, 1) -2 (-6, 0) <0.001
Transfusion 2 36 2 (0, 12) 0 (0, 0) -2 (-5, -1) <0.001
(events) 5 18 3 (1, 12) 0 (0, 1) -3 (-8, 0) 0.001
7 13 2 (1, 12) 0 (0, 0) -2 (-12, 0) 0.008
9 8 5 (0, 12) 0 (0, 0) -5 (-12, 0) 0.03
 
Analysis examined the change from baseline (year 0) for those variables that were measured on a continuous 
scale, but where the distribution of the changes over time was not found to be normally distributed. The figures 
reported are the median (inter-quartile range) at each time, along with the median (95% confidence interval) 
change over time, and p-value indicating the significance of each result. 
 
4.3.3 Clinical response 
A summary of the clinical findings are reported in Tables 4.3 and 4.4. The mean annual 
number of inpatient (IP) pain crisis events per patient decreased significantly from pre-
treatment for the first two years with a 35 percent reduction after one year and 46 percent 
after two years. A reduction in mean annual pain crisis events was observed thereafter but 
it was not statistically significant. Median number of annual IP days was statistically 
significantly reduced compared to pre-treatment throughout the follow-up period except 
after nine years. The absolute reduction is striking with the median ranging from 0- 2 days 
Chapter 4  131 
per annum after two years on HU from a median of 18 days per annum before treatment. 
The median number of annual ACS events and transfusion events decreased significantly 
from pre-treatment levels for each year analysed. 
 
To further assess the long-term clinical effectiveness of HU, for this cohort of patients, the 
adverse event rates per 100 patient-years of follow-up were computed. Number of inpatient 
admissions was 124.5 per 100 patient-years, number of inpatient days was 1108 and the 
pain crisis rate was 98. The pain crisis rate for patients with two or more inpatient 
admissions per year was 25 per 100 patient-years. The rate of ACS events and transfusion 
events was 9.6 and 50.6 per 100 patient-years respectively. 
 
4.3.4 Serious adverse events 
The death rate was 0.8 and the stroke rate was 1.2 per 100 patient-years. Two patients died 
during follow-up, one 39 year old female after four years treatment and a young man of 20 
after three and a half years. The female patient died from a subarachnoid haemorrhage; she 
had a history of deep venous thrombosis and was on long-term anticoagulant therapy. The 
20 year old male patient was admitted with an ACS and rapidly deteriorated with multi-
organ failure. He was non compliant with his outpatient appointments and HU regime. 
Two other patients had infarctive strokes, one after three and a half years and the other 
after eight years on HU. They were subsequently switched to long-term transfusion 
programmes. No patient developed cancer during the follow up period but two patients 
were diagnosed with cancer after data collection ceased. Causality could not be attributed 
to HU treatment in one case where the patients’ medical and social history was likely 
contributory factors in the development of cancer. This patient, with a history of long-term 
alcohol misuse, chronic depression and severe hepatic iron overload from previous blood 
transfusions, developed primary liver cancer (hepatocellar carcinoma) after 11 years on 
HU. The other patient developed thyroid cancer (papillary cell carcinoma), after 27 months 
therapy, which was effectively treated. This patient had complained of a lump in her 
thyroid three weeks after starting HU and two months later a fine needle aspirate was 
reported as benign. 
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4.3.5 Toxicities 
4.3.5.1 Myelosuppression and cutaneous side effects 
The aim of treatment, for the majority of patients, was maximum tolerated dose (MTD) 
which was calculated by inducing haematological toxicity. Therefore, it was expected that 
patients would experience dose-dependent myelosuppression on at least one occasion. 
Overall there were 174 episodes of transient toxicity, yielding a rate of 70 per 100/patient 
years. 
 
There was no increase or decrease in the incidence of leg ulcers with HU but the overall 
occurrence was very small. Four patients out of 59 suffered leg ulcers prior to treatment 
and three of these patients suffered leg ulcer events while on HU. Two patients with 
recurrent ulcers were found to have deep venous incompetency/ insufficiency. There was 
no information about venous circulation on the other patients who developed ulceration. 
 
Annual surveys, at one site, revealed that approximately 50 percent of patients experienced 
mild or moderate melanonychia; two had nail pigmentation prior to therapy. Skin 
hyperpigmentation occurred in between 5-20 percent of patients. None stopped treatment 
as a consequence of these side effects. Another patient experienced severe hair thinning 
and melanonychia after six months while on 34mg/kg/day. The dose was then reduced to 
26 mg/kg/day but the toxicities were still present at 12 months and subsequently the patient 
stopped therapy at 15 months. It is not known why the patient stopped but it is likely that 
the side effects influenced the decision. There was no statistically significant change in the 
incidence of nausea and vomiting, headaches or hair thinning compared with pre HU 
status. 
 
4.3.5.2 Pregnancy and birth outcomes 
There were eight pregnancies reported. Five pregnancies occurred in four patients while on 
HU. Treatment was stopped early in the first trimester when it was known they were 
pregnant. Pregnancy outcomes included two terminations, one miscarriage and two normal 
live births. These pregnancies happened despite pre treatment counselling advice to stop 
the drug three months prior to patient/partner conception. Two patients stopped HU pre 
conception which resulted in three normal live births. Another pregnant lady was excluded 
Chapter 4  133 
from the analysis because treatment was stopped after three months due to pregnancy; the 
outcome of this conception is unknown. 
 
4.3.5.3 Monitoring pregnancy risk 
The questions ‘date of last LMP (last menstrual period)’ and ‘contraception use’ (no, yes, 
not applicable) were added to the clinic follow-up questionnaire to help monitor risk of 
pregnancy. To assess the utility of these questions their completion rate was analysed at 
one site where the questionnaire was completed prospectively during clinic visits. The 
question ‘date of LMP’ was analysed from 1st January 2003 to 31st August 2007 for 12 
menstruating adult females (≥ 16 yrs). In 210 proformas the question was only completed 
on 19.5 percent of occasions. The completion rate for the ‘contraception’ question, which 
was introduced later, was analysed for the same site from 1st January 2006 to 31st August 
2007. It was completed in 33 percent of the proformas (55 of 82) for 11 adult females but 
only in 8.5 percent (13 of 153) for the 17 adult males on HU. 
 
4.3.6 Treatment regime 
Results of mean daily dose changes from start of treatment (year 0) to year 1,2,5,7 and 9 
are shown in Table 4.3. There was a statistically significant increase in dose from baseline 
for the first two years of therapy only, with a mean increase of 2.9 (CI 0.4, 5.4) mg/kg/day 
after one year and 3.5 (CI 0.7, 6.4) after two years. The highest mean daily dose reached 
was 20.3mg/kg/day and the dose varied little throughout the whole follow-up period, from 
18.1(SD 8.4) to 20.3 (SD 5.6) mg/kg/day. 
 
4.3.6.1 Attainment of MTD 
The goal of treatment was MTD for 91 percent of patients and it was achieved in 65 
percent of the cohort. The mean MTD was 20mg/kg/day (SD 4) which took a median time 
of nine months to achieve (IQR 5-18 mths). Achieving MTD was not straightforward and a 
variety of barriers were identified. In half of cases where MTD was not attained the 
problem was non compliance with the monitoring regime and/or the drug. In a further three 
cases there was insufficient opportunity to achieve MTD as these patients stopped therapy 
or continued to be frequently admitted to hospital and in receipt of transfusions. In two 
patients the dose was reduced by the doctor, because of an increase in Hb above 12g/dL 
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causing viscosity symptoms, and in another patient due to non compliance with outpatient 
department clinic visits. One patient chose to reduce the dose from MTD and in three 
patients it was not known why MTD was not established. 
 
4.3.6.2 Techniques for measuring drug non adherence 
Non compliance with monitoring regime was evaluated by counting the proportion of 
outpatient department (opd) visits the patient attended as compared with the number of 
scheduled opd visits. Non compliance with HU was assessed by a triangulation of 
information sources. These included the proportion of non attendance at scheduled opd 
visits and time period between each visit attended, comments about compliance in the free 
text portion of the follow-up proforma and from the answers to the question about non 
compliance on the proforma (average number of doses missed per week). As stated in 
Chapter 3 a patient was prescribed sufficient HU to cover the period between opd visits. 
Consequently if a patient missed a visit they would run out of their medication or, if not, 
they were not taking the full amount prescribed on a daily or weekly basis. The question 
about non compliance was completed at one centre only where the proforma was 
completed prospectively during clinic. In the other centres the proformas were completed 
retrospectively from the patient’s medical notes by the researcher. This question is not 
routinely asked during clinic consultations therefore it was invariably incomplete at these 
sites. Occasionally there were comments in the medical notes addressing the patient’s drug 
adherence, if the clinician was concerned about usage. These were ad hoc entries and not a 
good source for drug compliance information. In addition the electronic patient record, 
generated by the registry, was reviewed for evidence of non compliance. For example the 
trends and changes in MCV and HbF data were inspected to help verify drug usage over 
time. 
 
4.3.6.3 Maintenance on MTD 
Most patients (83 percent) were maintained at their MTD. Two patients became intolerant 
to their original MTD after four and five years of treatment respectively. In one patient the 
MTD reduced from 23mg/kg/day to 17mg/kg/day after four years and he was maintained 
on this dose thereafter. In the other case the patient became progressively anaemic on an 
MTD of 14mg/kg/day after five years and therapy was switched to monthly transfusions. 
The dose was reduced in one patient following an aplastic crisis event and another patient’s 
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dose was not increased after weight gain. One patient appeared to have dose reduction for 
leg ulceration and eventual cessation of therapy. In another case it was probable that there 
was insufficient opportunity to retain MTD as this patient continued to be admitted to two 
different hospitals for pain crises which frequently resulted in administration of blood 
transfusion and cessation of HU during the inpatient episodes. Of note one child, aged 13 
months at start of therapy, appeared to become more tolerant to HU with the MTD rising 
from 16mg/kg/day to 23/24mg/kg/day after two years. This patient’s drug adherence was 
judged as satisfactory by the clinicians. 
 
4.3.7 Patient attrition 
Twenty-three patients stopped the drug, 20 continued with treatment and were still being 
followed up at the end of the study. The remaining 19 patients were on HU but follow-up 
ceased for reasons outside the control of the registry such as relocation or care transferred 
to another hospital (5), did not turn up for appointments and were lost to follow-up (6) and 
funding for data collection ended in three of the hospitals (8). 
 
Eleven stopped treatment indefinitely for medical reasons, as shown in Table 4.5, seven 
refused HU and it was not known why the other five stopped the drug. The two patients 
who accrued no clinical benefit were on very low doses due to their susceptibility to 
myelosuppression. One patient had continual dose reduction for persistent neutropenia to 
the point that it was of no therapeutic value so treatment was stopped. The other patient 
had renal dysfunction and was started on a low dose to arrest anaemia, but it proved 
ineffective. 
 
Table 4.5: Reasons for stopping HU in 23 patients with sickle cell disease 
Reason N HU treatment (months) Treatment Post HU*
Infarctive stroke 2 42, 96 Tx programme (2)
Haemorragic stroke 1 44 Died
Progressive anaemia 1 80 Tx programme
Opiod addiction 1 12 Drug rehabilitation + Tx programme
No clinical benefit 2 13, 50 No active treatment (2)
Father child 1 90 Tx programme
Pregnancy (never restarted HU) 3 12, 32, 40 No active treatment (2), Tx programme (1)
Patient refused 7 11, 12, 24, 24, 43, 84,106 No active treatment (7)
Not known 5 12, 15, 24, 24, 36 Not known  
Abbreviations: Tx = Transfusion (of blood) 
*Numbers in brackets = number of patients 
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Chapter 5: Discussion, Conclusions and 
Recommendations 
This is the first British study to assess the use of hydroxycarbamide (HU) therapy for 
sickle cell disease (SCD) patients. Our findings support the results of previous studies that 
long-term HU is a feasible treatment option and associated with continual haematological 
and some clinical benefit for SCD patients. 
 
5.1 Improvement in blood indices 
Throughout follow-up there remained significant improvements in Hb, HbF%, MCV and 
absolute neutrophil count (ANC x109/L) from pre-treatment levels. After nine years of 
treatment the increase in mean Hb, from baseline, was not statistically significant and the 
improvement in mean ANC was less significant than in previous years, although the lack 
of significance is possibly due to the meagre number of participants analysed at this time 
point. Therefore there was no evidence of bone marrow exhaustion in patients after 
prolonged HU use. Haemolysis improved with evidence from a sustained absolute 
reduction in total bilirubin levels, even though the decrease was only statistically 
significant for the first two years and after seven years was weakly significant. There was 
also a sustained reduction in annual median reticulocyte counts which was statistically 
significant after one and five years treatment but this variable had fewer observations in 
later years, and therefore less power to detect a difference. Overall the haematological 
outcomes from the present study agree with other research findings. There were substantial 
and sustained improvement in the blood parameters of SCD patients treated with long-term 
HU therapy. 
 
5.2 Clinical effectiveness of treatment 
Clinically, patients derived benefit for as long as they were receiving therapy but the 
magnitude of the benefit, for some clinical outcomes, appeared to reduce over time. There 
was a statistically significant reduction in median annual number of hospital admission 
days, acute chest syndrome (ACS) events and blood transfusions. The mean number of 
inpatient (IP) pain crisis events nearly halved during the follow-up, except after seven 
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years, but this reduction was only highly statistically significant for the first year with 
some evidence of a reduction after two years (p= 0.02). Therefore the evidence is weak, in 
this study, for the long-term effectiveness of HU in reducing IP pain crisis events beyond 
two years of treatment. The reduction in inpatient days was highly statistically significant 
for the first two years of treatment and remained significant up to seven years (p = 0.02 
after 5 years and p = 0.01 after 7 years). There was also a sustained highly statistically 
significant reduction in median annual ACS events and blood transfusion events up to 
seven years of treatment.  
 
The number of patients in the clinical analysis at five years and above was less than 20 and 
this may have been too few for robust results. It will be necessary to reanalyse the data 
when there are more patients, with longer follow-up, to assess the long-term effectiveness 
of HU in reducing IP pain crisis events and number of days in hospital in routine clinical 
practice. 
 
5.2.1 Comparison of clinical event rates with other studies 
The adverse event rates per 100 person years for this study, the Belgium registry, the MSH 
follow-up study and the HUSOFT extension study are presented in Table 5.1 (Steinberg et 
al 2003; Gulbis et al 2005; Hankins et al 2005). The event rates, reported by Telfer and 
colleagues (2007), of an untreated cohort of children and young adults are also presented 
for comparison. Comparability of the studies is limited due to the differing age of the 
patients in each cohort, the difference in number of patient years of follow-up and the 
different methods of follow-up. 
 
The Belgian registry had some similarities with this NWL study because patients in both 
cohorts were treated with HU in routine clinical practice (Gulbis et al, 2005). Also both 
cohorts only included patients with severe SCD. This study and the Belgium registry had 
similar event rates per 100 patient-years for IP admissions, IP admission days and IP pain 
crises, for patients with two or more pain crises per year. The large difference between the 
annual rate of IP pain crisis events per 100 person years and the rate for patients with two 
or more crises per year was due to a small proportion of patients who continued to be 
admitted frequently with pain. This minority of patients accounted for most of the IP 
admission crisis rate. 
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The difference in event rates for transient haematologic toxicity can be explained by the 
differing treatment regimes for each cohort. In contrast to the NWL cohort there was no 
attempt to push patients to maximum tolerated dose (MTD) in the Belgian registry and 
consequently patients were not expected to become toxic, on prescribed doses. However 
differences may also be due to differences in methods of data collection. The Belgian 
registry collected data annually and therefore some variables are likely to be underreported 
(Gulbis et al, 2005). The data in the present study was subject to more rigorous data 
collection methods. Patients’ clinical and haematological data were collected at each clinic 
visit for entry into the NWL sickle database. A query developed by the Registry’s 
computer program identified episodes of haematological toxicity, as defined by the criteria 
for toxicity in the HU protocol. These criteria are explained in chapter 3, section 3.5.3 and 
Appendix 1. Therefore toxic episodes were automatically calculated and it is likely that 
this information is more complete, in the present study, than that collected by the Belgian 
registry. 
 
Table 5.1: Comparison of cumulative event rates -per 100 person years on HU therapy vs 
patients not on HU 
This study Gulbis et al (2005) Steinberg et al (2003) Hankins et al (2005) Telfer et al (2007)***
(NWL registry) (Belgian registry) (MSH follow-up study) (HUSOFT extension) (East London cohort)
Total no. patients 62 109 299 21 ≈ < 180
Patient-years of follow-up 249 426 2264 106.4 1456
Mean follow-up (yrs) 3* 3.9 7.6** 4.9
Median Age (yrs) 10 - children 6 Adults 3.4 ≈ 7.4
28 - adults
Events
IP adm, no. 124.5 138
IP adm, days 1108 1033
IP pain crises 98 33.8 63.9
IP pain crises ≥ 2/yr 25 22
ACS 9.6 3.3 7.5 17.1
Blood Tx events 50.6
Transient haematologic
toxicity 70 1.4
CVA 1.2 1.3 0.6 0.3
Malignancy 0 0.23 0.1
Death 0.8 0.23 3.3 0.94 0.1 and 0.27****  
Abbreviations: IP adm = inpatient admission, Tx = transfusion, ACS = acute chest syndrome, CVA = 
cerebrovascular accident 
Median age at start of treatment reported 
* Median reported 
** Mean length of follow-up, includes time on and off HU 
*** 180 with HbSS in cohort but those > 16 yrs were excluded from the event rate analysis. Patient years on 
Hu and blood Tx therapy were also excluded. 
**** The death rate was 0.1 if the two infants with HbSS that never attended clinic are excluded from the 
cohort 
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The inpatient pain crisis rates per hundred person years varied across all studies, measuring 
this outcome, in Table 5.1. This may be due to the difference in disease severity of the 
cohorts. All patients in the present study had severe SCD (because this was the criterion for 
commencing HU). In contrast the East London cohort excluded patients on HU or 
transfusion programmes, from the event rate calculations, therefore the most severe 
patients with SCD were excluded (Telfer et al, 2007). Similarly the patients in the original 
HUSOFT study were an unselected group chosen to commence HU therefore that cohort 
would be expected to include patients with a broad spectrum of disease severity, from mild 
to severe disease (Wang et al, 2001; Hankins et al, 2005). Comparison of the East London 
cohort and the HUSOFT patients shows that the pain crisis event rate was less in the group 
of patients taking HU treatment. Disparity between the studies’ patient selection criteria 
prohibit any conclusions being drawn about the differences between the NWL cohort’s 
pain crisis rates and the other studies measuring this outcome. 
 
Table 5.1 also shows that the ACS rate was lower in all studies, including the NWL cohort, 
compared with the East London cohort (Telfer et al, 2007). Indeed most studies have 
shown statistically significant reductions in numbers of ACS events for patients treated 
with HU (Charache et al, 1995; Maier-Redelsperger et al, 1999; Halsey and Roberts, 2003; 
Gulbis et al, 2005; Hankins et al, 2005). 
 
None of the patients, in the present study, suffered a severe adverse event that could be 
directly attributed to HU treatment. The rates of serious adverse events, for different 
patient cohorts, are shown in Table 5.1. These are useful for guidance on the magnitude of 
serious event rates for SCD patients managed with and without HU therapy. Again due to 
variation between the studies, in terms of patient selection criteria, it is not possible to 
compare serious adverse event rates. Patient characteristics that influence the risk of 
serious events, such as age and disease severity, are dissimilar in each cohort (Platt et al, 
1994; Ohene-Frempong et al, 1998). 
 
5.3 Cutaneous side effects 
Similar to other cohorts a proportion of patients experienced dermatological side effects 
including nail darkening and skin hyper pigmentation (de Montalembert et al, 1999; 
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Zimmerman et al, 2004; Brawley et al, 2008). Such side effects were acceptable to patients 
and did not warrant cessation of therapy. This study did not find any increase (or decrease) 
in the incidence of leg ulcers but the overall occurrence was small. A recent systematic 
literature review reported that HU does not affect the development of leg ulcers in SCD 
patients, although it is associated with increased incidence when used for patients with 
other illnesses (Lanzkron et al, 2008). Three of the four patients, in this cohort, with leg 
ulcers pre treatment developed ulcers while on therapy. Ulcers in SCD patients tend to 
recur and therefore it is likely that these patients would have developed ulcers irrespective 
of HU. Case series reports by Chaine et al (2001) and Mendpara et al (2004) found that the 
majority of the SCD patients who developed leg ulcers while on HU had a history of leg 
ulcers pre treatment. Does this evidence suggest that SCD patients with previous ulceration 
may be at greater risk of developing ulcers during treatment or that HU does not confer any 
protection against recurrence of leg ulcers in this group? 
 
5.4 Pregnancy outcomes 
The two patients who completed their pregnancies delivered healthy babies despite taking 
HU into the first trimester. Other studies have reported the birth of healthy newborns to 
women who conceive while on treatment (Charache et al, 1995; Thauvin-Robinet et al, 
2001; Gulbis et al, 2005). However, there is little data about the safety of HU at therapeutic 
doses in pregnant women (Thauvin-Robinet et al, 2001). Uncertainty about birth outcomes 
is a barrier to use and requires further investigation (Lanzkon et al, 2008). The literature is 
based on case series evidence and data from a few experimental studies, on rats and mice; 
therefore it is not known whether the incidence of adverse birth outcomes is higher than 
expected for the populations under study (Lanzkon et al, 2008). For instance in the largest 
case series of human exposure during pregnancy, by Trauvin-Robinet et al (2001), it was 
not possible to identify whether the adverse birth outcomes reported were due to maternal 
underlying disease or exposure to HU. 
 
In addition, the long-term effects on children exposed in utero are not known (Brawley et 
al, 2008). Research studies to date have not systematically followed-up the offspring of 
patients with SCD, after birth, to evaluate developmental abnormalities over time. Most 
cohort studies, including this sickle cell database, only report birth outcomes. If it is not 
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possible to follow-up every outcome of interest then targeted studies can be conducted 
using representative samples of patients identified by registry data. This strategy was used 
by the EUROCARE researchers, as discussed in Chapter 2. They conducted high 
resolution studies to investigate the causes of poor cancer outcomes in geographical areas 
or in groups of patients identified with comparatively inferior outcomes. 
 
5.5 Incidence of pregnancy on HU 
It is standard practice to advise patients to avoid conception while on HU treatment (de 
Montalembert et al, 1999; Davies and Gilmore, 2003; Gulbis et al, 2005). Patients entered 
in the present study were counselled, pre therapy, to avoid pregnancy. Should they decide 
to have a child, during treatment, the clinical management options were discussed. Despite 
these measures four patients conceived while on therapy. Unplanned pregnancies continue 
to be reported during HU exposure, not only in women with SCD but also in those treated 
for other conditions (Charache et al, 1995; Thauvin-Robinet et al, 2001; Gulbis et al 2005; 
de Montalembert et al, 2006). There is some evidence that up to 50 percent of pregnancies 
are unplanned therefore it is possible that some may result in unintentional fetal drug 
exposure (Skrabanek, 1992; Diav-Citrin, 1999). 
 
5.5.1 Strategies to reduce pregnancy risk 
In this study asking patients about contraception use and documenting date of last 
menstrual period (LMP) at each visit was not a successful strategy for monitoring 
pregnancy risk. Despite the use of a standardised proforma, data on these specific variables 
were often missing in the database. The proforma was checked against the patient’s 
medical record for accuracy and completion of missing data. Some doctors completed the 
proforma retrospectively, after clinic, or they were completed by the researcher 
retrospectively. If the information was not documented in the medical notes it could not be 
completed, and was missing in the database. Therefore the reason for missing information, 
in the database, for these variables was insufficient clinical documentation in the patient 
notes to complete the questions. The literature review, in Chapter 2, identified this problem 
as a major source of incompleteness and inaccuracy in registry data. Reported strategies to 
improve the data source include a standardised proforma for clinical data collection but if 
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the questions are not routinely asked during clinical consultations this may not help reduce 
missing data. This would appear to be the problem with these variables. Menstrual cycle 
and contraceptive use is not regularly documented in SCD patients’ clinical notes. In 
addition this information may have been seen as sensitive and some doctors might have 
been uncomfortable with this line of questioning or felt it was unnecessary. This 
information should be routinely asked at clinical consultations. Perhaps there is a need for 
the clinical staff to be better informed of the importance of asking these questions. 
 
5.5.2 Counselling and monitoring strategies 
Monitoring pregnancy risk is very important for patients taking HU. It is known that 
concerns about lack of vigilance with contraception is a substantial barrier to prescribing 
HU and interventions have not been tested to minimize pregnancy risk (Zumberg et al, 
2005). Unfortunately the experience from this study and that of other investigators 
suggests that reproductive counselling, at the outset of treatment, is not a totally effective 
strategy. Platt (2008) advises doctors to conduct systematic counselling sessions 
throughout the duration of HU use. 
 
Prescribing and monitoring HU has traditionally been the domain of the hospital doctor but 
it might be beneficial to enlist the help of other healthcare professionals. 
Haemoglobinopathy nurse specialists and counsellors could educate patients about HU 
risks and undertake surveillance of contraceptive use and adherence during therapy. 
Patients and parent/carers build up long-term supportive relationships with these 
practitioners (Gould et al, 2000; De, 2005). Likewise GPs could play a more active role in 
monitoring patients on therapy via shared care protocols. Most sickle cell patients already 
benefit from being cared for by multidisciplinary care teams. Therefore, the infrastructure 
is already in place for improving communications and links with other primary care health 
professionals. Indeed strengthening the primary and secondary care team approach is 
strongly advocated in the recent national guidelines for caring for children and adults with 
SCD (NHS Sickle Cell and Thalassaemia Screening Programme, 2006b; Sickle Cell 
Society, 2008). 
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5.6 Therapeutic dose and dosing schedule 
Mean daily dose was statistically significantly increased from start of treatment for the first 
two years only (p= 0.02). There was no significant change from baseline thereafter. Of 
note the mean daily dose remained modest at between 18.1 (SD 8.4) and 20.3(SD 5.6) 
mg/kg/day and MTD was 20mg/kg/day. Despite MTD being the main treatment objective 
it was only achieved in 65 percent of the whole cohort. It was evident from our rate of 
transient myelosuppressive episodes that dosing was pushed to MTD, where possible, but 
patients were not able to tolerate high doses. None were able to maintain a dose anywhere 
near 30mg/kg/day, as the stated aim in the treatment protocol. Non compliance with HU 
and/or the treatment regime was the main source of MTD non achievement. HU was not 
routinely stopped by the medical team if patients were non compliant with the drug or the 
treatment monitoring schedule. 
 
Non adherence to MTD and modest tolerance explains why the mean annual dose 
remained ≤ 20mg/kg/day. These doses are similar to the MSH, where two-thirds of adult 
patients in quartile 4, the most compliant and best responding group, averaged doses of 
between 15-22mg/kg/day (Steinberg et al, 1997). In contrast children appear to be able to 
achieve higher doses, with MTDs reaching at least 5-6 mg/kg/day more then in adults, 
possibly due to better bone marrow reserve, improved adherence to therapy and more 
rigorous monitoring (Kinney et al, 1999; Zimmerman et al, 2004; Hankins et al, 2005). 
 
5.6.1 Optimal treatment regime 
The results of different treatment strategies were compared, as shown in Table 5.2, to 
identify the optimal treatment regime for routine clinic practice. Unfortunately most 
studies have reported haematological responses with sparse clinical outcome data. If 
clinical outcomes (e.g. IP admissions, IP days, patient transfusion requirements or ACS 
events) were reported they were not easily comparable due to the different methods of 
analysis used by each study. Therefore, outcomes after two years of treatment were 
compared as these were consistently reported by most studies. 
 
The evidence from the Belgium registry, the French cohort and the present study suggests 
that both haematological and clinical benefits are sustained up to two years with modest 
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daily doses of between 19 -20.7 mg/kg/day, as shown in Table 5.2. Similar to the present 
study these cohorts were followed up in normal clinical practice with less stringent 
monitoring than in the US cohorts, where patients received treatment as part of formal 
clinical trials. Notably patients, in the European cohorts, that were seen to be non 
compliant were not excluded and treatment and monitoring schedules were decided by the 
individual patient’s clinician. The mean daily dose for the adults in quartile 3 and 4, of the 
MSH study, was 20mg/kg/day (Steinberg et al, 1997). 
 
In contrast most of the US studies, involving children, have succeeded in maintaining HU 
at MTD or fixed doses of 30 -35mg/kg/day but with more stringent monitoring procedures 
including withdrawing treatment if patients are non compliant. The studies by Zimmerman 
et al (2004) and Kinney et al (1999) managed a mean daily dose of between 24.4 -25.6 
mg/kg/day. In the HUSOFT extension study 21 children had their dose escalated to 
30mg/kg/day after two years of HU at 20mg/kg/day (Wang et al, 2001; Hankins et al, 
2005). All but one child managed to stay on this dose for up to four years. 
 
Maintaining a HbF of 20% and Hb of 9g/dl are thought to be the thresholds that confer 
therapeutic benefit for SCD patients (Powers et al, 1984; Noguchi et al, 1988; Ohene-
Frempong and Smith-Whitley 1997). The data in Table 5.2 shows that all cohorts, except 
the HUSOFT trial, were able to increase mean Hb to ≥ 9g/dl. The increase was not 
statistically significant in the French cohort. HbF% was also significantly increased, 
although only two of the cohorts achieved a HbF% ≥ 20%. Absolute neutrophil count was 
reduced in all the studies and, where reported, the reduction was statistically significant, 
except in the Belgian registry group. Only the European cohorts and the MSH reported 
differences in clinical outcomes achieved from pre-treatment. Number of IP days and 
number of pain crisis events were statistically significantly reduced after two years of 
treatment, where reported. 
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Two studies compared treatment regimes in the longer term. Gulbis et al (2005) compared 
a subset of their patients in receipt of HU for at least six years. They compared the clinical 
outcomes achieved from one to three years of therapy and from four to six years. 
Gulbis and colleagues (2005) found a tendency toward declining treatment intensity over 
time which was thought to result in HU being less effective in the long-term. The data 
presented in Tables 4.3 and 4.4 shows that the benefit achieved from pre-treatment with 
respect to mean annual IP pain crisis events and IP days were reduced over time in the 
NWL cohort. There was persistence to strive for MTD but dose reduction did occur over 
time, as shown in Table 4.3. Only 65% of patients were treated at MTD and the mean daily 
dose was very modest at between 18.1 to 20.3 mg/kg/day, the highest level achieved. 
Therefore there may have been some reduction in treatment intensity over time, in this 
NWL cohort. In addition, the mean daily dose achieved was below the optimal level, from 
the outset, for those patients not pushed to MTD. 
 
Zimmerman et al (2004) compared the haematological outcomes achieved within their US 
patient cohort with the Belgium cohort reported by Ferster et al (2001). Patients were 
compared for up to five years on HU. The US cohort had statistically significant higher 
Hb, HbF% and MCV when compared to the Belgian cohort. The better haematological 
results were attributed to the difference in treatment regime. The primary difference 
between the two patient groups was goal of treatment. In the US study, patients were 
treated at MTD whereas the Belgium cohort was not pushed to MTD. This resulted in the 
Belgian study participants being treated at lower daily doses of HU compared to the US 
cohort (Zimmerman et al, 2004; Gulbis et al, 2005). 
 
In light of this evidence it seems sensible to strive for MTD to ensure HU remains 
effective, but with a more realistic expectation of the doses patients can attain and maintain 
over time in normal clinical practice. Doses in adult patients appear to average around 
20mg/kg/day and up to 25mg/kg/day in children. Adult patients may be able to achieve a 
slightly higher dose, similar to that achieved by children, if there was more stringent 
monitoring and improved management of non-compliance to treatment and treatment 
protocol. 
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5.6.2 Maintaining MTD as treatment goal 
Maintaining MTD was challenging, which was similar to the experience of others, 
including the MSH where MTD was not determined in 43 percent of patients (Steinberg et 
al, 1997). A major barrier appears to be non compliance with treatment schedule, whereby 
patients do not attend clinic appointments or they fail to take their medication. No explicit 
explanation was given as to why so many failed to reach MTD in the MSH but many 
patients in quartiles 1 and 2 did not take their tablets (Steinberg et al, 1997). In other US 
studies, shown in Table 5.2, between 11 and 19 percent of children had their treatment 
stopped for non adherence. Adolescents and young adults are the most likely to prove non-
compliant and stop HU (Zimmermann et al, 2004; Gulbis et al, 2005). 
 
Patient non compliance not only affects the efficacy of HU but it appears to be a 
substantial contraindication for usage. In the survey by Zumberg and colleagues (2005) 80 
percent of doctors stated that non-compliance was a very important or important barrier to 
prescribing HU. The study by Lanzkron et al (2006) reported that six of seven eligible 
patients not on HU had problems with compliance such as no regular out-patient follow-up 
and non adherence to prescribed treatment. This problem is insufficiently researched but it 
is thought that the frequency of appointments for monitoring is a major issue along with 
simply forgetting to take the medication (Hutchins-Pullins, 2008). According to 
Zimmerman et al (2004) patient compliance problems should be managed by coordinated 
efforts from the medical team and frequent contact with families to provide support and 
encouragement. 
5.6.3 Interventions for monitoring treatment effectiveness in clinical practice 
The effect of reduction in treatment intensity over time could be mistaken for loss of 
efficacy and lead to the patient or doctor stopping therapy. In view of this it is important to 
monitor patient response in relation to daily dose and level of compliance. This can be 
achieved for individual patients using an electronic patient record like the one produced by 
the present NWL SCD registry. The graphical presentation of results, as shown in Figure 
4.5, presented longitudinal information, on a single sheet, covering patient daily dose, 
changes in blood indices, clinical outcomes and myelosuppressive toxic episodes. This 
concise and easy to read clinical management tool enables systematic monitoring in routine 
clinical practice. 
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Care providers and parents have reported uncertainty about HU effectiveness and efficacy 
as a barrier to use (Zumberg, et al 2005; Hankins et al, 2007). This clinical management 
tool has the potential to enable doctors, together with their patients, to systematically 
monitor treatment response over the duration of therapy. The UK Cystic Fibrosis Database 
provided software to participating sites to enable local data entry and analysis. A main 
output was individualized patient reports. These were successfully used during patient 
consultations to assist with clinical management and provide feedback to patients about 
their disease and care (Mehta et al, 2004). The cases reported in Chapter 4, section 4.2 
provide anecdotal evidence of the benefit derived from the patient reports developed for 
the present NWL registry. This intervention would need to be formally tested before 
widespread implementation due to the inherent difficulties in implementing change to 
clinical practice. The evidence, in Chapter 2, suggests that even when a new treatment or 
instrument has proven efficacy, effective implementation strategies must be developed to 
motivate care providers to change clinical practice (Dellinger and Vincent, 2005; 
Department of Health, 2007a; Richards, 2007). 
 
5.7 Managing patient attrition 
Patient attrition rates were substantial in this study, similar to other HU patient cohorts 
(Kinney et al, 1999; Zimmerman et al, 2004; Gulbis et al, 2005; de Montalembert et al, 
2006; Segal et al, 2008). This occurred because patients stopped treatment or were lost to 
follow-up. 
5.7.1 Reasons for stopping HU 
In this cohort medical contraindication was the reason for stopping therapy in nearly 50 
percent of cases. Other studies have also reported that many patients ceased treatment for 
medical reasons (Kinney et al, 1999; Gulbis et al, 2005; de Montalembert et al, 2006). HU 
is reserved for the most severely affected SCD patients, often with multiple co-morbidities. 
Therefore it is inevitable that in some cases of disease progression HU will no longer be 
the optimal treatment choice. In addition there will always be instances were treatment is 
interrupted for social and lifestyle reasons such as pregnancy or fathering a child, 
rehabilitation for substance misuse and so forth. 
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Ten patients refused to continue with HU, out of the 23 which stopped, including three 
who decided not to restart following an interruption for pregnancy. It is not known why 
these patients decided to stop therapy. Unfortunately studies have not investigated why 
patients refuse HU, which is a major impediment in quantification of risks versus benefits. 
For example it is not known if patients stop because of inadequate response, development 
of adverse events, side effects or complications (Segal et al, 2008). In addition patients 
may have stopped for the same reasons cited as barriers to usage such as concerns about 
side effects, safety and efficacy of HU, or inability to comply with the treatment regime 
(Zumberg et al, 2005; Hankins et al, 2007). 
 
5.7.2 Reasons for losses to follow-up 
Thirty percent of patients were lost to follow-up by the registry during the data collection 
period. These patients were receiving treatment when follow-up ceased. Substantial losses 
to follow-up have also been reported by other HU studies in SCD patients (Strouse et al, 
2008). 
 
Losses to follow-up and other types of patient attrition have two effects on the data. Firstly 
they reduce the sample size and secondly non-random losses may introduce selection bias 
which can affect the validity and generalisability of the study results. Random losses do 
not affect the validity of the results but the reduction in sample size will weaken power and 
precision of the study (Mortensen, 1995; Grimes and Schulz, 2002b). Some losses to 
follow-up, in this study, were likely to be random but others may not have been. Data 
collection ceased in some hospitals due to lack of funding. The curtailment of data 
collection in these patients was non random but there is no reason to expect that these 
patients differed in any way from the cohort that continued to be followed up. Therefore 
their loss did not introduce selection bias into the cohort to invalidate the study results. 
However, without this cohort the sample size was reduced over time and consequently the 
results are less robust for later years. The wider confidence intervals for some of the mean 
differences achieved in later years suggests that results might be partly due to random error 
and small numbers. 
 
 The group of patients for which it is unknown why they were lost to follow-up may be 
different to the group that remained in the cohort. These patients could be similar to the 
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group of patients for which the reasons for refusal of treatment are unknown. Possible 
reasons include non attendance due to relocation, not wanting to continue to be followed 
up in clinic or not wanting to continue with HU. The loss of these patients could introduce 
selection bias into the study if they are indeed different to the cohort that continued with 
treatment and continued to be followed up. 
 
5.7.3 Managing losses to follow-up and other sources of patient attrition 
Grimes and Schulz (2002b) suggest that the best way of dealing with loss to follow-up is to 
avoid it. Clinical networks and long-term investment in sickle cell research would enable 
clinical registries to follow-up these patients as they move around (Ohene-Frempong and 
Smith-Whitley, 1997). For example the number of patients lost to follow-up in the present 
cohort would have been cut by over 40 percent and the total size of the cohort increased if 
the part-time registry co-ordinator post had continued to be funded. Maintaining record-
linkage between data sources is an efficient method of increasing registry coverage and at 
the same time reducing the burden of data collection, as discussed in Chapter 2, which is a 
barrier to participation for clinicians (Mortensen, 1995). 
 
Reducing attrition rates due to treatment refusal and losses to follow-up from non 
attendance at clinic are different issues and probably more difficult problems to overcome. 
These problems may be partly due to ineffective dissemination of information concerning 
risks and benefits of HU by health professionals to patients and patient advocacy groups. 
Hankins and colleagues (2007) have shown that children with severe SCD and their 
parents can identify their treatment preferences if given appropriate written and oral 
information from health professionals. The majority of participants, in their study, 
preferred HU treatment over either chronic transfusions or bone marrow transplant. 
 
Researchers have previously identified a need to develop patient friendly and age-
appropriate education tools about the benefits of treatment to overcome some of the 
barriers to usage (Zumberg et al, 2005). In addition a centralized resource centre for HU, 
for example a Web page, has been proposed as a forum to equip patients and parents with 
the information they need and to provide an opportunity for them to share their experiences 
(Hutchins-Pullins, 2008). Considering the continued underutilization of HU, high treatment 
Chapter 5  151 
refusal and non compliance rates such initiatives are urgently required, particularly for 
adolescents and young adults. 
 
5.8 Strengths and weaknesses of the study design 
This study used patients as their own controls which is an alternative to using a 
comparison/control group. Other longitudinal studies of SCD patients on HU therapy have 
used this approach therefore it facilitated comparison with these studies. In addition it was 
easier to administer this study design in normal clinical practice. Patients on HU were 
monitored regularly and the registry used the patients’ routine data for the evaluation. 
Blood tests results were elicited from the hospitals' information systems and clinical data 
was also routinely available from the hospital information systems and the patients’ 
medical records. 
 
Assimilating the findings of this study with other small studies of HU treatment in SCD 
patients will help clinicians assess the effectiveness and tolerability of HU in the absence 
of better evidence (de Montalembert et al, 2006; Brawley et al, 2008). Similar results in 
different populations with different study designs increase the likelihood that the findings 
have external validity (Grimes and Schulz, 2002a). 
 
5.8.1 Controlling for confounders and information bias 
There are several methodological weaknesses with this study design. First it is very 
difficult to identify if an observed complication or side effect, such as leg ulcer, is due to 
the treatment or the patients’ underlying illness. This could be controlled for by comparing 
the cohort with a comparison group of SCD patients not on HU (Lanzkron et al, 2008). If 
both cohorts are followed up in the same manner then any observed difference in incidence 
rates between the groups could be regarded as a true difference. 
 
However patients on a potentially toxic treatment, like HU, are often followed up 
rigorously for side effects and adverse events and therefore there is the potential for 
information bias resulting from over investigation or estimation of risk in the treatment 
group. Side effects and adverse events will be specifically looked for in the treatment 
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group. Consequently risks of treatment are more likely to be better recorded in this group 
than for patients not on treatment or, if using the patient as their own control, than in the 
pre treatment period. It is not feasible or ethical to blind the data collectors or patients to 
the exposure in normal clinical practice. 
 
HU is underutilized for SCD patients and one of the main reasons is uncertainty about 
serious adverse events such as cancer risk, risk in pregnancy and risks to fertility (Brawley 
et al, 2008). Knowing the prevalence of HU use among SCD patients would help assess the 
relative risks of treatment (Brawley et al, 2008). This is only possible if there is reliable 
data on total numbers of SCD patients as well as the proportion being treated with HU. 
This can be achieved in the context of a registry, such as the NWL SCD registry, where all 
SCD patients are followed up, not just the group in receipt of HU therapy. 
 
5.8.2 Managing effect of regression to the mean due to selection bias 
The severity of SCD is very variable both between different patients and over the lifetime 
of individual patients. Patients are commenced on HU when they are severely ill therefore 
they could be experiencing a particularly severe period of the disease at the initiation of 
treatment which might revert back to steady state without any treatment. In this situation 
using the patient as their own control would over estimate the benefits of the treatment 
(Bland and Altman, 1994b).  
Regression to the mean is the phrase used to identify the phenomenon that a variable that is 
extreme on its first measurement will tend to be closer to the center of the distribution for a 
later measurement (Davis, 1976; Bland and Altman, 1994b). If admission to a cohort 
includes a group with extreme measurements, such as high/low laboratory values or high 
number of adverse clinical events, then lower mean values will arise at follow-up whether 
treatment is administered or not (Bland and Altman, 1994b; Grimes and Schulz, 2002a). 
The more extreme the variable from the population mean the more room there is to regress 
to the population mean. The initial high abnormal results could have occurred through 
chance therefore there is high probably that subsequent measurements will spontaneously 
regress towards the population mean value (Bland and Altman, 1994b; Morton and 
Torgerson, 2003). This variability can be attributed to the inherent variation in the variable 
being measured (biological variation) and measurement error. It is a statistical 
phenomenon and always occurs in practice (Bland and Altman, 1994a).  
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This unavoidable selection bias must be considered when evaluating results from cohort 
studies, especially studies without a control group. Any true improvement due to treatment 
must be separated from the effect of regression to the mean (Davis, 1976; Criqui et al, 
1983; Bland and Altman, 1994b). According to Grimes and Schulz (2002a) findings of 
strong associations suggest causation whereas weak associations, in observational studies, 
can easily be due to bias. Therefore the highly statistically significant results reported here 
can be considered a treatment effect (p = 0.001) whereas the smaller differences may or 
may not be real. 
 
5.9 Registry growth and survival 
A major structural problem with this registry was the lack of stable long-term funding. Due 
to lack of funding the registry was unable to expand coverage to other hospitals in the area 
and even maintain some of those hospitals already participating. Consequently the registry 
reverted back to a local, hospital based, clinical registry from a central registry, which 
aimed to cover the NWL region. The utility diminished due to the reduction in numbers of 
cases available for study and the potential decreased representativeness of the cohort 
because it became restricted to a single site. 
 
On the whole clinical registries/ databases tend to have precarious funding streams (Black 
et al, 2004; Raftery et al, 2005). However, the literature, reviewed in Chapter 2, suggests 
that survival and growth in the long-term is dependent on adequate, regular and reliable 
funding and support from reputable organisations such as the Department of Health, local 
Primary Care Trusts, clinician representative bodies and voluntary patient advocate groups 
(Keogh, 2004; Mehta et al, 2004). A prerequisite for success includes a centralized team of 
core staff to co-ordinate the registry and manage the computing requirements together with 
adequate research support to recruit patients and to complete data collection at 
participating sites (Morris et al, 1997; Every et al, 1999; Mehta et al, 2004). 
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5.10 Conclusions 
The experience reported here is a realistic example of what happens in normal clinical care 
settings. This study found that haematological benefits were maintained in the long-term 
with HU treatment but evidence of long term clinical effectiveness was less strong. This 
appeared to be due to the patterns of clinical management in everyday practice. Patients 
tend to be treated with modest doses due to intolerance or inability to attain or maintain 
MTD. Treatment protocols should be revised to reflect realistic dosing targets. There are 
significant barriers to optimal usage in routine clinical practice. Interventions need to be 
targeted at increasing utilisation, patient compliance and persistence with treatment. 
Special effort and creative thinking is required to devise methods to ensure the current 
literature on HU therapy filters through to patients, sickle cell advocacy groups and the 
healthcare community in general. 
 
The North West London HU Sub- Registry has proved a useful tool to measure long-term 
safety and effectiveness of HU. The novelty of this study lay in examination of the nuances 
of HU treatment in everyday practice. This detailed information helped explain why 
clinical outcomes varied over time and identify factors that impact on treatment 
effectiveness. Comparison with other studies illustrates that these issues are not unique to 
this study. The results should help clinicians devise effective treatment protocols and 
strategies for managing patients commenced on HU. 
 
A further innovation was the ability to use the routinely collected data for both clinical 
management purposes and research into SCD. The data enabled the development of a 
patient electronic record as a tool for clinical management. The information which enabled 
this study was relatively detailed but simple to collect. Most variables were routinely 
available from patient notes and hospital information systems. However, the study was 
conducted using stringent research methodology and required sufficient funding and 
research staff to administer. 
 
National recognition of the need for comprehensive strategies for managing 
haemoglobinopathies in The National Plan (2000) provided the clout and impetus for 
current developments in services for SCD patients. The Antenatal and Neonatal Screening 
Programme for SCD and Thalassaemia was set up in 2001 and subsequently national 
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guidelines for the clinical care and management of adults and children with SCD were 
developed. A National Haemoglobinopathy Registry was recently established which 
provides the first opportunity for collecting population based data on incidence and 
prevalence of SCD in England. Taken together these initiatives should translate into better 
care and management of SCD patients with improved patient outcomes. 
 
Establishing and maintaining successful registries/ clinical databases are fraught with 
difficulties. As stated in Chapter 2, registries are currently expected to collect better quality 
and more comprehensive and timely information in order that they are capable of more 
'than basic analysis' (Keogh et al, 2004; Department of Health, 2007a). Comprehensive 
data collection for SCD can be achieved if registries operate as clinical information 
systems. Models, like the NWL Registry, with active involvement of local care providers 
in data collection and where there is the ability to keep and utilize their own data provides 
an incentive to maintain participation (Every et al, 1999; Mehta et al, 2004). Clinicians 
require regular data reports which will enable them to benchmark their local outcomes with 
the aggregate data from the whole registry, providing the opportunity for continuous 
quality improvement activities (English et al 1984; Every et al, 1999). This is considered 
an incentive to conduct careful patient selection and chart review. A participatory model 
with health professionals taking ownership and responsibility for improving patient care 
appears to be a successful strategy, provided there are objective outcomes to measure and 
monitor quality of care (Keogh et al, 2004; Society for Cardiothoracic Surgery in Great 
Britain & Ireland, 2008). 
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5.11 Recommendations for future research and development 
i. Findings suggest that there is a need for further epidemiology/observational studies to be 
conducted into the diffusion and utilisation of HU treatment for SCD patients in routine 
clinical settings. In addition robust evidence is required on the long-term side effects of 
HU for this client group. 
 
ii. This research should be conducted in the context of a clinical registry or registries, 
which follows all patients with SCD. A large registry cohort would enable case control 
studies to be undertaken and follow-up of patients in the long-term. The case control study 
design would allow true incidence of side effects to be calculated. 
 
iii. SCD clinical registries should be set up as clinical information systems with local 
management and control by the patients' health care professionals. Data from these systems 
can be utilized locally for clinical care, research and audit. This data can then be uploaded 
to the National Registry for population based analysis. The model implemented by the 
Cardiac Surgical databases is a good example of how the system works in practice. 
 
iv. Hospital based clinical information systems for SCD would provide the infrastructure 
for record linkage to other clinical systems enabling complete data capture during the 
patient's journey through the health care system. 
 
v. Strategies should be developed to improve utilisation and compliance with HU 
treatment. The electronic patient record developed as part of this study requires multi-site 
evaluation for feasibility and benefit with patient monitoring during treatment. Other 
strategies, such as educational and information tools, should be developed in conjunction 
with patients and patient advocacy groups to improve understanding of HU benefits and 
risks. It may be that a qualitative in-depth study would be useful in ascertaining insight into 
patient refusal to continue or start HU therapy. 
 
vi. National guidance on feasible HU treatment protocols and follow-up regimes would 
assist health care professionals to manage patients effectively throughout treatment. These 
should be comprehensive and flexible to capture the heterogeneity of SCD patients treated 
with HU. 
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Glossary 
 
Adult haemoglobin (HbA) comprises over 95% of haemoglobin in an adult with normal 
haemoglobin. It has a α2β2 (alpha2beta2) chain structure therefore each haemoglobin 
molecule has two α and two β polypeptide chains. 
 
Erythrocyte 
The mature non-nucleated red blood cell rich in oxygen carrying pigment haemoglobin. 
 
Erythropoiesis 
Maturation of the red blood cells, usually in the bone marrow. 
 
Fetal haemoglobin (HbF) 
In utero the fetus produces haemoglobin F which is replaced by normal HbA as it develops 
and during the first year of life. The chain structure of HbF is α2γ2 (alpha2gamma2). In 
sickle cell disease a small amount of total haemoglobin persists as HbF after birth. The 
amount that persists varies between patients. 
 
F Cell 
A mature red blood cell with a high concentration of HbF. 
 
F Reticulocyte (retic) 
A young red blood cell containing a high concentration of HbF. 
 
Globin 
The protein parts of the haemoglobin molecule. 
 
Haemoglobin molecule 
The oxygen carrying part of red blood cells, composed of a closely integrated structure of 
four heme-globin units, called monomers. From infancy onward the majority of 
haemoglobin produced is adult haemoglobin (HbA). Haemoglobin is called 
oxyhaemoglobin when carrying oxygen and called deoxygenated haemoglobin when 
reduced of oxygen. 
 
Haemoglobinopathy 
This is a general term covering all inherited genetic disorders resulting from abnormal or 
underproduced haemoglobin proteins in the blood. An alteration occurs in the globin gene 
which results in the production of abnormal haemoglobin, underproduction or absence of 
globin. The abnormal haemoglobin results in sickle cell disease and the 
underproduction/absence of globin results in a thalassaemia syndrome. In a few cases both 
mechanisms occur (reduced synthesis of an abnormal haemoglobin e.g. HbE). 
 
Rarely acquired haemoglobinapathies arise as a secondary manifestation of another 
disease, most commonly from haematologic premalignant conditions such as 
myelodysplastic and myeloproliferative syndromes. The condition is not restricted to any 
specific population group or geography. Other conditions classified as acquired 
haemoglobinopathies result from drug toxicity, for example carbon monoxide poisoning 
and methemoglobinaemia. 
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Infarction 
Death of tissue caused by obstruction of the circulation. 
 
Neutrophil (also call ‘pus cell’) 
One of the cells that make up the polymorphonuclear leucocytes, the main phagocytic 
white cells in blood. They are collectively called granular cells. 
 
Leucocyte 
A white blood cell which includes lymphocytes, polymorphonuclear cells and monocytes. 
 
Painful crisis (painful vaso-occlusive crisis) 
The infarctive crisis that occurs after obstruction of the circulation by sickle cells in sickle 
cell disease. 
 
Polymer 
A substance formed by the linkage of a large number of smaller molecules known as 
monomers. When sickle haemoglobin is deoxygenated it can stick together to form 
crystalline groupings of haemoglobin or polymers. These polymers distort the red blood 
cells into sickle shapes. 
 
Priapism 
This is a prolonged painful erection of the penis that is not associated with sexual desire 
but caused by sickling in the corpora cavernosa with resultant blockage of the outflow 
vessels. 
 
Reticulocyte (retic) 
A young non-nucleated red blood cell. A raised retic count shows active erthropoiesis. The 
normal range is for retics to make up 0.2 or 2% of total red blood cells. 
 
Serious Adverse Event 
A clinical event which results in death, or is considered to be life-threatening for the 
patient. 
 
Sickle cell anaemia 
An inherited condition due to a single defective haemoglobin molecule, which results in 
the production of abnormal haemoglobin S (HbS) instead of normal haemoglobin A 
(HbA). It is characterised by sickle shaped red blood cells which are stiff and can block 
blood vessels. 
 
Sickle cell disease (SCD) 
This comprises the group of genetic conditions arising from the ‘sickle’ mutation. 
Inheriting the sickle gene from both parents’ results in homozygous SCD (HbSS). An 
individual who inherits one sickle gene in combination with a sickle variant or a beta 
thalassaemia gene will have a heterozygous SCD. Clinically significant variant 
combinations include HbSC, HbSDPunjab, HbSOArab and HbS/βthal syndromes. 
 
Spermatogenesis 
The process by which mature spermatozoa are produced in the testis. 
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Thalassaemia 
A group of inherited haemoglobinopathy disorders characterised by the underproduction of 
haemoglobin proteins resulting in anaemia of varying severity, depending on the form 
inherited. In beta thalassaemia major HbA is not produced at all and patients with this 
disorder suffer severe anaemia, requiring lifelong regular blood transfusions. 
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